• Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274: 17159-17163 (1999). *

• Abenavoli L, De Maria V, DeSiena M, DiSalvo S, Giancotti F, Gravina T, Abenavoli SM. Familial intrahepatic cholestasis. Novel advances. Recenti Prog. Med. 98: 569-573 (2007).

• Accatino L, Contreras A, Fernandez S, Quintana C. The effect of complete biliary obstruction on bile flow and bile acid excretion: postcholestatic choleresis in the rat. J. Lab. Clin. Med. 93: 706-717 (1979).

• Accatino L, Hono J, Koenig C, Pizarro M, Rodriguez L. Adaptive changes of hepatic bile salt transport in a model of reversible interruption of the enterohepatic circulation in the rat. J. Hepatol. 19: 95-104 (1993).

• Accatino L, Pizarro M, Solis N, Koenig CS, Vollrath V, Chianale J. Modulation of hepatic content and biliary excretion of P-glycoproteins in hepatocellular and obstructive cholestasis in the rat. J. Hepatol. 25: 349-361 (1996). *

• Adachi Y, Kamisako T. Intrahepatic cholestasis. Nippon Rinsho 54: 788-793 (1996).

• Adachi Y, Kamisako T, Okuyama Y, Miya H. Hepatic metabolism and transport of bilirubin and other organic anions. Nippon Rinsho 54: 2276-2290 (1996).

• Ahmed S, Vo NT, Thalhammer T, Thalhammer F, Gattringer KB, Jager W. Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. J. Pharm. Pharmacol. 60: 55-62 (2008). *

• Akashi M, Tanaka A, Takikawa H. Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatol. Res. 34: 193-198 (2006).

• Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim. Biophys. Acta 1511: 7-16 (2001). *

• Akita H, Suzuki H, Sugiyama Y. Sinusoidal efflux of taurocholate correlates with the hepatic expression level of Mrp3. Biochem. Biophys. Res. Commun. 299: 681-687 (2002). *

• Albrecht C, Elliott JI, Sardini A, Litman T, Stieger B, Meier PJ, Higgins CF. Functional analysis of candidate ABC transporter proteins for sitosterol transport. Biochim. Biophys. Acta 1567: 133-142 (2002). *

• Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *

• Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol. Sci. 108: 225-246 (2009). *

• Alpini G, Baiocchi L, Glaser S, Ueno Y, Marzioni M, Francis H, Phinizy JL, Angelico M, Lesage G. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology 35: 1041-1052 (2002). *

• Alpini G, Glaser S, Alvaro D, Ueno Y, Marzioni M, Francis H, Baiocchi L, Stati T, Barbaro B, Phinizy JL, Mauldin J, Lesage G. Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats. Gastroenterology 123: 1226-1237 (2002). *

• Alpini G, Glaser S, Baiocchi L, Francis H, Xia X, Lesage G. Secretin activation of the apical Na(+)-dependent bile acid transporter is associated with cholehepatic shunting in rats. Hepatology 41: 1037-1045 (2005). *

• Alpini G, Lenzi R, Zhai WR, Slott PA, Liu MH, Sarkozi L, Tavoloni N. Bile secretory function of intrahepatic biliary epithelium in the rat. Am. J. Physiol. 257: G124-G133 (1989).

• Alpini G, McGill JM, LaRusso NF. The pathobiology of biliary epithelia. Hepatology 35: 1256-1268 (2002). *

• Alpini G, Ueno Y, Glaser SS, Marzioni M, Phinizy JL, Francis H, Lesage G. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. Hepatology 34: 868-876 (2001). *

• Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24: 1803-1823 (2007). *

• Alrefai WA, Sarwar Z, Tyagi S, Saksena S, Dudeja PK, Gill RK. Cholesterol modulates human intestinal sodium-dependent bile acid transporter. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G978-G985 (2005). *

• Alvarez L, Jara P, Sanchez-Sabate E, Hierro L, Larrauri J, Diaz MC, Camarena C, De La Vega A, Frauca E, Lopez-Collazo E, Lapunzina P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13: 2451-2460 (2004). *

• Alvaro D, Benedetti A, Marucci L, Delle Monache M, Monterubbianesi R, Di Cosimo E, Perego L, Macarri G, Glaser S, Le Sage G, Alpini G. The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 32: 174-184 (2000). *

• Alves C, von Dippe P, Amoui M, Levy D. Bile acid transport into hepatocyte smooth endoplasmic reticulum vesicles is mediated by microsomal epoxide hydrolase, a membrane protein exhibiting two distinct topological orientations. J. Biol. Chem. 268: 20148-20155 (1993). *

• Amore A, Coppo R, Roccatello D, Piccoli G, Mazzucco G, Gomez-Chiarri M, Lamm ME, Emancipator SN. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab. Invest. 70: 68-77 (1994).

• Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276: 28857-28865 (2001). *

• Ananthanarayanan M, Li S, Balasubramaniyan N, Suchy FJ, Walsh MJ. Ligand-dependent activation of the farnesoid-X-receptor directs arginine methylation of histone H3 by CARM1. J. Biol. Chem. 279: 54348-54357 (2004). *

• Andrejko KM, Raj NR, Kim PK, Cereda M, Deutschman CS. IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters. Shock 29: 490-496 (2008).

• Anelli PL, Lattuada L, Lorusso V, Lux G, Morisetti A, Morosini P, Serleti M, Uggeri F. Conjugates of gadolinium complexes to bile acids as hepatocyte-directed contrast agents for magnetic resonance imaging. J. Med. Chem. 47: 3629-3641 (2004). *

• Angelin B, Eriksson M, Parini P, Rudling M. Bile acids and lipoproteins. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 31. June 18-19 (2004). *

• Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK, Alrefai WA. Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G489-G497 (2008). *

• Anosova NG, Chabot S, Shreedhar V, Borawski JA, Dickinson BL, Neutra MR. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol. 1: 59-67 (2008).

• Anwer MS. Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology 39: 581-590 (2004). *

• Anwer MS, Ananthanarayanan M, Suchy FJ. Role of Ntcp phosphorylation in cAMP-mediated stimulation of hepatic bile acid uptake. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 29 (2006). *

• Aoki K, Saso N, Kato S, Sugiyama Y, Sato H. Nitric oxide and peroxynitrite regulate transporter transcription in rat liver slices. Biol. Pharm. Bull. 31: 1882-1887 (2008). *

• Aoki T. Genetic disorders of copper transport - diagnosis and new treatment for the patients of Wilson's disease. No To Hattatsu 37: 99-109 (2005).

• Arrese M, Accatino L. From blood to bile: recent advances in hepatobiliary transport. Ann. Hepatol. 1: 64-71 (2002). *

• Arrese M, Ananthananarayanan M, Suchy FJ. Hepatobiliary transport: molecular mechanisms of development and cholestasis. Pediatr. Res. 44: 141-147 (1998).

• Arrese M, Ananthanarayanan M. The bile salt export pump: molecular properties, function and regulation. Pflugers Arch. 449: 123-131 (2004). *

• Arrese M, Macias RI, Briz O, Perez MJ, Marin JJ. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev. Mol. Med. 10: e9 (2008).

• Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle. Ann. Hepatol. 5: 202-205 (2006). *

• Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9: 558-564 (2003). *

• Arrese M, Trauner M, Ananthanarayanan M, Pizarro M, Solis N, Accatino L, Soroka C, Boyer JL, Karpen SJ, Miquel JF, Suchy FJ. Down-regulation of the Na+/taurocholate cotransporting polypeptide during pregnancy in the rat. J. Hepatol. 38: 148-155 (2003). *

• Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).

• Asamoto Y, Tazuma S, Ochi H, Chayama K, Suzuki H. Bile-salt hydrophobicity is a key factor regulating rat liver plasma-membrane communication: relation to bilayer structure, fluidity and transporter expression and function. Biochem. J. 359: 605-610 (2001). *

• Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat. 9: 227-246 (2006).

• Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2A as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279: 22250-22257 (2004). *

• Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, Soubrane O, Vacher-Lavenu MC, Perret C, Cavard C, Terris B. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J. Pathol. 212: 345-352 (2007). *

• Augustine LM, Markelewicz RJ Jr, Boekelheide K, Cherrington NJ. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab. Dispos. 33: 182-189 (2005). *

• Aydemir TB, Liuzzi JP, McClellan S, Cousins RJ. Zinc transporter ZIP8 (SLC39A8) and zinc influence IFN-gamma expression in activated human T cells. J. Leukoc. Biol. Apr 28 [Epub ahead of print] (2009). *

• Azer SA. A multimedia CD-ROM tool to improve student understanding of bile salts and bilirubin metabolism: evaluation of its use in a medical hybrid PBL course. Adv. Physiol. Educ. 29: 40-50 (2005). *

• Azer SA. Do recommended textbooks contain adequate information about bile salt transporters for medical students? Adv. Physiol. Educ. 28: 36-43 (2004). *

• Azer SA, Stacey NH. Current concepts of hepatic uptake, intracellular transport and biliary secretion of bile acids: physiological basis and pathophysiological changes in cholestatic liver dysfunction. J. Gastroenterol. Hepatol. 11: 396-407 (1996).

• Azzaroli F, Mennone A, Feletti V, Simoni P, Baglivo E, Montagnani M, Rizzo N, Pelusi G, DE Aloysio D, Lodato F, Festi D, Colecchia A, Roda E, Boyer JL, Mazzella G. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment. Pharmacol. Ther. 26: 1139-1146 (2007). *

• Bahar RJ, Stolz A. Bile acid transport. Gastroenterol. Clin. North Am. 28: 27-58 (1999).

• Baier PK, Hempel S, Waldvogel B, Baumgartner U. Zonation of hepatic bile salt transporters. Dig. Dis. Sci. 51: 587-593 (2006). *

• Bajor A, Kilander A, Galman C, Rudling M, Ung KA. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. Aliment. Pharmacol. Ther. 24: 1643-1649 (2006). *

• Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol. Pharm. 3: 223-230 (2006). *

• Balakrishnan A, Sussman DJ, Polli JE. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm. Res. 22: 1269-1280 (2005). *

• Balakrishnan A, Wring SA, Coop A, Polli JE. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol. Pharm. 3: 282-292 (2006). *

• Balakrishnan A, Wring SA, Polli JE. Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm. Res. 23: 1451-1459 (2006). *

• Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M. Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G251-G260 (2005). *

• Balesaria S, Pell RJ, Abbott LJ, Tasleem A, Chavele KM, Barley NF, Khair U, Simon A, Moriarty KJ, Brydon WG, Walters JR. Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. Eur. J. Gastroenterol. Hepatol. 20: 413-422 (2008).

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *

• Balkova K, Gbelska Y. ABC transporter proteins in multidrug resistance of microorganisms. Epidemiol. Mikrobiol. Imunol. 56: 129-139 (2007).

• Ballatori N. Biology of a novel organic solute and steroid transporter, OSTalpha-OSTbeta. Exp. Biol. Med. (Maywood) 230: 689-698 (2005). *

• Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42: 1270-1279 (2005). *

• Ballatori N, Fang F, Christian WV, Li N, Hammond CL. Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G179-G186 (2008). *

• Ballatori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 204: 238-255 (2005). *

• Ballatori N, Henson JH, Seward DJ, Cai SY, Runnegar M, Fricker G, Miller DS, Boyer JL. Retention of structural and functional polarity in cultured skate hepatocytes undergoing in vitro morphogenesis. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 144: 167-179 (2006). *

• Ballatori N, Rebbeor JF. Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Semin. Liver Dis. 18: 377-387 (1998).

• Ballatori N, Rebbeor JF, Connolly GC, Seward DJ, Lenth BE, Henson JH, Sundaram P, Boyer JL. Bile salt excretion in skate liver is mediated by a functional analog of Bsep/Spgp, the bile salt export pump. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G57-G63 (2000). *

• Ballestero MR, Monte MJ, Briz O, Jimenez F, Gonzalez-San Martin F, Marin JJ. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol. 72: 729-738 (2006). *

• Banerjee A, Hussainzada N, Khandelwal A, Swaan PW. Electrostatic and potential cation-pi forces may guide the interaction of extracellular loop III with Na+ and bile acids for human apical Na+-dependent bile acid transporter. Biochem. J. 410: 391-400 (2008). *

• Banerjee A, Ray A, Chang C, Swaan PW. Site-directed mutagenesis and use of bile acid-MTS conjugates to probe the role of cysteines in the human apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry 44: 8908-8917 (2005). *

• Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, De Giorgio R, Corinaldesi R. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 2560-2568 (2005). *

• Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 717-726 (2002). *

• Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, Staels B. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124: 1926-1940 (2003). *

• Barbier O, Trottier J, Kaeding J, Caron P, Verreault M. Lipid-activated transcription factors control bile acid glucuronidation. Mol. Cell. Biochem. 326: 3-8 (2009). *

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken M, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab. Dispos. 35: 1963-1969 (2007). *

• Barth A, Braun J, Muller D. Bile acid transport and metabolism in rat liver slices. Exp. Toxicol. Pathol. 57: 313-319 (2006).

• Barth A, Braun J, Muller D. Influence of verapamil and cyclosporin A on bile acid metabolism and transport in rat liver slices. Exp. Toxicol. Pathol. 58: 31-37 (2006). *

• Barth A, Rost M, Kindt A, Peiker G. Serum bile acid profile in women during pregnancy and childbed. Exp. Clin. Endocrinol. Diabetes 113: 372-375 (2005).

• Batta AK, Tint GS, Xu G, Shefer S, Salen G. Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid. J. Lipid Res. 39: 1641-1646 (1998). *

• Beath SV. Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346 (2003).

• Beaussier M, Schiffer E, Housset C. Ischaemic cholestasis in intensive care unit. Ann. Fr. Anesth. Reanim. 27: 709-718 (2008).

• Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional disorders of gallbladder and sphincter of oddi. Gastroenterology 130: 1498-1509 (2006). *

• Beilke LD, Besselsen DG, Cheng Q, Kulkarni S, Slitt AL, Cherrington NJ. Minimal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis. Toxicol. Sci. 102: 196-204 (2008). *

• Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, Di Sario. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 26: 9-21 (1997). *

• Berard AM, Dumon MF, Darmon M. Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion. FEBS Lett. 559: 125-128 (2004). *

• Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Bergheim I, Harsch S, Mueller O, Schimmel S, Fritz P, Stange EF. Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J. Lipid Res. 47: 42-50 (2006). *

• Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, Knutson L, Lennernas H. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur. J. Pharm. Sci. 29: 205-214 (2006). *

• Bertolotti M, Gabbi C, Anzivino C, Carulli L, Loria P, Carulli N. Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insights from evidence on hepatic cholesterol degradation and gallstone disease in humans. Curr. Med. Chem. 15: 2271-2284 (2008).

• Bertrams A, Ziegler K. Hepatocellular uptake of peptides by bile acid transporters: relationship of carrier-mediated transport of linear peptides with renin-inhibiting activity to multispecific bile acid carriers. Biochim. Biophys. Acta 1091: 337-348 (1991).

• Besnard P, Landrier JF, Grober J, Niot I. Is the ileal bile acid-binding protein (I-BABP) gene involved in cholesterol homeostasis? Med. Sci. (Paris) 20: 73-77 (2004).

• Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 318-328 (2006). *

• Beuers U. Mechanisms of action of ursodeoxycholic acid in cholestasis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 49-50. October 15-16 (2003). *

• Beuers U. Mechanisms of action of ursodeoxycholic acid for treatment of primary sclerosing cholangitis. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 12 (2006). *

• Beuers U, Bilzer M, Chittattu A, Kullak-Ublick GA, Keppler D, Paumgartner G, Dombrowski F. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33: 1206-1216 (2001). *

• Beukeveld GJ, In 't Veld G, Havinga R, Groen AK, Wolthers BG, Kuipers F. Relationship between biliary lipid and protoporphyrin secretion; potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport. J. Hepatol. 24: 343-352 (1996). *

• Bi YA, Kazolias DC, Duignan DB. Use of cryopreserved human hepatocytes in sandwich-culture to measure hepatobiliary transport. Drug Metab. Dispos. 34: 1658-1665 (2006). *

• Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 49: 637-645 (2009). *

• Bijvelds MJ, Jorna H, Verkade HJ, Bot AG, Hofmann F, Agellon LB, Sinaasappel M, de Jonge HR. Activation of CFTR by ASBT-mediated bile salt absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G870-G879 (2005). *

• Bird NC, Ooi RC, Luo XY, Chin SB, Johnson AG. Investigation of the functional three-dimensional anatomy of the human cystic duct: a single helix? Clin. Anat. 19: 528-534 (2006).

• Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. U.S.A. 101: 3668-3673 (2004). *

• Bjornsson E, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275 (2003).

• Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia 47: 104-112 (2004). *

• Bloomer J, Wang Y, Singhal A, Risheg H. Molecular studies of liver disease in erythropoietic protoporphyria. J. Clin. Gastroenterol. 39: S167-S175 (2005).

• Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat. Med. 14: 828-836 (2008). *

• Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *

• Bode KA, Donner MG, Leier I, Keppler D. Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem. Pharmacol. 64: 151-158 (2002). *

• Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278: 23529-23537 (2003). *

• Bogert PT, LaRusso NF. Cholangiocyte biology. Curr. Opin. Gastroenterol. 23: 299-305 (2007).

• Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv. Enzyme Regul. 34: 371-380 (1994).

• Bohme M, Muller M, Leier I, Jedlitschky G, Keppler D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107: 255-265 (1994).

• Bolder U, Jeschke MG, Landmann L, Wolf F, de Sousa C, Schlitt HJ, Przkora R. Heat stress enhances recovery of hepatocyte bile acid and organic anion transporters in endotoxemic rats by multiple mechanisms. Cell Stress Chaperones 11: 89-100 (2006). *

• Bolder U, Schmidt A, Landmann L, Kidder V, Tange S, Jauch KW. Heat stress prevents impairment of bile acid transport in endotoxemic rats by a posttranscriptional mechanism. Gastroenterology 122: 963-973 (2002). *

• Bolder U, Thasler WE, Hofmann AF, Jauch KW. Hepatocellular transport of bile acids and organic anions in infection and SIRS - evidence for different mechanisms for regulating membrane transport proteins. Langenbecks Arch. Chir. Suppl. Kongressbd. 115 (Suppl. I): 391-396 (1998).

• Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: impaired uptake and secretion. Gastroenterology 112: 214-225 (1997). *

• Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu HT, Cerre C, Elferink RP, Hofmann AF. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 117: 962-971 (1999). *

• Borgognone M, Perez LM, Basiglio CL, Ochoa JE, Roma MG. Signaling modulation of bile salt-induced necrosis in isolated rat hepatocytes. Toxicol. Sci. 83: 114-125 (2005). *

• Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 453: 661-673 (2007). *

• Borst P, Oude Elferink RP. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71: 537-592 (2002). *

• Bosse T, Piaseckyj CM, Burghard E, Fialkovich JJ, Rajagopal S, Pu WT, Krasinski SD. Gata4 is essential for the maintenance of jejunal-ileal identities in the adult mouse small intestine. Mol. Cell. Biol. 26: 9060-9070 (2006). *

• Boucherie S, Koukoui O, Nicolas V, Combettes L. Cholestatic bile acids inhibit gap junction permeability in rat hepatocyte couplets and normal rat cholangiocytes. J. Hepatol. 42: 244-251 (2005) (2005). *

• Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J. 24: 2624-2633 (2005). *

• Bouscarel B, Kroll SD, Fromm H. Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. Gastroenterology 117: 433-452 (1999). *

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Boyer JL. Bile duct epithelium: frontiers in transport physiology. Am. J. Physiol. 270: G1-G5 (1996).

• Boyer JL. New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46: 365-371 (2007). *

• Boyer JL, Denk G, Bohan A, Chen WS, Soroka C, Denson L. Adaptive regulation of bile salt transporters in cholestasis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 46-47. June 18-19 (2004). *

• Boyer JL, Ng OC, Ananthanarayanan M, Hofmann AF, Schteingart CD, Hagenbuch B, Stieger B, Meier PJ. Expression and characterization of a functional rat liver Na+ bile acid cotransport system in COS-7 cells. Am. J. Physiol. 266: G382-G387 (1994).

• Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. Up-regulation of a basolateral FXR-dependent bile acid efflux transporter, OSTalpha-OSTbeta, in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1124-G1130 (2006). *

• Bradford W, Allen D, Shelburne J, Spock A. Hepatic parenchymal cells in cystic fibrosis: ultrastructural evidence for abnormal intracellular transport. Pediatr. Pathol. 1: 269-279 (1983).

• Brandoni A, Anzai N, Kanai Y, Endou H, Torres AM. Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat. The role of OAT1 and OAT3. Biochim. Biophys. Acta 1762: 673-682 (2006). *

• Brandoni A, Torres AM. Characterization of the mechanisms involved in the increased renal elimination of bromosulfophthalein during cholestasis: involvement of Oatp1. J. Histochem. Cytochem. 57: 449-456 (2009). *

• Brandtzaeg P, Bjerke K, Kett K, Kvale D, Rognum TO, Scott H, Sollid LM, Valnes K. Production and secretion of immunoglobulins in the gastrointestinal tract. Ann. Allergy 59: 21-39 (1987).

• Breen CM, Sykes DB, Baehr C, Fricker G, Miller DS. Fluorescien-methotrexate transport in rat choroid plexus analyzed using confocal microscopy. Am. J. Physiol. Renal Physiol. 287: F562-F569 (2004). *

• Briz O, Macias RI, Perez MJ, Serrano MA, Marin JJ. Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290: R749-R756 (2006). *

• Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG, Marin JJ. OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J. Biol. Chem. 281: 30326-30335 (2006). *

• Brousseau ME. ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption. Curr. Opin. Lipidol. 14: 35-40 (2003).

• Buis CI, Geuken E, Visser DS, Kuipers F, Haagsma EB, Verkade HJ, Porte RJ. Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. J. Hepatol. 50: 69-79 (2009). *

• Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, Klomp LW, Lomri N, Berger R, Scharschmidt BF, Knisely AS, Houwen RH, Freimer NB. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18: 219-224 (1998). *

• Bunce J, Achila D, Hetrick E, Lesley L, Huffman DL. Copper transfer studies between the N-terminal copper binding domains one and four of human Wilson protein. Biochim. Biophys. Acta 1760: 907-912 (2006). *

• Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs 15: 1337-1351 (2006).

• Buscher HP, Miltenberger C, MacNelly S, Gerok W. The histoautoradiographic localization of taurocholate in rat liver after bile duct ligation. Evidence for ongoing secretion and reabsorption processes. J. Hepatol. 8: 181-191 (1989).

• Buts JP, De Keyser N, Collette E, Bonsignore M, Lambotte L, Desjeux JF, Sokal EM. Intestinal transport of calcium in rat biliary cirrhosis. Pediatr. Res. 40: 533-541 (1996).

• Buxbaum J, Qian P, Khuu C, Shneider BL, Daikh DI, Gershwin ME, Allen PM, Peters MG. Novel model of antigen-specific induction of bile duct injury. Gastroenterology 131: 1899-1906 (2006). *

• Byrne JA, Strautnieks SS, Ihrke G, Knisely AS, Jirsa M, Cebecauerova D, Linton KJ, Higgins CF, Mieli-Vergani G, Thompson RJ. Investigation of the disease mechanisms associated with missense mutations in the bile salt export pump, BSEP. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 61 (2006). *

• Byrne JA, Strautnieks SS, Ihrke G, Pagani F, Knisely AS, Linton KJ, Mieli-Vergani G, Thompson RJ. Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing. Hepatology 49: 553-567 (2009).

• Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123: 1649-1658 (2002). *

• Cai SY, Boyer JL. FXR: a target for cholestatic syndromes? Expert Opin. Ther. Targets 10: 409-421 (2006).

• Cai SY, Gautam S, Nguyen T, Soroka CJ, Rahner C, Boyer JL. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 136: 1060-1069.e4 (2009). *

• Cai SY, Wang L, Ballatori N, Boyer JL. Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G316-G322 (2001). *

• Calamita G, Ferri D, Bazzini C, Mazzone A, Botta G, Liquori GE, Paulmichl M, Portincasa P, Meyer G, Svelto M. Expression and subcellular localization of the AQP8 and AQP1 water channels in the mouse gallbladder epithelium. Biol. Cell 97: 415-423 (2005). *

• Calamita G, Ferri D, Gena P, Liquori GE, Marinelli RA, Meyer G, Portincasa P, Svelto M. Water transport into bile and role in bile formation. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 137-142 (2005).

• Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, Kusters JG. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am. J. Gastroenterol. 103: 1510-1516 (2008). *

• Carlton VE, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, Strauss KA, Shneider BL, Lim WA, Salen G, Morton DH, Bull LN. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat. Genet. 34: 91-96 (2003). *

• Carrella M, Roda E. Evolving concepts in the pathophysiology of biliary lipid secretion. Ital. J. Gastroenterol. Hepatol. 31: 643-648 (1999).

• Carreras F, Lehmann GL, Ferri D, Tioni MF, Calamita G, Marinelli RA. Defective hepatocyte aquaporin-8 expression and educed canalicular membrane water permeability in estrogen-induced cholestasis. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G905-G912 (2007). *

• Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 277-287 (2007). *

• Cassio D, Macias RI, Grosse B, Marin JJ, Monte MJ. Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3-1 and Can 10. Cell Tissue Res. 330: 447-460 (2007). *

• Cater MA, Forbes J, La Fontaine S, Cox D, Mercer JF. Intracellular trafficking of the human Wilson protein: the role of the six N-terminal metal binding sites. Biochem. J. 380: 805-813 (2004). *

• Cerf E, Gasper R, Rychnovsky S, Chang XB, Buyse F, Ruysschaert JM. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem. Biophys. Res. Commun. 355: 1025-1030 (2007). *

• Chae HW, Kim IW, Jin HE, Kim DD, Chung SJ, Shim CK. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch. Pharm. Res. 31: 103-110 (2008).

• Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W. The bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology Mar 16 [Epub ahead of print] (2009).

• Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21: 719-735 (2004). *

• Chandra P, Johnson BM, Zhang P, Pollack GM, Brouwer KL. Modulation of hepatic canalicular or basolateral transport alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metab. Dispos. 33: 1238-1243 (2005). *

• Chazouilleres O, Marteau P, Haniche M, Jian R, Poupon R. Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA). Dig. Dis. Sci. 41: 2417-2422 (1996).

• Chen BC, Kuo KK, Chen YH, Liu CH, Tsai LY, Hsu HK, Hsu C. Retinoid X receptor alpha participation in dexamethasone induced rat bile acid coenzyme A-amino acid N-acyltransferase expression in septic liver. Shock Nov 11 [Epub ahead of print] (2008).

• Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely As A, Strautnieks SS, Thompson RJ, Magid MS, Gordon R, Balasubramanian N, Suchy FJ, Shneider BL. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126: 756-764 (2004). *

• Chen F, Ma L, Al-Ansari N, Shneider B. The role of AP-1 in the transcriptional regulation of the rat apical sodium-dependent bile acid transporter. J. Biol. Chem. 276: 38703-38714 (2001). *

• Chen F, Ma L, Dawson PA, Sinal CJ, Sehayek E, Gonzalez FJ, Breslow J, Ananthanarayanan M, Shneider BL. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278: 19909-19916 (2003). *

• Chen HL, Chen HL, Liu YJ, Feng CH, Wu CY, Shyu MK, Yuan RH, Chang MH. Developmental expression of canalicular transporter genes in human liver. J. Hepatol. 43: 472-477 (2005). *

• Chen HL, Liu YJ, Chen HL, Wu SH, Ni YH, Ho MC, Lai HS, Hsu WM, Tseng HC, Jeng YM, Chang MH. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr. Res. 63: 667-673 (2008).

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Chen J, Terada T, Ogasawara K, Katsura T, Inui KI. Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am. J. Physiol. Renal Physiol. 295: F247-F252 (2008). *

• Chen W, Cai SY, Xu S, Denson L, Soroka C, Boyer JL. Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1221-G1227 (2007). *

• Chen X, Chen F, Liu S, Glaeser H, Dawson PA, Hofmann AF, Kim RB, Shneider BL, Pang KS. Transactivation of rat ASBT and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor (VDR). Mol. Pharmacol. 69: 1913-1923 (2006). *

• Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD. Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. 67: 545-557 (2005). *

• Cheng X, Buckley D, Klaassen CD. Regulation of hepatic bile acid transporters Ntcp and Bsep expression. Biochem. Pharmacol. 74: 1665-1676 (2007). *

• Cheng X, Klaassen CD. Critical role of PPARalpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced down-regulation of Oatp uptake transporters in mouse livers. Toxicol. Sci. 106: 37-45 (2008). *

• Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 32: 734-741 (2004). *

• Chiang JY. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin. Drug Metab. Toxicol. 5: 137-147 (2009).

• Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr. Rev. 23: 443-463 (2002). *

• Chiang JY. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G349-G356 (2003). *

• Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res. Apr 3 [Epub ahead of print] (2009). *

• Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 40: 539-551 (2004). *

• Chignard N, Mergey M, Veissiere D, Parc R, Capeau J, Poupon R, Paul A, Housset C. Bile acid transport and regulating functions in the human biliary epithelium. Hepatology 33: 496-503 (2001). *

• Chinet T, Fouassier L, Dray-Charier N, Imam-Ghali M, Morel H, Mergey M, Dousset B, Parc R, Paul A, Housset C. Regulation of electrogenic anion secretion in normal and cystic fibrosis gallbladder mucosa. Hepatology 29: 5-13 (1999). *

• Chloupkova M, Pickert A, Lee JY, Souza S, Trinh YT, Connelly SM, Dumont ME, Dean M, Urbatsch IL. Expression of 25 human ABC transporters in the yeast Pichia pastoris and characterization of the purified ABCC3 ATPase activity. Biochemistry 46: 7992-8003 (2007). *

• Cho WK, Boyer JL. Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. Gastroenterology 117: 420-428 (1999). *

• Choudhuri S, Cherrington NJ, Li N, Klaassen CD. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab. Dispos. 31: 1337-1345 (2003). *

• Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25: 231-259 (2006). *

• Chu X, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R. Characterization of mice lacking the multidrug resistance protein Mrp2 (Abcc2). J. Pharmacol. Exp. Ther. 317: 579-589 (2006). *

• Chuang YH, Lan RY, Gershwin ME. The immunopathology of human biliary cell epithelium. Semin. Immunopathol. Jun 17 [Epub ahead of print] (2009).

• Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25: 2020-2030 (2005). *

• Claudel T, Sturm E, Kuipers F, Staels B. The farnesoid X receptor: a novel drug target? Expert Opin. Investig. Drugs 13: 1135-1148 (2004).

• Clerici C, Castellani D, Asciutti S, Pellicciari R, Setchell KD, O'connell NC, Sadeghpour B, Camaioni E, Fiorucci S, Renga B, Nardi E, Sabatino G, Clementi M, Giuliano V, Baldoni M, Orlandi S, Mazzocchi A, Morelli A, Morelli O. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. Toxicol. Appl. Pharmacol. 214: 199-208 (2006). *

• Coleman JP, Kirby LC, Setchell KD, Hylemon PB, Pandak M, Heuman DM, Vlahcevic ZR. Metabolic fate and hepatocyte toxicity of reverse amide analogs of conjugated ursodeoxycholate in the rat. J. Steroid Biochem. Mol. Biol. 64: 91-101 (1998).

• Colombo C. Liver disease in cystic fibrosis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 31-33 (2006). *

• Colombo C, Crosignani A, Apostolo MG, Marzano MT, Bettinardi N, Giunta A. Oral bile acids in cystic fibrosis-associated liver disease. J. R. Soc. Med. 87 Suppl. 21: 20-24 (1994). *

• Cooper AD, Craig WY, Taniguchi T, Everson GT. Characteristics and regulation of bile salt synthesis and secretion by human hepatoma HepG2 cells. Hepatology 20: 1522-1531 (1994).

• Copaci I, Micu L, Iliescu L, Voiculescu M. New therapeutical indications of ursodeoxycholic acid. Rom. J. Gastroenterol. 14: 259-266 (2005). *

• Cornelius CE. Hepatic bilirubin-IX-alpha-glycosyltransferase activities in animals excreting primarily biliverdin into bile. Vet. Clin. Pathol. 10: 27-31 (1981).

• Craig TA, Sommer S, Sussman CR, Grande JP, Kumar R. Expression and regulation of the vitamin D receptor in the zebrafish, Danio rerio. J. Bone Miner. Res. 23: 1486-1496 (2008). *

• Cravetto C, Molino G, Hofmann AF, Belforte G, Bona B. Computer simulation of portal venous shunting and other isolated hepatobiliary defects of the enterohepatic circulation of bile acids using a physiological pharmacokinetic model. Hepatology 8: 866-878 (1988).

• Crestani M, De Fabiani E, Caruso D, Mitro N, Gilardi F, Vigil Chacon AB, Patelli R, Godio C, Galli G. LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. Biochem. Soc. Trans. 32: 92-96 (2004). *

• Crocenzi FA, Basiglio CL, Perez LM, Portesio MS, Pozzi EJ, Roma MG. Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP. Biochem. Pharmacol. 69: 1113-1120 (2005). *

• Crocenzi FA, D'Andrea V, Catania VA, Luquita MG, Pellegrino JM, Ochoa JE, Mottino AD, Sanchez Pozzi E. Prevention of Mrp2 activity impairment in ethinylestradiol-induced cholestasis by ursodeoxycholate in the rat. Drug Metab. Dispos. 33: 888-891 (2005). *

• Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, Coleman R, Roma MG. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G449-G459 (2003). *

• Crocenzi FA, Mottino AD, Roma MG. Regulation of synthesis and trafficking of canalicular transporters and its alteration in acquired hepatocellular cholestasis. Experimental therapeutic strategies for its prevention. Curr. Med. Chem. 11: 501-524 (2004).

• Crocenzi FA, Mottino AD, Sanchez Pozzi EJ, Pellegrino JM, Rodriguez Garay EA, Milkiewicz P, Vore M, Coleman R, Roma MG. Impaired localisation and transport function of canalicular Bsep in taurolithocholate induced cholestasis in the rat. Gut 52: 1170-1177 (2003). *

• Crocenzi FA, Roma MG. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr. Med. Chem. 13: 1055-1074 (2006).

• Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, Rodriguez Garay EA, Mottino AD, Roma MG. Preventive effect of silymarin against taurolithocholate-induced cholestasis in the rat. Biochem. Pharmacol. 66: 355-364 (2003). *

• Crocenzi FA, Sanchez Pozzi EJ, Ruiz ML, Zucchetti AE, Roma MG, Mottino AD, Vore M. Ca(2+)-dependent protein kinase C isoforms are critical to estradiol 17beta-D-glucuronide-induced cholestasis in the rat. Hepatology 48: 1885-1895 (2008).

• Crosignani A, Podda M, Bertolini E, Battezzati PM, Zuin M, Setchell KD. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 13: 1076-1083 (1991).

• Cuesta de Juan S, Monte MJ, Macias RI, Wauthier V, Buc Calderon P, Marin JJ. Ontogenic development and effect of weaning on the expression of enzymes, transporters and nuclear receptors involved in rat bile acid homeostasis. J. Lipid Res. 48: 1362-1370 (2007). *

• Cuevas MJ, Almar M, Gonzalez-Gallego J. Effects of epomediol on ethinyloestradiol-induced changes in glutathione homeostasis in the rat. Pharmacol. Toxicol. 90: 121-126 (2002). *

• Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278: 10214-10220 (2003). *

• Cui Y, Cheng X, Miao Weaver Y, Klaassen CD. Tissue distribution, gender-divergent expression, ontogeny and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab. Dispos. 37: 203-210 (2009). *

• Cui YJ, Aleksunes LM, Tanaka Y, Goedken MJ, Klaassen CD. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol. Sci. 110: 47-60 (2009). *

• Cuthbert JA. Wilson's disease: a new gene and an animal model for an old disease. J. Investig. Med. 43: 323-336 (1995).

• Dastani Z, Engert JC, Genest J, Marcil M. Genetics of high-density lipoproteins. Curr. Opin. Cardiol. 21: 329-335 (2006).

• Davis HR Jr, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 like 1 (NPC1L1). Atheroscler. Suppl. 9: 77-81 (2008).

• Davis RA, Attie AD. Deletion of the ileal basolateral bile acid transporter identifies the cellular sentinels that regulate the bile acid pool. Proc. Natl. Acad. Sci. U.S.A. 105: 4965-4966 (2008). *

• Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4: 1 (2009). *

• Dawson PA. Molecular pathways for intestinal bile acid transport. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 53. June 18-19 (2004). *

• Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278: 33920-33927 (2003). *

• Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, Ballatori N. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J. Biol. Chem. 280: 6960-6968 (2005). *

• Dawson PA, Rao A, Craddock AL, Haywood J. Analysis of the molecular mechanisms responsible for intestinal basolateral bile acid transport. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 43 (2006). *

• de Rooij FW, van den Berg JW, Sinaasappel M, Bosman-Jacobs EP, Touw-Blommesteijn AC. Bile acid malabsorption in cystic fibrosis; membrane vesicles, a tool for revealing the role of the ileal brush border membrane. Acta Paediatr. Scand. Suppl. 317: 28-30 (1985).

• de Waart DR, Paulusma CC, Kunne C, Oude Elferink RP. Multidrug resistance associated protein 2 mediates transport of prostaglandin E. Liver Int. 26: 362-368 (2006). *

• Dean M. The genetics of ATP-binding cassette transporters. Methods Enzymol. 400: 409-429 (2005).

• Dean M, Allikmets R. Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr. 33: 475-479 (2001). *

• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42: 1007-1017 (2001). *

• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11: 1156-1166 (2001). *

• Dekaney CM, von Allmen DC, Garrison AP, Rigby RJ, Lund PK, Henning SJ, Helmrath MA. Bacterial-dependent up-regulation of intestinal bile acid binding protein and transport is FXR-mediated following ileo-cecal resection. Surgery 144: 174-181 (2008).

• Delerive P, Galardi CM, Bisi JE, Nicodeme E, Goodwin B. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18: 2378-2387 (2004). *

• Demeilliers C, Jacquemin E, Barbu V, Mergey M, Paye F, Fouassier L, Chignard N, Housset C, Lomri NE. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Hepatology 43: 1125-1134 (2006). *

• Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc. Drug Rev. 25: 375-390 (2007).

• Denk GU, Soroka CJ, Mennone A, Koepsell H, Beuers U, Boyer JL. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology 39: 1382-1389 (2004). *

• Denson LA, Auld KL, Schiek DS, McClure MH, Mangelsdorf DJ, Karpen SJ. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J. Biol. Chem. 275: 8835-8843 (2000). *

• Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121: 140-147 (2001). *

• Diaz GJ. Basolateral and canalicular transport of xenobiotics in the hepatocyte: a review. Cytotechnology 34: 225-235 (2000). *

• Diczfalusy U. Analysis of cholesterol oxidation products in biological samples. J. AOAC Int. 87: 467-473 (2004).

• Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788-1795 (2003). *

• Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RP, Matern S, Gartung C. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology 126: 1044-1053 (2004). *

• Dietrich CG, Geier A, Wasmuth HE, Matern S, Gartung C, de Waart DR, Elferink RP. Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen. Gut 53: 1850-1855 (2004). *

• Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 167: 73-81 (2001). *

• Dirusso CC, Darwis D, Obermeyer T, Black PN. Functional domains of the fatty acid transport proteins: studies using protein chimeras. Biochim. Biophys. Acta 1781: 135-143 (2008). *

• Dixon PH, van Mil S, Chambers J, Strautnieks S, Thompson R, Lammert F, Kubitz R, Keitel V, Glantz A, Mattsson LA, Marschall HU, Molokhia M, Moore G, Linton K, Williamson C. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 58: 537-544 (2009).

• Doctor RB, Johnson S, Brodsky KS, Amura CR, Gattone V, Fitz JG. Regulated ion transport in mouse liver cyst epithelial cells. Biochim. Biophys. Acta 1772: 345-354 (2007). *

• Doggrell SA. New targets in and potential treatments for cholesterol gallstone disease. Curr. Opin. Investig. Drugs 7: 344-348 (2006).

• Doherty MM, Poon K, Tsang C, Pang KS. Transport is not rate-limiting in morphine glucuronidation in the single pass perfused rat liver preparation. J. Pharmacol. Exp. Ther. 317: 890-900 (2006). *

• Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab. Invest. 86: 166-174 (2006). *

• Dongowski G, Fritzsch B, Giessler J, Hartl A, Kuhlmann O, Neubert RH. The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. Eur. J. Pharm. Biopharm. 60: 147-151 (2005). *

• Donner MG, Schumacher S, Warskulat U, Heinemann J, Haussinger D. Obstructive cholestasis induces TNF-alpha- and IL-1beta-mediated periportal down-regulation of Bsep and zonal regulation of Ntcp, Oatp1a4 and Oatp1b2. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1134-G1146 (2007). *

• Douglas JG, Beckett GJ, Percy-Robb IW, Finlayson ND. Bile salt transport in the Dubin-Johnson syndrome. Gut 21: 890-893 (1980). *

• Dranoff JA, McClure M, Burgstahler AD, Denson LA, Crawford AR, Crawford JM, Karpen SJ, Nathanson MH. Short-term regulation of bile acid uptake by microfilament-dependent translocation of rat ntcp to the plasma membrane. Hepatology 30: 223-229 (1999). *

• Dransfeld O, Gehrmann T, Kohrer K, Kircheis G, Holneicher C, Haussinger D, Wettstein M. Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int. 25: 1243-1258 (2005). *

• Dray-Charier N, Paul A, Veissiere D, Mergey M, Scoazec JY, Capeau J, Brahimi-Horn C, Housset C. Expression of cystic fibrosis transmembrane conductance regulator in human gallbladder epithelial cells. Lab. Invest. 73: 828-836 (1995).

• Duane WC, Hartich LA, Bartman AE, Ho SB. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J. Lipid Res. 41: 1384-1389 (2000). *

• Duane WC, Xiong W, Lofgren J. Transactivation of the human apical sodium-dependent bile acid transporter gene by human serum. J. Steroid Biochem. Mol. Biol. 108: 137-148 (2008).

• Duane WC, Xiong W, Wolvers J. Effects of bile acids on expression of the human apical sodium dependent bile acid transporter gene. Biochim. Biophys. Acta 1771: 1380-1388 (2007). *

• Dubrac S, Lear SR, Ananthanarayanan M, Balasubramaniyan N, Bollineni J, Shefer S, Hyogo H, Cohen DE, Blanche PJ, Krauss RM, Batta AK, Salen G, Suchy FJ, Maeda N, Erickson SK. Role of CYP27A in cholesterol and bile acid metabolism. J. Lipid Res. 46: 76-85 (2005). *

• Duch BU, Andersen H, Gregersen H. Mechanical properties of the porcine bile duct wall. Biomed. Eng. Online 3: 23 (2004). *

• Dumont M, Jacquemin E, D'Hont C, Descout C, Cresteil D, Haouzi D, Desrochers M, Stieger B, Hadchouel M, Erlinger S. Expression of the liver Na+-independent organic anion transporting polypeptide (oatp-1) in rats with bile duct ligation. J. Hepatol. 27: 1051-1056 (1997). *

• Dutta AK, Woo K, Doctor RB, Fitz JG, Feranchak AP. Extracellular nucleotides stimulate Cl- currents in biliary epithelia through receptor-mediated IP3 and Ca2+ release. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G1004-G1015 (2008). *

• Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS, Bernstein H. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol. 104: 302-309 (2009).

• Echchgadda I, Song CS, Oh T, Ahmed M, De La Cruz IJ, Chatterjee B. The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase. Mol. Endocrinol. 21: 2099-2111 (2007). *

• Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43: 2-12 (2002). *

• Elam MB, Cowan GS Jr, Rooney RJ, Hiler ML, Yellaturu CR, Deng X, Howell GE, Park EA, Gerling IC, Patel D, Corton JC, Cagen LM, Wilcox HG, Gandhi M, Bahr MH, Allan MC, Wodi LA, Cook GA, Hughes TA, Raghow R. Hepatic gene expression in morbidly obese women: implications for disease susceptibility. Obesity (Silver Spring) Mar 5 [Epub ahead of print] (2009). *

• Elamiri A, Perwaiz S, Tuchweber B, Yousef IM. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol. Res. 48: 467-472 (2003). *

• Elferink MG, Olinga P, Draaisma AL, Merema MT, Faber KN, Slooff MJ, Meijer DK, Groothuis GM. LPS-induced down-regulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G1008-G1016 (2004). *

• Elias E, Mills CO. Coordinated defence and the liver. Clin. Med. 7: 180-184 (2007).

• Eliseo T, Ragona L, Catalano M, Assfalg M, Paci M, Zetta L, Molinari H, Cicero DO. Structural and dynamic determinants of ligand binding in the ternary complex of chicken liver bile acid binding protein with two bile salts revealed by NMR. Biochemistry 46: 12557-12567 (2007). *

• Elkins CA, Savage DC. CbsT2 from Lactobacillus johnsonii 100-100 is a transport protein of the major facilitator superfamily that facilitates bile acid antiport. J. Mol. Microbiol. Biotechnol. 6: 76-87 (2004).

• Ellinger I, Fuchs R. Biliary secretion of fluid phase markers is modified under post-cholestatic conditions. Wien. Med. Wochenschr. 158: 579-582 (2008). *

• Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433: 397-412 (2005). *

• Eloranta JJ, Kullak-Ublick GA. The role of FXR in disorders of bile acid homeostasis. Physiology (Bethesda) 23: 286-295 (2008).

• Eloranta JJ, Meier PJ, Kullak-Ublick GA. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol. 400: 511-530 (2005).

• Erickson RP, Bhattacharyya A, Hunter RJ, Heidenreich RA, Cherrington NJ. Liver disease with altered bile acid transport in Niemann-Pick C mice on a high fat, 1% cholesterol diet. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G300-G307 (2005). *

• Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009 (2003). *

• Erlejman AG, Fraga CG, Oteiza PI. Procyanidins protect Caco-2 cells from bile acid- and oxidant-induced damage. Free Radic. Biol. Med. 41: 1247-1256 (2006).

• Erlinger S. Cystic fibrosis: bile secretion. Br. Med. Bull. 48: 860-876 (1992).

• Erlinger S. Mechanisms of hepatic transport and bile secretion. Acta Gastroenterol. Belg. 59: 159-162 (1996).

• Erlinger S. Formation of the bile. Rev. Prat. 41: 2341-2346 (1991).

• Erlinger S. Role of intracellular organelles in the hepatic transport of bile acids. Biomed. Pharmacother. 44: 409-416 (1990).

• Erlinger S. Drug-induced cholestasis. J. Hepatol. 26 Suppl. 1: 1-4 (1997).

• Erlinger S. Review article: new insights into the mechanisms of hepatic transport and bile secretion. J. Gastroenterol. Hepatol. 11: 575-579 (1996).

• Esteller A. Physiology of bile secretion. World J. Gastroenterol. 14: 5641-5649 (2008). *

• Ewerth S. On the enterohepatic circulation of bile acids in man. Acta Chir. Scand. Suppl. 513: 1-38 (1982).

• Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55: 107-124 (2003). *

• Fagan EA. Intrahepatic cholestasis of pregnancy. Clin. Liver Dis. 3: 603-632 (1999).

• Fagerholm U. Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J. Pharm. Pharmacol. 60: 535-542 (2008).

• Fang C, Dean J, Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 67: 9039-9046 (2007). *

• Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V. Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology 167: 37-46 (2001). *

• Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32: 82-86 (2000). *

• Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69: 223-231 (2001). *

• Fausther M, Lecka J, Kukulski F, Levesque SA, Pelletier J, Zimmermann H, Dranoff JA, Sevigny J. Cloning, purification and identification of the liver canalicular ecto-ATPase as NTPDase8. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G785-G795 (2007). *

• Fava G, Marzioni M, Francis H, Glaser S, Demorrrow S, Ueno Y, Benedetti A, Alpini G. Novel interaction of bile acid and neural signaling in the regulation of cholangiocyte function. Hepatol. Res. 37 Suppl. 3: S420-S429 (2007). *

• Fayard E, Schoonjans K, Auwerx J. Xol INXS: role of the liver X and the farnesol X receptors. Curr. Opin. Lipidol. 12: 113-120 (2001).

• Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant. Proc. 38: 801-802 (2006). *

• Faybik P, Krenn CG, Baker A, Lahner D, Berlakovich G, Steltzer H, Hetz H. Comparison of invasive and noninvasive measurement of plasma disappearance rate of indocyanine green in patients undergoing liver transplantation: a prospective investigator-blinded study. Liver Transpl. 10: 1060-1064 (2004). *

• Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF. Role of hepatic transporters in the disposition and hepatotoxicity of a Her2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108: 492-500 (2009). *

• Feranchak AP, Fitz JG. Adenosine triphosphate release and purinergic regulation of cholangiocyte transport. Semin. Liver Dis. 22: 251-262 (2002).

• Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin. Liver Dis. 21: 471-488 (2001).

• Ferenci P, Zollner G, Trauner M. Hepatic transport systems. J. Gastroenterol. Hepatol. 17: S105-S112 (2002). *

• Fernandes CF, Godoy JR, Doring B, Cavalcanti MC, Bergmann M, Petzinger E, Geyer J. The novel putative bile acid transporter SLC10A5 is highly expressed in liver and kidney. Biochem. Biophys. Res. Commun. 361: 26-32 (2007). *

• Fernandez E, Galan AI, Moran D, Gonzalez-Buitrago JM, Munoz ME, Jimenez R. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. J. Pharmacol. Exp. Ther. 275: 442-449 (1995).

• Fernandez-Veledo S, Huber-Ruano I, Aymerich I, Duflot S, Casado FJ, Pastor-Anglada M. Bile acids alter the subcellular localization of CNT2 and increase CNT2-related transport activity in liver parenchymal cells. Biochem. J. 395: 337-344 (2006). *

• Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am. J. Pathol. 168: 410-422 (2006). *

• Fickert P, Stoger U, Fuchsbichler A, Moustafa T, Marschall HU, Weiglein AH, Tsybrovskyy O, Jaeschke H, Zatloukal K, Denk H, Trauner M. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am. J. Pathol. 171: 525-536 (2007). *

• Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481 (2006). *

• Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121: 170-183 (2001). *

• Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R, Shneider BL, Chen F, Stoltenberg E, Spatz K, Hoda F, Cohen DE, Green RM. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis. J. Biol. Chem. 279: 2790-2799 (2004). *

• Figge A, Matern S, Lammert F. Molecular genetics of cholesterol cholelithiasis: identification of human and murine gallstone genes. Z. Gastroenterol. 40: 425-432 (2002).

• Fiorucci S, Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25: 252-259 (2009).

• Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour B, Sabatino G, Russo G, Castellani D, Willson TM, Pellicciari R, Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor (FXR) ligand, in estrogen induced cholestasis. J. Pharmacol. Exp. Ther. 313: 604-612 (2005). *

• Fitz JG. Regulation of cholangiocyte secretion. Semin. Liver Dis. 22: 241-249 (2002).

• Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J. Mol. Med. 80: 271-281 (2002). *

• Fletcher N, Wahlstrom D, Lundberg R, Nilsson CB, Nilsson KC, Stockling K, Hellmold H, Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 207: 1-24 (2005). *

• Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Mazzella G. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment. Pharmacol. Ther. 23: 1649-1653 (2006). *

• Fouassier L, Beaussier M, Schiffer E, Rey C, Barbu V, Mergey M, Wendum D, Callard P, Scoazec JY, Lasnier E, Stieger B, Lienhart A, Housset C. Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G25-G35 (2007). *

• Frank C, Makkonen H, Dunlop TW, Matilainen M, Vaisanen S, Carlberg C. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol. 346: 505-519 (2005). *

• Frankenberg T, Miloh T, Chen FY, Ananthanarayanan M, Sun AQ, Balasubramaniyan N, Arias I, Setchell KD, Suchy FJ, Shneider BL. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48: 1896-1905 (2008). *

• Frederiks WM, Van Noorden CJ, Aronson DC, Marx F, Bosch KS, Jonges GN, Vogels IM, James J. Quantitative changes in acid phosphatase, alkaline phosphatase and 5'-nucleotidase activity in rat liver after experimentally induced cholestasis. Liver 10: 158-166 (1990).

• Frei P, Gao B, Hagenbuch B, Mate A, Biber J, Murer H, Meier PJ, Stieger B. Identification and localization of sodium/phosphate cotransporters in hepatocytes and cholangiocytes of rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G771-G778 (2005). *

• Fukumoto Y, Okita K, Kodama T, Noda K, Harada T, Mizuta M, Takemoto T. Studies of alpha-napthylisothiocyanate-induced hepatic disturbance. Hepatogastroenterology 27: 457-464 (1980).

• Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59: 627-635 (2001). *

• Galan AI, Jimenez R, Munoz ME, Gonzalez J. Effects of ursodeoxycholate on maximal biliary secretion of bilirubin in the rat. Biochem. Pharmacol. 39: 1175-1180 (1990).

• Galan AI, Munoz ME, Jimenez R. S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. J. Pharmacol. Exp. Ther. 290: 774-781 (1999). *

• Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig. Dis. Sci. 25: 108-112 (1980).

• Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267 (2003). *

• Gao B, St Pierre MV, Stieger B, Meier PJ. Differential expression of bile salt and organic anion transporters in developing rat liver. J. Hepatol. 41: 201-208 (2004). *

• Garner CE, Solon E, Lai CM, Lin J, Luo G, Jones K, Gan LS, Qian M, Prakash SR, Decicco CP, Duan J, Maduskuie T, Mercer S, Shen HS, Lee FW. Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in rodents. Drug Metab. Dispos. 36: 1102-1110 (2008). *

• Gartner U, Goeser T, Stiehl A, Raedsch R, Wolkoff AW. Transport of chenodeoxycholic acid and its 3-alpha- and 7-alpha-sulfates by isolated perfused rat liver. Hepatology 12: 738-742 (1990).

• Gartung C, Ananthanarayanan M, Rahman MA, Schuele S, Nundy S, Soroka CJ, Stolz A, Suchy FJ, Boyer JL. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 110: 199-209 (1996). *

• Gartung C, Matern S. Molecular regulation of sinusoidal liver bile acid transporters during cholestasis. Yale J. Biol. Med. 70: 355-363 (1997).

• Gatmaitan ZC, Nies AT, Arias IM. Regulation and translocation of ATP-dependent apical membrane proteins in rat liver. Am. J. Physiol. 272: G1041-G1049 (1997).

• Gautier T, Tietge UJ, Boverhof R, Perton FG, Le Guern N, Masson D, Rensen PC, Havekes LM, Lagrost L, Kuipers F. Hepatic lipid accumulation in apolipoprotein CI-deficient mice is potentiated by cholesteryl ester transfer protein. J. Lipid Res. 48: 30-40 (2007). *

• Geier A, Dietrich CG, Gerloff T, Haendly J, Kullak-Ublick GA, Stieger B, Meier PJ, Matern S, Gartung C. Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim. Biophys. Acta 1609: 87-94 (2003). *

• Geier A, Dietrich CG, Grote T, Beuers U, Prufer T, Fraunberger P, Matern S, Gartung C, Gerbes AL, Bilzer M. Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J. Hepatol. 43: 1021-1030 (2005). *

• Geier A, Dietrich CG, Trauner M, Gartung C. Extrahepatic cholestasis downregulates Oatp1 by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver. Liver Int. 27: 1056-1065 (2007). *

• Geier A, Gartung C, Dietrich CG, Lammert F, Wasmuth HE, Matern S. Diagnosis of cholestatic disorders. Med. Klin. (Munich) 98: 499-509 (2003).

• Geier A, Gartung C, Matern S. Regulation of hepatobiliary transporters in cholestatic liver disease. Med. Klin. (Munich) 99: 7-17 (2004).

• Geier A, Kim SK, Gerloff T, Dietrich CG, Lammert F, Karpen SJ, Stieger B, Meier PJ, Matern S, Gartung C. Hepatobiliary organic anion transporters are differentially regulated in acute toxic liver injury induced by carbon tetrachloride. J. Hepatol. 37: 198-205 (2002). *

• Geier A, Martin IV, Dietrich CG, Balasubramaniyan N, Strauch S, Suchy FJ, Gartung C, Trautwein C, Ananthanarayanan M. Hepatocyte nuclear factor 4alpha is a central transactivator of the mouse Ntcp gene. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G226-G233 (2008). *

• Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773: 283-308 (2007). *

• Geier A, Zollner G, Dietrich CG, Wagner M, Fickert P, Denk H, van Rooijen N, Matern S, Gartung C, Trauner M. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Hepatology 41: 470-477 (2005). *

• Gerk PM, Li W, Megaraj V, Vore M. Human multidrug resistance protein 2 (MRP2/ABCC2) transports the therapeutic bile salt tauroursodeoxycholate. J. Pharmacol. Exp. Ther. 320: 893-899 (2007). *

• Gerk PM, Vore M. The ileocyte basolateral organic solute transporter (OSTalpha-OSTbeta) complex: finding the missing link in enterohepatic circulation. Mol. Interv. 5: 8-10 (2005). *

• Gerloff T, Geier A, Stieger B, Hagenbuch B, Meier PJ, Matern S, Gartung C. Differential expression of basolateral and canalicular organic anion transporters during regeneration of rat liver. Gastroenterology 117: 1408-1415 (1999). *

• Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273: 10046-10050 (1998). *

• Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, de Jong KP, Peeters PM, Jansen PL, Slooff MJ, Gouw AS, Porte RJ. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J. Hepatol. 41: 1017-1025 (2004). *

• Geuken E, Visser DS, Leuvenink HG, de Jong KP, Peeters PM, Slooff MJ, Kuipers F, Porte RJ. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. Hepatology 42: 1166-1174 (2005). *

• Geyer J, Fernandes CF, Doring B, Burger S, Godoy JR, Rafalzik S, Hubschle T, Gerstberger R, Petzinger E. Cloning and molecular characterization of the orphan carrier protein Slc10a4: expression in cholinergic neurons of the rat central nervous system. Neuroscience 152: 990-1005 (2008).

• Geyer J, Godoy JR, Petzinger E. Identification of a sodium-dependent organic anion transporter from rat adrenal gland. Biochem. Biophys. Res. Commun. 316: 300-306 (2004). *

• Geyer J, Wilke T, Petzinger E. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn. Schmiedebergs. Arch. Pharmacol. 372: 413-431 (2006). *

• Ghibellini G, Leslie EM, Brouwer KL. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol. Pharm. 3: 198-211 (2006). *

• Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of Tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm. Res. 25: 1851-1860 (2008). *

• Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Integration of nuclear receptors and cell signaling pathways on bile acid physiology. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 44. June 18-19 (2004). *

• Ghose R, Mulder J, von Furstenberg RJ, Thevananther S, Kuipers F, Karpen SJ. Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J. Hepatol. 46: 115-123 (2007). *

• Gimeno RE. Fatty acid transport proteins. Curr. Opin. Lipidol. 18: 271-276 (2007).

• Godoy JR, Fernandes C, Doring B, Beuerlein K, Petzinger E, Geyer J. Molecular and phylogenetic characterization of a novel putative membrane transporter (SLC10A7), conserved in vertebrates and bacteria. Eur. J. Cell Biol. 86: 445-460 (2007).

• Goldiner I, van der Velde AE, Vandenberghe KE, van Wijland MA, Halpern Z, Gilat T, Konikoff FM, Veldman RJ, Groen AK. ABCA1-dependent but ApoA-I-independent cholesterol efflux mediated by fatty acid-bile acid conjugates (FABACs). Biochem. J. 396: 529-536 (2006). *

• Goldsmith MA, Huling S, Jones AL. Hepatic handling of bile salts and protein in the rat during intrahepatic cholestasis. Gastroenterology 84: 978-986 (1983).

• Gonzalez MA, Alvarez Mdel L, Pisani GB, Bernal CA, Roma MG, Carrillo MC. Involvement of oxidative stress in the impairment in biliary secretory function induced by intraperitoneal administration of aluminum to rats. Biol. Trace Elem. Res. 116: 329-348 (2007).

• Gonzalez MA, Bernal CA, Mahieu S, Carrillo MC. The interactions between the chronic exposure to aluminum and liver regeneration on bile flow and organic anion transport in rats. Biol. Trace Elem. Res. 127: 164-176 (2009).

• Gonzalez MA, Roma MG, Bernal CA, Alvarez Mde L, Carrillo MC. Biliary secretory function in rats chronically intoxicated with aluminum. Toxicol. Sci. 79: 189-195 (2004). *

• Gonzalez PM, Polli JE. Impact of impurity on kinetic estimates from transport and inhibition studies. J. Pharmacol. Exp. Ther. 326: 296-305 (2008).

• Goodwin B, Kliewer SA. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G926-G931 (2002). *

• Gorelik J, Patel P, Ng'andwe C, Vodyanoy I, Diakonov I, Lab M, Korchev Y, Williamson C. Genes encoding bile acid, phospholipid and anion transporters are expressed in a human fetal cardiomyocyte culture. BJOG 113: 552-558 (2006). *

• Goss JA, Barshes NR, Karpen SJ, Gao FQ, Wyllie S. Liver ischemia and ischemia-reperfusion induces and trafficks the multi-specific metal transporter Atp7b to bile duct canaliculi: possible preferential transport of iron into bile. Biol. Trace Elem. Res. 122: 26-41 (2007). *

• Gotthardt D, Runz H, Keitel V, Fischer C, Flechtenmacher C, Wirtenberger M, Weiss KH, Imparato S, Braun A, Hemminki K, Stremmel W, Ruschendorf F, Stiehl A, Kubitz R, Burwinkel B, Schirmacher P, Knisely AS, Zschocke J, Sauer P. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 48: 1157-1166 (2008).

• Govindarajan R, Endres CJ, Whittington D, Lecluyse E, Pastor-Anglada M, Tse CM, Unadkat JD. Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G570-G580 (2008). *

• Gradilone SA, Tietz PS, Splinter PL, Marinelli RA, LaRusso NF. Expression and subcellular localization of aquaporin water channels in the polarized hepatocyte cell line, WIF-B. BMC Physiol. 5: 13 (2005). *

• Green RM, Hoda F, Ward KL. Molecular cloning and characterization of the murine bile salt export pump. Gene 241: 117-123 (2000). *

• Groen A, Kunne C, Oude Elferink RP. Increased serum concentrations of secondary bile salts during cholate feeding are due to coprophagy. A study with wild-type and Atp8b1-deficient mice. Mol. Pharm. 3: 756-761 (2006). *

• Groen A, Kunne C, Paulusma CC, Kramer W, Agellon LB, Bull LN, Oude Elferink RP. Intestinal bile salt absorption in Atp8b1 deficient mice. J. Hepatol. 47: 114-122 (2007). *

• Groen AK, Kosters A, Kunne C, Oude Elferink RPJ. The molecular mechanism of biliary lipid secretion - influence of bile salt hydrophilicity and role of Abcg5 and Abcg8. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 50. June 18-19 (2004). *

• Groen AK, Oude Elferink RP. Lipid transport into bile and role in bile formation. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 131-135 (2005).

• Groen AK, Oude Elferink RP, Tager JM. Control analysis of biliary lipid secretion. J. Theor. Biol. 182: 427-436 (1996). *

• Groen AK, Oude Elferink RP, Verkade HJ, Kuipers F. The ins and outs of reverse cholesterol transport. Ann. Med. 36: 135-145 (2004).

• Grunhage F, Jungck M, Lamberti C, Keppeler H, Becker U, Schulte-Witte H, Plassmann D, Friedrichs N, Buettner R, Aretz S, Sauerbruch T, Lammert F. Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on the development of sporadic and familial colorectal cancer: a case control study. BMC Med. Genet. 9: 70 (2008). *

• Grunhage F, Lammert F. Pathogenesis of gallstones: a genetic perspective. Best Pract. Res. Clin. Gastroenterol. 20: 997-1015 (2006).

• Guariento M, Raimondo D, Assfalg M, Zanzoni S, Pesente P, Ragona L, Tramontano A, Molinari H. Identification and functional characterization of the bile acid transport proteins in non-mammalian ileum and mammalian liver. Proteins 70: 462-472 (2008).

• Gundala S, Wells LD, Milliano MT, Talkad V, Luxon BA, Neuschwander-Tetri BA. The hepatocellular bile acid transporter Ntcp facilitates uptake of the lethal mushroom toxin alpha-amanitin. Arch. Toxicol. 78: 68-73 (2004). *

• Hagenbuch B. Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Pract. Res. Clin. Endocrinol. Metab. 21: 209-221 (2007).

• Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch. 447: 566-570 (2004). *

• Hagenbuch B, Meier PJ. Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin. Liver Dis. 16: 129-136 (1996).

• Hagenbuch B, Scharschmidt BF, Meier PJ. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in Xenopus laevis oocytes. Biochem. J. 316: 901-904 (1996). *

• Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J. Hepatol. 34: 881-887 (2001). *

• Haikal Z, Play B, Landrier JF, Giraud A, Ghiringhelli O, Lairon D, Jourdheuil-Rahmani D. NPC1L1 and SR-BI are involved in intestinal cholesterol absorption from small-size lipid donors. Lipids 43: 401-408 (2008).

• Haisa M, Matsumoto T, Komatsu T, Mariyama Y. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am. J. Physiol. Cell Physiol. 291: C678-C686 (2006). *

• Halilbasic E, Fickert P, Foirotto R , Marschall HU, Moustafa T, Fuchsbichler A, Gumhold J, Silbert D, Langner C, Maitra U, Denk H , Strazzabosco M, Trauner M. Side-chain-modification critically determines the physiologic and therapeutic properties of 24-nor-ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice and isolated bile duct units. Falk Symposium 165: XX International Bile Acid Meeting. Bile Acid Biology and Therapeutic Actions. June 13-14, 2008, Amsterdam, Netherlands, p. 55 (2008). *

• Halilbasic E, Fickert P, Fuchbichler A , Langner C, Gumhold J, Silbert D, Maitra U, Zatloukal K, Denk H, Trauner M. Taurine-conjugation critically determines the therapeutic effectiveness of 24-nor-ursodeoxycholic acid (norUDCA) in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. J. Hepatol. 46: S51 (2007). *

• Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology 49: 1972-1981 (2009). *

• Hall EA, Ren S, Hylemon PB, Redford K, del Castillo A, Gil G, Pandak WM. Mitochondrial cholesterol transport: a possible target in the management of hyperlipidemia. Lipids 40: 1237-1244 (2005).

• Hall EA, Ren S, Hylemon PB, Rodriguez-Agudo D, Redford K, Marques D, Kang D, Gil G, Pandak WM. Detection of the steroidogenic acute regulatory protein, StAR, in human liver cells. Biochim. Biophys. Acta 1733: 111-119 (2005). *

• Halpern MD, Dvorak B. Does abnormal bile acid metabolism contribute to NEC? Semin. Perinatol. 32: 114-121 (2008). *

• Halpern MD, Holubec H, Saunders TA, Dvorak K, Clark JA, Doelle SM, Ballatori N, Dvorak B. Bile acids induce ileal damage during experimental necrotizing enterocolitis. Gastroenterology 130: 359-372 (2006). *

• Hannivoort RA, Dunning S, Vander Borght S, Schroyen B, Woudenberg J, Oakley F, Buist-Homan M, van den Heuvel FA, Geuken M, Geerts A, Roskams T, Faber KN, Moshage H. Multidrug resistance-associated proteins are crucial for the viability of activated rat hepatic stellate cells. Hepatology 48: 624-634 (2008). *

• Harada LM, Amigo L, Cazita PM, Salerno AG, Rigotti AA, Quintao EC, Oliveira HC. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 191: 313-318 (2007).

• Hardcastle J, Hardcastle PT, Chapman J, Taylor CJ. Ursodeoxycholic acid action on the transport function of the small intestine in normal and cystic fibrosis mice. J. Pharm. Pharmacol. 53: 1457-1467 (2001). *

• Hardcastle J, Harwood MD, Taylor CJ. Absorption of taurocholic acid by the ileum of normal and transgenic DeltaF508 cystic fibrosis mice. J. Pharm. Pharmacol. 56: 445-452 (2004).

• Hardison WG, Hatoff DE, Miyai K, Weiner RG. Nature of bile acid maximum secretory rate in the rat. Am. J. Physiol. 241: G337-G343 (1981).

• Harris MJ, Kagawa T, Dawson PA, Arias IM. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells. J. Gastroenterol. Hepatol. 19: 819-825 (2004). *

• Harris MJ, LE Couteur DG, Arias IM. Progressive familial intrahepatic cholestasis: genetic disorders of biliary transporters. J. Gastroenterol. Hepatol. 20: 807-817 (2005). *

• Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303: 273-281 (2002). *

• Hashimoto W, Sudo R, Fukasawa K, Ikeda M, Mitaka T, Tanishita K. Ductular network formation by rat biliary epithelial cells in the dynamical culture with collagen gel and dimethylsulfoxide stimulation. Am. J. Pathol. 173: 494-506 (2008). *

• Hayashi H, Sugiyama Y. 4-Phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 45: 1506-1516 (2007). *

• Hayashi H, Takada T, Suzuki H, Akita H, Sugiyama Y. Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11. Hepatology 41: 916-924 (2005). *

• Hayashi H, Takada T, Suzuki H, Onuki R, Hofmann AF, Sugiyama Y. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. Biochim. Biophys. Acta 1738: 54-62 (2005). *

• Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21: 1393-1403 (2001). *

• He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98: 192-199 (2006). *

• Heathcote J, Wanless IR. Hepatotoxicity: newer aspects of pathogenesis and treatment. Gastroenterologist 3: 119-129 (1995).

• Heemskerk S, van Koppen A, van den Broek L, Poelen GJ, Wouterse AC, Dijkman HB, Russel FG, Masereeuw R. Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers Arch. 454: 321-334 (2007). *

• Hendrikse NH, Kuipers F, Meijer C, Havinga R, Bijleveld CM, Van Der Graaf WT, Vaalburg W, De Vries EG. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother. Pharmacol. 54: 131-138 (2004). *

• Hernandez S, Tsuchiya Y, Garcia-Ruiz JP, Lalioti V, Nielsen S, Cassio D, Sandoval IV. ATP7B copper-regulated traffic and association with the tight junctions: copper excretion into the bile. Gastroenterology 134: 1215-1223 (2008). *

• Herraez E, Macias RI, Vazquez-Tato J, Hierro C, Monte MJ, Marin JJ. Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicol. Appl. Pharmacol. Apr 28 [Epub ahead of print] (2009). *

• Heynekamp JJ, Hunsaker LA, Vander Jagt TA, Royer RE, Deck LM, Vander Jagt DL. Isocoumarin-based inhibitors of pancreatic cholesterol esterase. Bioorg. Med. Chem. 16: 5285-5294 (2008). *

• Hierro L, Jara P. Childhood cholestasis and bile transporters. Gastroenterol. Hepatol. 28: 388-395 (2005).

• Hillaire S, Ballet F, Franco D, Setchell KD, Poupon R. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture. Hepatology 22: 82-87 (1995).

• Hirano H, Kurata A, Onishi Y, Sakurai A, Saito H, Nakagawa H, Nagakura M, Tarui S, Kanamori Y, Kitajima M, Ishikawa T. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol. Pharm. 3: 252-265 (2006). *

• Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a non-bile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314: 876-882 (2005). *

• Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. 68: 800-807 (2005). *

• Hirata K, Nathanson MH. Bile duct epithelia regulate biliary bicarbonate excretion in normal rat liver. Gastroenterology 121: 396-406 (2001). *

• Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem. 275: 2905-2910 (2000). *

• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78: 260-277 (2005). *

• Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806 (2006). *

• Hobbs HH, Cohen JC. ABCG5 and ABCG8 play major role in defense against sterol accumulation. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 55. June 18-19 (2004). *

• Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 80: 36-39 (2009).

• Hoda F, Green RM. Hepatic canalicular membrane transport of bile salt in C57L/J and AKR/J mice: implications for cholesterol gallstone formation. J. Membr. Biol. 196: 9-14 (2003). *

• Hoeke MO, Plass JR, Heegsma J, Geuken M, van Rijsbergen D, Baller JF, Kuipers F, Moshage H, Jansen PL, Faber KN. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters. Hepatology 49: 151-159 (2009).

• Hoekstra H, Porte RJ, Tian Y, Jochum W, Stieger B, Moritz W, Slooff MJ, Graf R, Clavien PA. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice. Hepatology 43: 1022-1031 (2006). *

• Hoekstra H, Tian Y, Jochum W, Stieger B, Graf R, Porte RJ, Clavien PA. Dearterialization of the liver causes intrahepatic cholestasis due to reduced bile transporter expression. Transplantation 85: 1159-1166 (2008).

• Hoffmann U, Kroemer HK. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev. 36: 669-701 (2004). *

• Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. 311: 1203-1210 (2004). *

• Hofmann AF. Bile acid secretion, bile flow and biliary lipid secretion in humans. Hepatology 12: 17S-22S (1990).

• Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 49: 1403-1418 (2009). *

• Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159: 2647-2658 (1999). *

• Hofmann AF. Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol. 27: 106-113 (1995).

• Hofmann AF. Regulation of ileal bile acid transport: desirability of measuring transport function as well as transporter activity. Hepatology 29: 1335-1337 (1999). *

• Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand. J. Gastroenterol. Suppl. 204: 1-15 (1994).

• Hofmann AF. Progress in idiopathic bile acid malabsorption. Gut 43: 738-739 (1998). *

• Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14: 24-29 (1999). *

• Hofmann AF. Current concepts of biliary secretion. Dig. Dis. Sci. 34: 16S-20S (1989).

• Hofmann AF, Cravetto C, Molino G, Belforte G, Bona B. Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism. Gastroenterology 93: 693-709 (1987).

• Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65: 2461-2483 (2008). *

• Hofmann AF, Molino G, Milanese M, Belforte G. Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man. J. Clin. Invest. 71: 1003-1022 (1983). *

• Hofmann AF, Schteingart CD, Lillienau J. Biological and medical aspects of active ileal transport of bile acids. Ann. Med. 23: 169-175 (1991).

• Hojo M, Sano N, Takikawa H. Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats. J. Gastroenterol. Hepatol. 18: 815-821 (2003). *

• Holzer A, Harsch S, Renner O, Strohmeyer A, Schimmel S, Wehkamp J, Fritz P, Stange EF. Diminished expression of apical sodium-dependent bile acid transporter in gallstone disease is independent of ileal inflammation. Digestion 78: 52-59 (2008). *

• Holzinger F, Schteingart CD, Ton-Nu HT, Cerre C, Steinbach JH, Yeh HZ, Hofmann AF. Transport of fluorescent bile acids by the isolated perfused rat liver: kinetics, sequestration, and mobilization. Hepatology 28: 510-520 (1998). *

• Holzinger F, Schteingart CD, Ton-Nu HT, Eming SA, Monte MJ, Hagey LR, Hofmann AF. Fluorescent bile acid derivatives: relationship between chemical structure and hepatic and intestinal transport in the rat. Hepatology 26: 1263-1271 (1997). *

• Honda A, Salen G, Matsuzaki Y, Batta AK, Xu G, Hirayama T, Tint GS, Doy M, Shefer S. Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis. J. Lipid Res. 46: 287-296 (2005). *

• Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. Pharmacol. 143: 856-864 (2004). *

• Hooiveld GJ, van Montfoort JE, Meijer DK, Muller M. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. Eur. J. Pharm. Sci. 12: 525-543 (2001). *

• Hooiveld GJ, Vos TA, Scheffer GL, Van Goor H, Koning H, Bloks V, Loot AE, Meijer DK, Jansen PL, Kuipers F, Muller M. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117: 678-687 (1999). *

• Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab. Pharmacokinet. 18: 16-22 (2004). *

• Houten S, Auwerx J. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 36: 482-491 (2004).

• Hruz P, Zimmermann C, Gutmann H, Degen L, Beuers U, Terracciano L, Drewe J, Beglinger C. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 55: 395-402 (2006). *

• Hsu YC, Chen HL, Wu MZ, Liu YJ, Lee PH, Sheu JC, Chen CH. Adult progressive intrahepatic cholestasis associated with genetic variations in ATP8B1 and ABCB11. Hepatol. Res. 39: 625-631 (2009). *

• Huang L, Smit JW, Meijer DK, Vore M. Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology 32: 66-72 (2000). *

• Huang L, Wang Y, Grimm SW. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistant protein. Drug Metab. Dispos. 34: 738-742 (2006). *

• Huang YT, Hsu YC, Chen CJ, Liu CT, Wei YH. Oxidative-stress-related changes in the livers of bile-duct-ligated rats. J. Biomed. Sci. 10: 170-178 (2003). *

• Hubbard B, Doege H, Punreddy S, Wu H, Huang X, Kaushik VK, Mozell RL, Byrnes JJ, Stricker-Krongrad A, Chou CJ, Tartaglia LA, Lodish HF, Stahl A, Gimeno RE. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130: 1259-1269 (2006). *

• Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, Hollis GF, Young PR, Mukherjee R, Burn TC. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290: 35-43 (2002). *

• Hui DY, Howles PN. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin. Cell. Dev. Biol. 16: 183-192 (2005). *

• Hulzebos CV, Voshol PJ, Wolters H, Kruit JK, Ottenhof R, Groen AK, Stellaard F, Verkade HJ, Kuipers F. Bile duct proliferation associated with bile salt-induced hypercholeresis in Mdr2 P-glycoprotein-deficient mice. Liver Int. 25: 604-612 (2005). *

• Hulzebos CV, Wolters H, Plosch T, Kramer W, Stengelin S, Stellaard F, Sauer PJ, Verkade HJ, Kuipers F. Cyclosporin A and enterohepatic circulation of bile salts in rats: decreased cholate synthesis but increased intestinal reabsorption. J. Pharmacol. Exp. Ther. 304: 356-363 (2003). *

• Hussainzada N, Claro da Silva T, Zhang EY, Swaan PW. Conserved aspartic acid residues lining extracellular loop I of sodium-coupled bile acid transporter ASBT interact with Na+ and 7alpha -OH moieties on the ligand cholestane skeleton. J. Biol. Chem. 283: 20653-20663 (2008). *

• Hussainzada N, Khandewal A, Swaan PW. Conformational flexibility of helix VI is essential for substrate permeation of the human apical sodium-dependent bile acid transporter. Mol. Pharmacol. 73: 305-313 (2008). *

• Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J. Lipid Res. Apr 3 [Epub ahead of print] (2009). *

• Hyogo H, Tazuma S, Nishioka T, Ochi H, Yamaguchi A, Numata Y, Kanno K, Sakomoto M, Asamoto Y, Tsuboi K, Nakai K, Yasumiba S, Sunami Y, Kajiyama G. Phospholipid alterations in hepatocyte membranes and transporter protein changes in cholestatic rat model. Dig. Dis. Sci. 46: 2089-2097 (2001). *

• Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol. Res. 38: 123-131 (2008). *

• Ikegawa S, Ito H, Oshima M, Maeda M, Hofmann AF, Mitamura K. Chemical synthesis of bile acid acyl-adenylates and formation by a rat liver microsomal fraction. Steroids Apr 16 [Epub ahead of print] (2009).

• Ikegawa S, Yamamoto T, Ito H, Ishiwata S, Sakai T, Mitamura K, Maeda M. Identification of lithocholic acid-tagged proteins in the liver of bile duct-ligated rat by means of immunoaffinity capture and MALDI-TOFMS. J. Lipid Res. 49: 2463-2473 (2008). *

• Imamine T, Okuno M, Moriwaki H, Ninomiya M, Nishiwaki S, Noma A, Muto Y. Plasma retinol transport system and taste acuity in patients with obstructive jaundice. Gastroenterol. Jpn. 25: 206-211 (1990).

• Inokuchi A, Hinoshita E, Iwamoto Y, Kohno K, Kuwano M, Uchiumi T. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J. Biol. Chem. 276: 46822-46829 (2001). *

• Ismair MG, Hausler S, Stuermer CA, Guyot C, Meier PJ, Roth J, Stieger B. ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 49: 1673-1682 (2009).

• Ismair MG, Stanca C, Ha HR, Renner EL, Meier PJ, Kullak-Ublick GA. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol. Res. 26: 343-347 (2003).

• Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K. Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter. Drug Metab. Pharmacokinet. 18: 238-244 (2004). *

• Ito K, Hoekstra D, van Ijzendoorn SC. Cholesterol but not association with detergent resistant membranes is necessary for the transport function of MRP2/ABCC2. FEBS Lett. 582: 4153-4157 (2008). *

• Ito K, Koresawa T, Nakano K, Horie T. Mrp2 is involved in benzylpenicillin-induced choleresis. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G42-G49 (2004). *

• Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22: 1559-1577 (2005). *

• Iwakiri T, Okumura M, Matsunaga N, Ichihara E, Shiotsuki S, Nagata M, Kumagai Y, Kai H, Arimori K. Hepatocyte growth factor increases uptake of estradiol 17beta-d-glucuronide and Oatp1 protein level in rat hepatocytes. Eur. J. Pharmacol. 580: 19-26 (2008). *

• Iwanaga T, Nakakariya M, Yabuuchi H, Maeda T, Tamai I. Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis. Biol. Pharm. Bull. 30: 739-744 (2007). *

• Jacquemin E. Progressive familial intrahepatic cholestasis. J. Gastroenterol. Hepatol. 14: 594-599 (1999).

• Jansen PL. Endogenous bile acids as carcinogens. J. Hepatol. 47: 434-435 (2007). *

• Jansen PL. Genetics of cholestasis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 37-40 (2006). *

• Jansen PL. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 14: 571-583 (2000).

• Jansen PL. Foreword: from classic bile physiology to cloned transporters. Semin. Liver Dis. 20: 245-250 (2000).

• Jansen PL, Muller M. Genetic cholestasis: lessons from the molecular physiology of bile formation. Can. J. Gastroenterol. 14: 233-238 (2000).

• Jansen PL, Muller M, Kuipers F. Bile formation and cholestasis. Ned. Tijdschr. Geneeskd. 144: 2384-2391 (2000).

• Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *

• Janvilisri T, Shahi S, Venter H, Balakrishnan L, Van Veen HW. Arginine-482 is not essential for the transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem. J. 385: 419-426 (2005). *

• Javitt NB. 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J. Lipid Res. 43: 665-670 (2002). *

• Javitt NB. Diagnostic value of serum bile acids. Clin. Gastroenterol. 6: 219-226 (1977).

• Javitt NB. 26-Hydroxycholesterol: synthesis, metabolism, and biologic activities. J. Lipid Res. 31: 1527-1533 (1990). *

• Javitt NB. Cholesterol, hydroxycholesterols, and bile acids. Biochem. Biophys. Res. Commun. 292: 1147-1153 (2002). *

• Jessen N, Buhl ES, Schmitz O, Lund S. Impaired insulin action despite upregulation of proximal insulin signaling: novel insights into skeletal muscle insulin resistance in liver cirrhosis. J. Hepatol. 45: 797-804 (2006). *

• Jessner W, Zsembery A, Graf J. Transcellular water transport in hepatobiliary secretion and role of aquaporins in liver. Wien. Med. Wochenschr. 158: 565-569 (2008). *

• Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 34: 1756-1763 (2006). *

• Jin SY, Liu YL, Xu LN, Jiang Y, Wang Y, Yang BX, Yang H, Ma TH. Cloning and characterization of porcine aquaporin 1 water channel expressed extensively in gastrointestinal system. World J. Gastroenterol. 12: 1092-1097 (2006). *

• Jindal C, Kumar S, Choudhari G, Goel H, Mittal B. Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease. Indian J. Med. Res. 129: 170-175 (2009).

• Johnson BM, Zhang P, Schuetz JD, Brouwer KL. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab. Dispos. 34: 556-562 (2006). *

• Johnson DR, Habeebu SS, Klaassen CD. Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. Toxicol. Sci. 66: 16-26 (2002). *

• Jonas E, Slezak P, Miller N. Imaging-based dynamic liver testing - a computerized simulation. Hepatogastroenterology 47: 967-972 (2000).

• Jones AL, Huling S, Altorfer J. Synthesis and biliary secretion of immunoglobulins by rat liver. Immunol. Invest. 18: 299-312 (1989).

• Jonker JW, Stedman CA, Liddle C, Downes M. Hepatobiliary ABC transporters: physiology, regulation and implications for disease. Front. Biosci. 14: 4904-4920 (2009).

• Joseph B, Kapoor S, Schilsky ML, Gupta S. Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology 49: 1616-1624 (2009).

• Jung D, Elferink MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 27: 137-144 (2007). *

• Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 53: 78-84 (2004). *

• Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277: 30559-30566 (2002). *

• Jung D, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse and rat NTCP gene. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G752-G761 (2004). *

• Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J. Biol. Chem. 276: 37206-37214 (2001). *

• Jung D, Inagaki T, Dawson PA, Kliewer SA, Mangelsdorf DJ, Moschetta A. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48: 2693-2700 (2007). *

• Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37: 622-631 (2003). *

• Kadmon M, Klunemann C, Bohme M, Ishikawa T, Gorgas K, Otto G, Herfarth C, Keppler D. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 104: 1507-1514 (1993).

• Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, Tanaka H, Arias IM, Mine T. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G58-G67 (2008). *

• Kagawa T, Watanabe N, Sato M, Nakano A, Nishizaki Y, Hosoi K, Takashimizu S, Uchiyama J, Kimura M, Matsuzaki S. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats. Biochem. Mol. Biol. Int. 44: 443-452 (1998).

• Kahle KT, Gimenez I, Hassan H, Wilson FH, Wong RD, Forbush B, Aronson PS, Lifton RP. WNK4 regulates apical and basolateral Cl- flux in extrarenal epithelia. Proc. Natl. Acad. Sci. U.S.A. 101: 2064-2069 (2004). *

• Kakyo M, Unno M, Tokui T, Nakagomi R, Nishio T, Iwasashi H, Nakai D, Seki M, Suzuki M, Naitoh T, Matsuno S, Yawo H, Abe T. Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology 117: 770-775 (1999). *

• Kaler B, Karram T, Morgan WA, Bach PH, Yousef IM, Bomzon A. Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats. Ren. Fail. 26: 507-516 (2004).

• Kalia N, Hardcastle J, Grasa L, Keating C, Pelegrin P, Bardhan KD, Grundy D. Intestinal secretory and absorptive function in Trichinella spiralis mouse model of post-infective gut dysfunction: role of bile acids. Gut 57: 41-49 (2008).

• Kamath AV, Chong S, Chang M, Marathe PH. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother. Pharmacol. 55: 110-116 (2005). *

• Kamisako T, Gabazza EC, Ishihara T, Adachi Y. Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. J. Gastroenterol. Hepatol. 14: 405-412 (1999). *

• Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, Gabazza EC, Adachi Y. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J. Gastroenterol. 35: 659-664 (2000). *

• Kamisako T, Ogawa H. Alteration of the expression of adenosine triphosphate-binding cassette transporters associated with bile acid and cholesterol transport in the rat liver and intestine during cholestasis. J. Gastroenterol. Hepatol. 20: 1429-1434 (2005). *

• Kanai S, Sato Y, Kitani K. The effect of age on the biliary transport maximum (Tm) of bile salts in rats. Arch. Gerontol. Geriatr. 14: 101-115 (1992).

• Kanchanapoo J, Ao M, Prasad R, Moore C, Kay C, Piyachaturawat P, Rao MC. Role of protein kinase C-delta in the age-dependent secretagogue action of bile acids in mammalian colon. Am. J. Physiol. Cell Physiol. 293: C1851-C1861 (2007). *

• Kanchanapoo J, Rao MC, Sophasan S, Suksamrarn A, Piyachaturawat P. Inhibitory effects of choleretic hydroxyacetophenones on ileal bile acid transport in rats. Life Sci. 78: 1630-1636 (2006). *

• Kanno K, Tazuma S, Niida S, Chayama K. Unique reciprocal changes of hepatocellular membrane transporter expression and fluidity in rats with selective biliary obstruction. Hepatol. Res. 26: 157-163 (2003).

• Kaplowitz N. Hepatology highlights. Hepatology 39: 271-272 (2004). *

• Karlsen TH, Boberg KM, Schrumpf E. Role of polymorphisms in genes involved in bile acid detoxification pathways in primary sclerosing cholangitis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 87 (2006). *

• Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab. Dispos. 36: 1088-1096 (2008). *

• Kawabata Y, Kamada E, Furuta S, Takei M, Kurimoto T, Okudaira K, Nishigaki R. ATP-dependent transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) and its xenobiotic taurine conjugate (Z-335-Tau) by rat bile canalicular membrane vesicles. Pharm. Res. 21: 467-475 (2004). *

• Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 31: 1285-1295 (2000). *

• Keane MH, Overmars H, Wikander TM, Ferdinandusse S, Duran M, Wanders RJ, Faust PL. Bile acid treatment alters hepatic disease and bile acid transport in peroxisome-deficient PEX2 Zellweger mice. Hepatology 45: 982-997 (2007). *

• Keitel V, Burdelski M, Vojnisek Z, Schmitt L, Haussinger D, Kubitz R. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology [In Press] (2009).

• Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, Kubitz R. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41: 1160-1172 (2005). *

• Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology [In press] (2009).

• Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131: 624-629 (2006). *

• Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol. Sci. 83: 207-214 (2005). *

• Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol. 400: 531-542 (2005).

• Keppler D, Konig J. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 20: 265-272 (2000).

• Keppler D, Konig J. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 11: 509-516 (1997). *

• Keppler D, Konig J, Buchler M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv. Enzyme Regul. 37: 321-333 (1997). *

• Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 378: 787-791 (1997).

• Keppler D, Leier I, Jedlitschky G, Mayer R, Buchler M. The function of the multidrug resistance proteins (MRP and cMRP) in drug conjugate transport and hepatobiliary excretion. Adv. Enzyme Regul. 36: 17-29 (1996). *

• Keppler D, Rius M. The concept of basolateral efflux pumps of the hepatocyte. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 30-31 (2006). *

• Keppler D, Rius M, Nies AT. Bile salt efflux mediated by multidrug resistance protein MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 38. June 18-19 (2004). *

• Kevresan S, Kuhajda K, Kandrac J, Fawcett JP, Mikov M. Biosynthesis of bile acids in mammalian liver. Eur. J. Drug Metab. Pharmacokinet. 31: 145-156 (2006).

• Khantwal CM, Swaan PW. Cytosolic half of transmembrane domain IV of the human bile acid transporter hASBT (SLC10A2) forms part of the substrate translocation pathway. Biochemistry 47: 3606-3614 (2008). *

• Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196 (2004). *

• Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 44: 1728-1736 (2003). *

• Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98: 1303-1310 (2007). *

• Kip NS, Lazaridis KN, Masyuk AI, Splinter PL, Huebert RC, LaRusso NF. Differential expression of cholangiocyte and ileal bile acid transporters following bile acid supplementation and depletion. World J. Gastroenterol. 10: 1440-1446 (2004). *

• Kipp H, Arias IM. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters. Semin. Liver Dis. 20: 339-351 (2000).

• Kipp H, Arias IM. Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver. J. Biol. Chem. 275: 15917-15925 (2000). *

• Kipp H, Arias IM. Trafficking of canalicular ABC transporters in hepatocytes. Annu. Rev. Physiol. 64: 595-608 (2002). *

• Kis E, Ioja E, Nagy T, Szente L, Heredi-Szabo K, Krajcsi P. Effect of membrane cholesterol on BSEP/Bsep activity - species specificity studies for substrates and inhibitors. Drug Metab. Dispos. Jun 11 [Epub ahead of print] (2009). *

• Kis E, Rajnai Z, Ioja E, Heredi Szabo K, Nagy T, Mehn D, Krajcsi P. Mouse Bsep ATPase assay: a nonradioactive tool for assessment of the cholestatic potential of drugs. J. Biomol. Screen. 14: 10-15 (2009).

• Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J. Biol. Chem. 278: 17838-17844 (2003). *

• Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 36: 2014-2023 (2008). *

• Kitamura T, Jansen P, Hardenbrook C, Kamimoto Y, Gatmaitan Z, Arias IM. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc. Natl. Acad. Sci. U.S.A. 87: 3557-3561 (1990). *

• Kitayama K, Nakai D, Kono K, van der Hoop AG, Kurata H, de Wit EC, Cohen LH, Inaba T, Kohama T. Novel non-systemic inhibitor of ileal apical Na(+)-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur. J. Pharmacol. 539: 89-98 (2006). *

• Kitzberger R, Madl C, Ferenci P. Wilson disease. Metab. Brain Dis. 20: 295-302 (2005). *

• Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24: 239-247 (2007). *

• Klaassen CD, Lu H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101: 186-196 (2008). *

• Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 6: 309-328 (2005).

• Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S. NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis. Hepatology 43: 126-133 (2005). *

• Klein K, Kullak-Ublick GA, Wagner M, Trauner M, Eloranta JJ. Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G936-G947 (2009). *

• Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res. 43: 359-364 (2002). *

• Kloppel TM, Hoops TC, Gaskin D, Le M. Uncoupling of the secretory pathways for IgA and secretory component by cholestasis. Am. J. Physiol. 253: G232-G240 (1987).

• Kneuer C, Honscha W, Gabel G, Honscha KU. Adaptive response to increased bile acids: induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch. 454: 587-594 (2007). *

• Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, Bull LN, Pawlikowska L, Bilezikci B, Ozcay F, Laszlo A, Tiszlavicz L, Moore L, Raftos J, Arnell H, Fischler B, Nemeth A, Papadogiannakis N, Cielecka-Kuszyk J, Jankowska I, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44: 478-486 (2006). *

• Ko J, Hamilton JA, Ton-Nu HT, Schteingart CD, Hofmann AF, Small DM. Effects of side chain length on ionization behavior and transbilayer transport of unconjugated dihydroxy bile acids: a comparison of nor-chenodeoxycholic acid and chenodeoxycholic acid. J. Lipid Res. 35: 883-892 (1994). *

• Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by Mrp2 in rats. J. Pharmacol. Exp. Ther. 309: 1029-1035 (2004). *

• Kojima K, Yamamuro W, Mori T, Hata S, Machida Y, Higa M. A case of gas-forming pyogenic liver abscess. Nippon Shokakibyo Gakkai Zasshi 104: 1063-1068 (2007).

• Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369: 539-547 (2003). *

• Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, Stellaard F, Shan B, Schwarz M, Kuipers F. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. 278: 41930-41937 (2003). *

• Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124: 160-171 (2003). *

• Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901 (2005). *

• Kong FM, Sui CY, Li YJ, Guo KJ, Guo RX. Hepatobiliary membrane transporters involving in the formation of cholesterol calculus. Hepatobiliary Pancreat. Dis. Int. 5: 286-289 (2006). *

• Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275: 23161-23168 (2000). *

• Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn. Schmiedebergs. Arch. Pharmacol. 372: 432-443 (2006). *

• Koopen NR, Wolters H, Havinga R, Vonk RJ, Jansen PL, Muller M, Kuipers F. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol-induced cholestasis in the rat. Hepatology 27: 537-545 (1998). *

• Koopen NR, Wolters H, Muller M, Schippers IJ, Havinga R, Roelofsen H, Vonk RJ, Stieger B, Meier PJ, Kuipers F. Hepatic bile salt flux does not modulate level and activity of the sinusoidal Na+-taurocholate cotransporter (ntcp) in rats. J. Hepatol. 27: 699-706 (1997). *

• Koopen NR, Wolters H, Voshol P, Stieger B, Vonk RJ, Meier PJ, Kuipers F, Hagenbuch B. Decreased Na+-dependent taurocholate uptake and low expression of the sinusoidal Na+-taurocholate cotransporting protein (Ntcp) in livers of mdr2 P-glycoprotein-deficient mice. J. Hepatol. 30: 14-21 (1999). *

• Kopplow K, Letschert K, Konig J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68: 1031-1038 (2005). *

• Kosters A, Karpen SJ. Bile acid transporters in health and disease. Xenobiotica 38: 1043-1071 (2008). *

• Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, Kubik R, Hanson J, Urda E, Mutlib AE. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci. 90: 451-459 (2006). *

• Kovacs WJ, Shackelford JE, Tape KN, Richards MJ, Faust PL, Fliesler SJ, Krisans SK. Disturbed cholesterol homeostasis in a peroxisome-deficient PEX2 knockout mouse model. Mol. Cell Biol. 24: 1-13 (2004). *

• Krahenbuhl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. Hepatology 20: 1595-1601 (1994).

• Krahenbuhl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 15: 1160-1166 (1992).

• Kramer W, Girbig F, Corsiero D, Pfenninger A. Molecular elucidation of intestinal cholesterol absorption. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 54. June 18-19 (2004). *

• Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13: 997-1016 (2006).

• Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-deficient mice without inducing liver steatosis and hypertriglyceridemia. J. Lipid Res. 50: 312-326 (2009). *

• Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 453: 675-684 (2007). *

• Kruit JK, Plosch T, Havinga R, Boverhof R, Groot PH, Groen AK, Kuipers F. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128: 147-156 (2005). *

• Kubitz R, Haussinger D. Osmoregulation of bile formation. Methods Enzymol. 428: 313-324 (2007).

• Kubitz R, Helmer A, Haussinger D. Biliary transport systems: short-term regulation. Methods Enzymol. 400: 542-557 (2005).

• Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *

• Kubitz R, Saha N, Kuhlkamp T, Dutta S, Vom Dahl S, Wettstein M, Haussinger D. Ca2+-dependent protein kinase C-isoforms induce cholestasis in rat liver. J. Biol. Chem. 279: 10323-10330 (2004). *

• Kubitz R, Sutfels G, Kuhlkamp T, Kolling R, Haussinger D. Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology 126: 541-553 (2004). *

• Kudo A, Kashiwagi S, Kajimura M, Yoshimura Y, Uchida K, Arii S, Suematsu M. Kupffer cells alter organic anion transport through multidrug resistance protein 2 in the post-cold ischemic rat liver. Hepatology 39: 1099-1109 (2004). *

• Kuhajda K, Kevresan S, Kandrac J, Fawcett JP, Mikov M. Chemical and metabolic transformations of selected bile acids. Eur. J. Drug Metab. Pharmacokinet. 31: 179-235 (2006).

• Kulaksiz H, Schlenker T, Rost D, Stiehl A, Volkmann M, Lehnert T, Cetin Y, Stremmel W. Guanylin regulates chloride secretion in the human gallbladder via the bile fluid. Gastroenterology 126: 732-740 (2004). *

• Kullak-Ublick GA. Regulation of hepatic and intestinal bile acid transport by FXR controlled signaling pathways. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 51-52 (2006). *

• Kullak-Ublick GA. Regulation of bile salt transporter genes by nuclear receptors. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 43. June 18-19 (2004). *

• Kullak-Ublick GA, Baretton GB, Oswald M, Renner EL, Paumgartner G, Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol. Res. 23: 78-82 (2002).

• Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. 35: 305-317 (2003).

• Kullak-Ublick GA, Beuers U, Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology 23: 1053-1060 (1996). *

• Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J. Hepatol. 32: S3-S18 (2000).

• Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120: 525-533 (2001). *

• Kullak-Ublick GA, Meier PJ. Mechanisms of cholestasis. Clin. Liver Dis. 4: 357-385 (2000).

• Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin. Liver Dis. 20: 273-292 (2000). *

• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342 (2004). *

• Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol. Res. 38: 745-761 (2008). *

• Kurbegov AC, Setchell KD, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 125: 1227-1234 (2003). *

• Kurihara H, Sano N, Takikawa H. Biliary excretion of taurocholate, organic anions and vinblastine in rats with alpha-naphthylisothiocyanate-induced cholestasis. J. Gastroenterol. Hepatol. 20: 1069-1074 (2005). *

• Labori KJ, Arnkvaern K, Bjornbeth BA, Press CM, Raeder MG. Cholestatic effect of large bilirubin loads and cholestasis protection conferred by cholic acid co-infusion: a molecular and ultrastructural study. Scand. J. Gastroenterol. 37: 585-596 (2002). *

• Lacaille F. Bile acids and their therapeutic use in children. Arch. Pediatr. 2: 1200-1208 (1995).

• Lam P, Pearson CL, Soroka C, Xu S, Mennone A, Boyer JL. The level of plasma membrane expression in progressive and benign mutations of the bile salt export pump (BSEP/ABCB11) correlate with severity of cholestatic diseases. Am. J. Physiol. Cell. Physiol. 293: C1709-C1716 (2007). *

• Lam P, Wang R, Ling V. Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry 44: 12598-12605 (2005). *

• Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).

• Lammert F, Matern S. Evidence-based prevention of cholecystolithiasis. Dtsch. Med. Wochenschr. 129: 1548-1550 (2004).

• Lammert F, Matern S. The genetic background of cholesterol gallstone formation: an inventory of human lithogenic genes. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 163-170 (2005).

• Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy? J. Hepatol. 48: S124-S135 (2008). *

• Lammert F, Paigen B, Carey MC. Localization of the ileal sodium-bile salt cotransporter gene (Slc10a2) to mouse chromosome 8. Mamm. Genome 9: 173-174 (1998). *

• Lammert F, Wasmuth HE, Mendez-Sanchez N, Rahbar-Tabrizi N, Schirin-Sokhan R, King-Martinez AC, Marschall HU, Wittenburg H, Uribe M, Matern S. Common haplotypes of the ABCG5/G8 genes encoding the hepatocanalicular cholesterol transporter are associated with cholecystolithiasis. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 56. June 18-19 (2004). *

• Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates the human organic solute transporter-alpha and -beta genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G476-G485 (2006). *

• Lane ME, Corrigan OI. Paracellular and transcellular pathways facilitate insulin permeability in rat gut. J. Pharm. Pharmacol. 58: 271-275 (2006).

• Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17: 47-60 (2007).

• Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, Stieger B, Kullak-Ublick G, Kerb R. Genetic variability, haplotype structures, and ethnical diversity of hepatic transporters MDR3 (ABCB4) and BSEP (ABCB11). Drug Metab. Dispos. 34: 1582-1599 (2006). *

• Langheim S, Yu L, von Bergmann K, Lutjohann D, Xu F, Hobbs HH, Cohen JC. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J. Lipid Res. 46: 1732-1738 (2005). *

• Langmann T, Mauerer R, Schmitz G. Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin. Chem. 52: 310-313 (2006). *

• Larocca MC, Soria LR, Espelt MV, Lehmann GL, Marinelli RA. The knockdown of hepatocyte aquaporin-8 by RNA interference induces defective bile canalicular water transport. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G93-G100 (2009). *

• LaRusso NF, Ishii M, Vroman BT. The ins and outs of membrane movement in biliary epithelia. Trans. Am. Clin. Climatol. Assoc. 102: 245-258 (1990).

• Lasker JN, Sogolow ED, Sharim RR. The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis mailinglist. J. Med. Internet Res. 7: e10 (2005). *

• Lavoie JC, Chessex P, Gauthier C, Levy E, Alvarez F, St-Louis P, Rouleau T. Reduced bile flow associated with parenteral nutrition is independent of oxidant load and parenteral multivitamins. J. Pediatr. Gastroenterol. Nutr. 41: 108-114 (2005). *

• Lazaridis KN, LaRusso NF. Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220 (2003). *

• Lazaridis KN, Pham L, Tietz P, Marinelli RA, deGroen PC, Levine S, Dawson PA,LaRusso NF. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J. Clin. Invest. 100: 2714-2721 (1997). *

• Lazaridis KN, Tietz P, Wu T, Kip S, Dawson PA, LaRusso NF. Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties. Proc. Natl. Acad. Sci. U.S.A. 97: 11092-11097 (2000). *

• Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the pro-inflammatory cytokine interleukin-1beta. Drug Metab. Dispos. 36: 217-222 (2008). *

• Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the pro-inflammatory cytokines TNF-alpha or IL-6. Drug Metab. Dispos. 37: 685-693 (2009). *

• Lecureur V, Courtois A, Payen L, Verhnet L, Guillouzo A, Fardel O. Expression and regulation of hepatic drug and bile acid transporters. Toxicology 153: 203-219 (2000). *

• Lee H, Hubbert ML, Osborne TF, Woodford K, Zerangue N, Edwards PA. Regulation of the sodium/sulfate co-transporter by farnesoid X receptor alpha. J. Biol. Chem. 282: 21653-21661 (2007). *

• Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA. FXR regulates organic solute transporter alpha and beta in the adrenal gland, kidney and intestine. J. Lipid Res. 47: 201-214 (2006). *

• Lee J, Azzaroli F, Wang L, Soroka CJ, Gigliozzi A, Setchell KD, Kramer W, Boyer JL. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 121: 1473-1484 (2001). *

• Lee J, Boyer JL. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin. Liver Dis. 20: 373-384 (2000). *

• Lee J, Choi HS. Reverse cholesterol transport in cultured gallbladder epithelial cells. Korean J. Gastroenterol. 43: 145-152 (2004).

• Lee J, Shirk A, Oram JF, Lee SP, Kuver R. Polarized cholesterol and phospholipid efflux in cultured gall-bladder epithelial cells: evidence for an ABCA1-mediated pathway. Biochem. J. 364: 475-484 (2002). *

• Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology 118: 163-172 (2000). *

• Lee S. Gallstones: how do we translate an old story into future therapy? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3 (2004). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 19: 185-193 (2003).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 18: 290-298 (2002).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Lehmann GL, Carreras FI, Soria LR, Gradilone SA, Marinelli RA. LPS induces the TNFalpha-mediated down-regulation of rat liver aquaporin-8: role in sepsis-associated cholestasis. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G567-G575 (2008). *

• Lehmann GL, Larocca MC, Soria LR, Marinelli RA. Aquaporins: their role in cholestatic liver disease. World J. Gastroenterol. 14: 7059-7067 (2008). *

• LeLeiko NS, Gribetz D. Pediatric gastroenterology at the Mount Sinai hospital. Mt. Sinai J. Med. 68: 102-105 (2001). *

• Lemaitre-Coelho I, Altamirano GA, Barranco-Acosta C, Meykens R, Vaerman JP. In vivo experiments involving secretory component in the rat hepatic transfer of polymeric IgA from blood into bile. Immunology 43: 261-270 (1981). *

• Leslie EM, Watkins PB, Kim RB, Brouwer KL. Differential inhibition of rat and human Na+-dependent taurocholate co-transporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321: 1170-1178 (2007). *

• Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14: 441-452 (2004).

• Letschert K, Komatsu M, Hummel-Eisenbeiss J, Keppler D. Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2 (MRP2). J. Pharmacol. Exp. Ther. 313: 549-556 (2005). *

• Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *

• Lewindon PJ, Pereira TN, Hoskins AC, Bridle KR, Williamson RM, Shepherd RW, Ramm GA. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am. J. Pathol. 160: 1705-1715 (2002). *

• Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr. Opin. Cardiol. 21: 345-352 (2006).

• Li D, Zimmerman TL, Thevananther S, Lee HY, Kurie JM, Karpen SJ. Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent. J. Biol. Chem. 277: 31416-31422 (2002). *

• Li FC, Liu Y, Huang GT, Chiou LL, Liang JH, Dong CY, Lee HS. In vivo dynamic metabolic imaging of obstructive cholestasis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1091-G1097 (2009). *

• Li GX, Pei QL, Gao Y, Liu KM, Nie JS, Han G, Qiu YL, Zhang WP. Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats. Exp. Toxicol. Pathol. 58: 447-453 (2007). *

• Li H, Chen F, Shang Q, Pan L, Shneider BL, Chiang JY, Forman BM, Ananthanarayanan M, Tint GS, Salen G, Xu G. FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G60-G66 (2005). *

• Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, Salen G. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7alpha-hydroxylase. Metabolism 53: 927-932 (2004). *

• Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement C3 expression by the bile acid receptor FXR. J. Biol. Chem. 280: 7427-7434 (2005). *

• Li T, Chen W, Chiang JY. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 48: 373-384 (2007). *

• Liang CP, Tall AR. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276: 49066-49076 (2001). *

• Liang XJ, Aszalos A. Multidrug transporters as drug targets. Curr. Drug Targets 7: 911-921 (2006).

• Libra A, Fernetti C, Lorusso V, Visigalli M, Anelli PL, Staud F, Tiribelli C, Pascolo L. Molecular determinants in the transport of a bile acid derived diagnostic agent in tumoral and non-tumoral cell lines of human liver. J. Pharmacol. Exp. Ther. 319: 809-817 (2006). *

• Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J. Clin. Invest. 90: 1313-1322 (1992). *

• Lickteig AJ, Slitt AL, Arkan MC, Karin M, Cherrington NJ. Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab. Dispos. 35: 402-409 (2007). *

• Lillienau J, Borgstrom B. Bacterial deconjugation and enterohepatic circulation of norursocholic acid conjugates in rats. Am. J. Physiol. 261: G1065-G1071 (1991).

• Lillienau J, Crombie DL, Munoz J, Longmire-Cook SJ, Hagey LR, Hofmann AF. Negative feedback regulation of the ileal bile acid transport system in rodents. Gastroenterology 104: 38-46 (1993).

• Lillienau J, Hagey LR, Borgstrom B. Hepatic and ileal transport and effect on biliary secretion of norursocholic acid and its conjugates in rats. Am. J. Physiol. 261: G1057-G1064 (1991).

• Ling V, Lam P, Forrest D, Liu L, Wang R. Bile acid transport in Spgp (BSEP) knockout mice. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 37. June 18-19 (2004). *

• Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 1-7 (2002). *

• Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis. Paediatr. Drugs 2: 205-222 (2000).

• Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr. Pulmonol. 41: 35-49 (2006).

• Liu JJ, Glickman JN, Masyuk AI, LaRusso NF. Cholangiocyte bile salt transporters in cholesterol gallstone-susceptible and resistant inbred mouse strains. J. Gastroenterol. Hepatol. 23: 1596-1602 (2008). *

• Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112: 1678-1687 (2003). *

• Liu Y, Havinga R, van der Leij FR, Boverhof R, Sauer PJ, Kuipers F, Stellaard F. Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. Pediatr. Res. 63: 375-381 (2008). *

• Liu Z, Mutlib AE, Wang J, Talaat RE. Liquid chromatography/mass spectrometry determination of endogenous plasma acetyl and palmitoyl carnitines as potential biomarkers of beta-oxidation in mice. Rapid Commun. Mass Spectrom. 22: 3434-3442 (2008). *

• Lo Sasso G, Petruzzelli M, Moschetta A. A translational view on the biliary lipid secretory network. Biochim. Biophys. Acta 1781: 79-96 (2008). *

• Lobaccaro JM, Repa JJ, Lu TT, Caira F, Henry-Berger J, Volle DH, Mangelsdorf DJ. Regulation of lipid metabolism by the orphan nuclear receptors. Ann. Endocrinol. (Paris) 62: 239-247 (2001).

• Lomri N, Fitz JG, Scharschmidt BF. Hepatocellular transport: role of ATP-binding cassette proteins. Semin. Liver Dis. 16: 201-210 (1996).

• Love MW, Craddock AL, Angelin B, Brunzell JD, Duane WC, Dawson PA. Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21: 2039-2045 (2001). *

• Love MW, Dawson PA. New insights into bile acid transport. Curr. Opin. Lipidol. 9: 225-229 (1998).

• Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AF, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer HB Jr, Salen G, Dean M, Srivastava A, Patel SB. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am. J. Hum. Genet. 69: 278-290 (2001). *

• Lundasen T, Andersson EM, Schreyer S, Ostlund-Lindqvist AM, Angelin B, Rudling M. Ileal bile acid transport inhibition lowers plasma glucose and lipid levels in ob/ob mice. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 45 (2006). *

• Luoma PV. Cytochrome P450 - physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Ann. Med. 39: 359-370 (2007).

• Lutjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol. Scand. Suppl. 185: 33-42 (2006).

• Macias RI, Jimenez S, Serrano MA, Monte MJ, Marin JJ. Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sci. 79: 1014-1019 (2006). *

• Maeda T, Miyata M, Yotsumoto T, Kobayashi D, Nozawa T, Toyama K, Gonzalez FJ, Yamazoe Y, Tamai I. Regulation of drug transporters by the farnesoid X receptor in mice. Mol. Pharm. 1: 281-289 (2004).

• Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 (OATP1B1/OATP-C) and 1B3 (OATP1B3/OATP-8) function as bidirectional carriers and do not mediate GSH-bile acid co-transport. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G271-G278 (2007). *

• Mahagita C, Tanphichai K, Suksamrarn A, Ballatori N, Piyachaturawat P. 4-Hydroxyacetophenone-induced choleresis in rats is mediated by the Mrp2-dependent biliary secretion of its glucuronide conjugate. Pharm. Res. 23: 2603-2610 (2006). *

• Maher JM, Cherrington NJ, Slitt AL, Klaassen CD. Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. Life Sci. 78: 2219-2225 (2006). *

• Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem. Pharmacol. 72: 512-522 (2006). *

• Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J. Pharmacol. Sci. 97: 177-183 (2005). *

• Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365 (1999). *

• Makowski P, Pikula S. Participation of the multispecific organic anion transporter in hepatobiliary excretion of glutathione S-conjugates, drugs and other xenobiotics. Pol. J. Pharmacol. 49: 387-394 (1997).

• Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos. 28: 13-18 (2006). *

• Mano Y, Usui T, Kamimura H. Hepatobiliary transport of YM466, a novel factor Xa inhibitor, in rats. Eur. J. Drug Metab. Pharmacokinet. 31: 117-121 (2006).

• Mansour NM, Sawhney M, Tamang DG, Vogl C, Saier MH Jr. The bile/arsenite/riboflavin transporter (BART) superfamily. FEBS J. 274: 612-629 (2007). *

• Marcus SN, Schteingart CD, Marquez ML, Hofmann AF, Xia Y, Steinbach JH, Ton-Nu HT, Lillienau J, Angellotti MA, Schmassmann A. Active absorption of conjugated bile acids in vivo. Kinetic parameters and molecular specificity of the ileal transport system in the rat. Gastroenterology 100: 212-221 (1991).

• Mareninova O, Shin JM, Vagin O, Turdikulova S, Hallen S, Sachs G. Topography of the membrane domain of the liver Na(+)-dependent bile acid transporter. Biochemistry 44: 13702-13712 (2005). *

• Marin JJ, Macias RI, Briz O, Perez MJ, Serrano MA. Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Ann. Hepatol. 4: 70-76 (2005).

• Marin JJG, Romero MR, Vallejo M, Perez MJ, Briz O. Emerging interest in bile acid transporters in pathophysiology and pharmacology. Med. Hypotheses Res. 2: 425-448 (2005). *

• Marinelli RA, Gradilone SA, Carreras FI, Calamita G, Lehmann GL. Liver aquaporins: significance in canalicular and ductal bile formation. Ann. Hepatol. 3: 130-136 (2004). *

• Marion TL, Leslie EM, Brouwer KL. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm. 4: 911-918 (2007). *

• Markovich D. Sulfate transport by SLC26 transporters. Novartis Found. Symp. 273: 42-51 (2006).

• Marschall HU, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Sjovall J, Trauner M. Fxr -/- mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J. Lipid Res. 47: 582-592 (2006). *

• Marschall HU, Wagner M, Zollner G, Fickert P, Diczfalusy U, Gumhold J, Silbert D, Fuchsbichler A, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129: 476-485 (2005). *

• Marschall HU, Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Diczfalusy U, Benthin L, Grundstrom R, Gustafsson U, Sahlin S, Einarsson C, Trauner M. Comprehensive study of the effects of rifampicin and ursodeoxycholic acid on genes and proteins involved in regulation, transport and detoxification of biliary compounds in gallstone patients. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 47. June 18-19 (2004). *

• Martin GG, Atshaves BP, McIntosh AL, Mackie JT, Kier AB, Schroeder F. Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. Biochem. J. 391: 549-560 (2005). *

• Martinez-Anso E, Castillo JE, Diez J, Medina JF, Prieto J. Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology 19: 1400-1406 (1994).

• Martinez-Augustin O, Sanchez de Medina F. Intestinal bile acid physiology and pathophysiology. World J. Gastroenterol. 14: 5630-5640 (2008). *

• Martinez-Fernandez P, Hierro L, Jara P, Alvarez L. Knockdown of ATP8B1 expression leads to specific down-regulation of the bile acid sensor FXR in HepG2 cells. Effect of the FXR agonist GW4064. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1119-G1129 (2009). *

• Marumo T, Fukusato T, Takikawa H. Biliary excretion of bile acids and organic anions in rats with dichloroethylene-induced bile canalicular injury. J. Gastroenterol. 39: 981-987 (2004). *

• Marzioni M, Glaser SS, Francis H, Phinizy JL, LeSage G, Alpini G. Functional heterogeneity of cholangiocytes. Semin. Liver Dis. 22: 227-240 (2002).

• Marzioni M, LeSage GD, Glaser S, Patel T, Marienfeld C, Ueno Y, Francis H, Alvaro D, Tadlock L, Benedetti A, Marucci L, Baiocchi L, Phinizy JL, Alpini G. Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G837-G852 (2003). *

• Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21: 1769-1780 (2007). *

• Masson D, Qatanani M, Sberna AL, Xiao R, Pais de Barros JP, Grober J, Deckert V, Athias A, Gambert P, Lagrost L, Moore DD, Assem M. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J. Lipid Res. 49: 1682-1691 (2008). *

• Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, Sugiyama Y. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73: 1474-1483 (2008). *

• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double transfected MDCKII cells expressing human OATP1B1/MRP2, OATP1B1/MDR1 and OATP1B1/BCRP. J. Pharmacol. Exp. Ther. 314: 1059-1067 (2005). *

• Matsuzaki T, Tajika Y, Ablimit A, Aoki T, Hagiwara H, Takata K. Aquaporins in the digestive system. Med. Electron Microsc. 37: 71-80 (2004). *

• Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145: 1237-1245 (1994). *

• Mazzone A, Tietz P, Jefferson J, Pagano R, LaRusso NF. Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. Hepatology 43: 287-296 (2006). *

• McCarthy TC, Li X, Sinal CJ. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein-3 gene expression by bile acids. J. Biol. Chem. 280: 23232-23242 (2005). *

• McGill JM, Williams DM, Hunt CM. Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig. Dis. Sci. 41: 540-542 (1996).

• McNeil CJ, Hay SM, Rucklidge GJ, Reid M, Duncan G, Maloney CA, Rees WD. Disruption of lipid metabolism in the liver of the pregnant rat fed folate-deficient and methyl donor-deficient diets. Br. J. Nutr. 99: 262-271 (2008). *

• McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, Kashuba AD. Ritonavir, saquinavir and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318: 1068-1075 (2006). *

• Medina JF, Martinez-Anso, Vazquez JJ, Prieto J. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25: 12-17 (1997). *

• Meerman L, Koopen NR, Bloks V, Van Goor H, Havinga R, Wolthers BG, Kramer W, Stengelin S, Muller M, Kuipers F, Jansen PL. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 117: 696-705 (1999). *

• Meier PJ. Canalicular bile formation: beyond single transporter functions. J. Hepatol. 37: 272-273 (2002). *

• Meier PJ. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Am. J. Physiol. 269: G801-G812 (1995).

• Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26: 1667-1677 (1997). *

• Meier PJ, Stieger B. Bile salt transporters. Annu. Rev. Physiol. 64: 635-661 (2002). *

• Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, Stieger B. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44: 62-74 (2006). *

• Meier-Abt F, Faulstich H, Hagenbuch B. Identification of phalloidin uptake systems of rat and human liver. Biochim. Biophys. Acta 1664: 64-69 (2004). *

• Meier-Abt F, Hammam-Hanni A, Stieger B, Ballatori N, Boyer JL. The organic anion transport polypeptide 1d1 (Oatp1d1) mediates hepatocellular uptake of phalloidin and microcystin into skate liver. Toxicol. Appl. Pharmacol. 218: 274-279 (2007). *

• Meier-Abt PJ. Cellular mechanisms of intrahepatic cholestasis. Drugs 40 Suppl. 3: 84-97 (1990).

• Meier-Abt PJ. Transport and metabolic functions. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 21-22. October 20 - 21 (2003). *

• Melero S, Spirli C, Zsembery A, Medina JF, Joplin RE, Duner E, Zuin M, Neuberger JM, Prieto J, Strazzabosco M. Defective regulation of cholangiocyte Cl-/HCO3- and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology 35: 1513-1521 (2002). *

• Mendez-Sanchez N, Brink MA, Paigen B, Carey MC. Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology 115: 722-732 (1998). *

• Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. New molecular features of cholestatic diseases of the liver. Rev. Invest. Clin. 55: 546-556 (2003).

• Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, Medarde M, Marin JJ. Physiological characteristics of allo-cholic acid. J. Lipid Res. 44: 84-92 (2003). *

• Meng LJ, Reyes H, Axelson M, Palma J, Hernandez I, Ribalta J, Sjovall J. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology 26: 1573-1579 (1997). *

• Meng LJ, Wang P, Wolkoff AW, Kim RB, Tirona RG, Hofmann AF, Pang KS. Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. Hepatology 35: 1031-1040 (2002). *

• Mesotten D, Van den Berghe G, Liddle C, Coulter S, McDougall F, Baxter RC, Delhanty PJ. Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology 144: 4008-4017 (2003). *

• Meyer G, Guizzardi F, Rodighiero S, Manfredi R, Saino S, Sironi C, Garavaglia ML, Bazzini C, Botta G, Portincasa P, Calamita G, Paulmichl M. Ion transport across the gallbladder epithelium. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 143-151 (2005).

• Micheline D, Emmanuel J, Serge E. Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J. Pediatr. Gastroenterol. Nutr. 35: 185-191 (2002). *

• Mikami M, Takikawa H. Effect of genipin on the biliary excretion of cholephilic compounds in rats. Hepatol. Res. 38: 614-621 (2008). *

• Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. 19: 171-179 (2004). *

• Mikov M, Fawcett JP, Kuhajda K, Kevresan S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur. J. Drug Metab. Pharmacokinet. 31: 237-251 (2006).

• Milkiewicz P, Gallagher R, Chambers J, Eggington E, Weaver J, Elias E. Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J. Gastroenterol. Hepatol. 18: 1283-1286 (2003). *

• Milkiewicz P, Mills CO, Hubscher SG, Cardenas R, Cardenas T, Williams A, Elias E. Visualization of the transport of primary and secondary bile acids across liver tissue in rats: in vivo study with fluorescent bile acids. J. Hepatol. 34: 4-10 (2001). *

• Miller WL. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim. Biophys. Acta 1771: 663-676 (2007). *

• Mills CO, Milkiewicz P, Muller M, Roma MG, Havinga R, Coleman R, Kuipers F, Jansen PL, Elias E. Different pathways of canalicular secretion of sulfated and non-sulfated fluorescent bile acids: a study in isolated hepatocyte couplets and TR- rats. J. Hepatol. 31: 678-684 (1999). *

• Mills CO, Milkiewicz P, Saraswat V, Elias E. Cholyllysyl fluroscein and related lysyl fluorescein conjugated bile acid analogues. Yale J. Biol. Med. 70: 447-457 (1997).

• Misra S, Varticovski L, Arias IM. Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G316-G324 (2003). *

• Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y. Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G550-G556 (2006). *

• Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab. Dispos. 34: 1575-1581 (2006). *

• Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y. Vectorial transport of bile salts across MDCK cells expressing both rat Na+/taurocholate cotransporting polypeptide and rat bile salt export pump. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G159-G167 (2005). *

• Mitro N, Gilardi F, Godio C, Scotti E, Fabiani ED, Caruso D, Crestani M. Bile acids and gene regulation: from nuclear receptors to chromatin. Front. Biosci. 13: 6276-6288 (2008).

• Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63: 1161-1169 (2007).

• Miyata M, Matsuda Y, Nomoto M, Takamatsu Y, Sato N, Hamatsu M, Dawson PA, Gonzalez FJ, Yamazoe Y. Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorption. Drug Metab. Dispos. 37: 338-344 (2009). *

• Mizuno K, Hoshino M, Hayakawa T, Yamada H, Nakazawa T, Inagaki T, Takeuchi T, Kunimatsu M. Uncoupling of biliary lipid from bile acid secretion by formyl-methionyl-leucyl-phenylalanine in the rat. Hepatology 24: 1224-1229 (1996). *

• Mochizuki K, Kagawa T, Numari A, Harris MJ, Itoh J, Watanabe N, Mine T, Arias IM. Two N-linked glycans are required to maintain transport activity of the bile salt export pump (ABCB11) in MDCK II cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G818-G828 (2007). *

• Mock MR, Meier PJ, Stieger B. Protein-protein interactions and their importance in the function of the canalicular bile salt export pump (Bsep). Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 35-36. June 18-19 (2004). *

• Molina H, Azocar L, Ananthanarayanan M, Arrese M, Miquel JF. Localization of the sodium-taurocholate cotransporting polypeptide in membrane rafts and modulation of its activity by cholesterol in vitro. Biochim. Biophys. Acta 1778: 1283-1291 (2008). *

• Molino G, Hofmann AF, Cravetto C, Belforte G, Bona B. Simulation of the metabolism and enterohepatic circulation of endogenous chenodeoxycholic acid in man using a physiological pharmacokinetic model. Eur. J. Clin. Invest. 16: 397-414 (1986).

• Montagnani M, Abrahamsson A, Galman C, Eggertsen G, Marschall HU, Ravaioli E, Einarsson C, Dawson PA. Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption. World J. Gastroenterol. 12: 7710-7714 (2006). *

• Montagnani M, Love MW, Rossel P, Dawson PA, Qvist P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand. J. Gastroenterol. 36: 1077-1080 (2001). *

• Monte MJ, Fernandez-Tagarro M, Macias RI, Jimenez F, Gonzalez-San Martin F, Marin JJ. Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin. Sci. (Lond.) 109: 199-207 (2005). *

• Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15: 804-816 (2009). *

• Moore JT, Goodwin B, Willson TM, Kliewer SA. Nuclear receptor regulation of genes involved in bile acid metabolism. Crit. Rev. Eukaryot. Gene Expr. 12: 119-135 (2002).

• Moran D, De Buitrago JM, Fernandez E, Galan AI, Munoz ME, Jimenez R. Inhibition of biliary glutathione secretion by cyclosporine A in the rat: possible mechanisms and role in the cholestasis induced by the drug. J. Hepatol. 29: 68-77 (1998).

• Moreno M, Molina H, Amigo L, Zanlungo S, Arrese M, Rigotti A, Miquel JF. Hepatic overexpression of caveolins increases bile salt secretion in mice. Hepatology 38: 1477-1488 (2003). *

• Morisawa Y, Takikawa H. Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol. Res. 39: 595-600 (2009).

• Moriwaki T, Yasui H, Yamamoto A. Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats. Pharm. Res. 21: 1055-1064 (2004). *

• Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, Puffenberger E, Bull L, Knisely AS. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 119: 188-195 (2000). *

• Moschetta A. Welcoming Foxa2 in the bile acid entourage. Cell. Metab. 8: 276-278 (2008). *

• Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M. Altered localization and activity of canalicular Mrp2 in estradiol-17beta-D-glucuronide-induced cholestasis. Hepatology 35: 1409-1419 (2002). *

• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *

• Mottino AD, Veggi LM, Wood M, Roman JM, Vore M. Biliary secretion of glutathione in estradiol 17beta-D-glucuronide-induced cholestasis. J. Pharmacol. Exp. Ther. 307: 306-313 (2003). *

• Moustafa MA, Ogino D, Nishimura M, Ueda N, Naito S, Furukawa M, Uchida T, Ikai I, Sawada H, Fukumoto M. Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci. 95: 530-536 (2004). *

• Mrowczynska L, Bobrowska-Hagerstrand M, Wrobel A, Soderstrom T, Hagerstrand H. Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts. Anticancer Res. 25: 3173-3178 (2005).

• Muchatuta MN, Gattone VH, Witzmann FA, Blazer-Yost BL. Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease. Exp. Biol. Med. (Maywood) 234: 17-27 (2009). *

• Muehlenberg K, Wiedmann K, Keppeler H, Sauerbruch T, Lammert F. Recurrent intrahepatic cholestasis of pregnancy and chain-like choledocholitiasis in a female patient with stop codon in the ABCB4-gene of the hepatobiliary phospholipid transporter. Z. Gastroenterol. 46: 48-53 (2008).

• Muhlfeld A, Kubitz R, Dransfeld O, Haussinger D, Wettstein M. Taurine supplementation induces multidrug resistance protein 2 and bile salt export pump expression in rats and prevents endotoxin-induced cholestasis. Arch. Biochem. Biophys. 413: 32-40 (2003). *

• Mullally BA, Hansen WF. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet. Gynecol. Surv. 57: 47-52 (2002).

• Mullenbach R, Lammert F. The transporter "variome": the missing link between gene variants and bile salt transporter function. Hepatology 49: 352-354 (2009).

• Muller M. Transcriptional control of hepatocanalicular transporter gene expression. Semin. Liver Dis. 20: 323-337 (2000).

• Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am. J. Physiol. 272: G1285-G1303 (1997).

• Muller O, Schalla C, Scheibner J, Stange EF, Fuchs M. Expression of liver plasma membrane transporters in gallstone-susceptible and gallstone-resistant mice. Biochem. J. 361: 673-679 (2002). *

• Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur. J. Clin. Pharmacol. 64: 257-266 (2008). *

• Nagasaka H, Miida T, Hirano KI, Ota A, Murayama K, Yorifuji T, Kobayashi K, Takatani T, Tsukahara H, Hui SP, Takayanagi M, Chiba H. Fluctuation of lipoprotein metabolism linked with bile acid-activated liver nuclear receptors in Alagille syndrome. Atherosclerosis 198: 434-440 (2008).

• Nakagaki M, Danzinger RG, Hofmann AF, DiPietro RA. Biliary secretion and hepatic metabolism of taurine-conjugated 7 alpha-hydroxy and 7 beta-hydroxy bile acids in the dog. Defective hepatic transport and bile hyposecretion. Gastroenterology 87: 647-659 (1984).

• Nakahara M, Furuya N, Takagaki K, Sugaya T, Hirota K, Fukamizu A, Kanda T, Fujii H, Sato R. Ileal bile acid-binding protein functionally associated with the farnesoid X receptor or ileal bile acid transporter regulates bile acid activity in the small intestine. J. Biol. Chem. 280: 42283-42289 (2005). *

• Nathanson MH, Burgstahler AD, Mennone A, Dranoff JA, Rios-Velez L. Stimulation of bile duct epithelial secretion by glybenclamide in normal and cholestatic rat liver. J. Clin. Invest. 101: 2665-2676 (1998). *

• Neghab M, Stacey NH. Toluene-induced elevation of serum bile acids: relationship to bile acid transport. J. Toxicol. Environ. Health 52: 249-268 (1997).

• Neimark E, Chen F, Li X, Magid MS, Alasio TM, Frankenberg T, Sinha J, Dawson PA, Shneider BL. c-Fos is a critical mediator of inflammatory-mediated repression of the apical sodium-dependent bile acid transporter. Gastroenterology 131: 554-567 (2006). *

• Neimark E, Chen F, Li X, Shneider BL. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40: 149-156 (2004). *

• Newton DJ, Wang RW, Evans DC. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR(-) and EHBR rats. Life Sci. 77: 1106-1115 (2005). *

• Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab. Dispos. 34: 718-723 (2006). *

• Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr. Pharm. Des. 7: 231-259 (2001). *

• Nilsson A, Duan RD. Absorption and lipoprotein transport of sphingomyelin. J. Lipid Res. 47: 154-171 (2006). *

• Nishio A, Keeffe EB, Gershwin ME. Immunopathogenesis of primary biliary cirrhosis. Semin. Liver Dis. 22: 291-302 (2002). *

• Nishioka T, Hyogo H, Numata Y, Yamaguchi A, Kobuke T, Komichi D, Nonaka M, Inoue M, Nabeshima Y, Ogi M, Iwamoto K, Ishitobi T, Ajima T, Chayama K, Tazuma S. A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. J. Atheroscler. Thromb. 12: 211-217 (2005). *

• Nishiya T, Kataoka H, Mori K, Goto M, Sugawara T, Furuhama K. Tienilic acid enhances hyperbilirubinemia in Eisai hyperbilirubinuria rats through hepatic multidrug resistance-associated protein 3 and heme oxygenase-1 induction. Toxicol. Sci. 91: 651-659 (2006). *

• Noe J, Hagenbuch B, Meier PJ, St-Pierre MV. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology 33: 1223-1231 (2001). *

• Noe J, Kullak-Ublick GA, Jochum W, Stieger B, Kerb R, Haberl M, Mullhaupt B, Meier PJ, Pauli-Magnus C. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J. Hepatol. 43: 536-543 (2005). *

• Noe J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123: 1659-1666 (2002). *

• Norata GD, Catapano AL. Lipid lowering activity of drugs affecting cholesterol absorption. Nutr. Metab. Cardiovasc. Dis. 14: 42-51 (2004).

• Norlin M, Wikvall K. Enzymes in the conversion of cholesterol into bile acids. Curr. Mol. Med. 7: 199-218 (2007).

• Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos. 32: 291-294 (2004). *

• O'Leary JG, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 23: 232-236 (2007).

• Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J. Clin. Invest. 99: 1880-1887 (1997). *

• Ogata T. Bicarbonate secretion by rat bile duct brush cells indicated by immunohistochemical localization of CFTR, anion exchanger AE2, Na(+)/HCO (3) (-) cotransporter, carbonic anhydrase II, Na (+)/H (+) exchangers NHE1 and NHE3, H (+)/K (+)-ATPase … Med. Mol. Morphol. 39: 44-48 (2006). *

• Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G438-G446 (2000). *

• Ogura M, Nishida S, Ishizawa M, Sakurai K, Shimizu M, Matsuo S, Amano S, Uno S, Makishima M. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther. 328: 564-570 (2009). *

• Ohta Y, Kongo-Nishimura M, Imai Y, Kitagawa A. Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment. J. Pineal Res. 42: 159-165 (2007). *

• Okamoto K, Hanazaki K, Akimori T, Okabayashi T, Okada T, Kobayashi M, Ogata T. Immunohistochemical and electron microscopic characterization of brush cells of the rat cecum. Med. Mol. Morphol. 41: 145-150 (2008).

• Omland E, Mathisen O. Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis. Scand. J. Gastroenterol. 26: 513-522 (1991).

• Orioni B, Roversi M, La Mesa C, Asaro F, Pellizer G, D'Errico G. Polymorphic behavior in protein-surfactant mixtures: the water-bovine serum albumin-sodium taurodeoxycholate system. J. Phys. Chem. B. Condens. Matter Mater. Surf. Interfaces Biophys. 110: 12129-12140 (2006). *

• Ortiz DF, Li S, Iyer R, Zhang X, Novikoff P, Arias IM. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am. J. Physiol. 276: G1493-G1500 (1999). *

• Ortiz DF, Moseley J, Calderon G, Swift AL, Li S, Arias IM. Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells. J. Biol. Chem. 279: 32761-32770 (2004). *

• Ortiz DF, St Pierre MV, Abdulmessih A, Arias IM. A yeast ATP-binding cassette-type protein mediating ATP-dependent bile acid transport. J. Biol. Chem. 272: 15358-15365 (1997). *

• Ory DS. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ. Res. 95: 660-670 (2004). *

• Oshima H, Kon J, Ooe H, Hirata K, Mitaka T. Functional expression of organic anion transporters in hepatic organoids reconstructed by rat small hepatocytes. J. Cell. Biochem. 104: 68-81 (2008). *

• Oshio H, Abe T, Onogawa T, Ohtsuka H, Sato T, Ii T, Fukase K, Muto M, Katayose Y, Oikawa M, Rikiyama T, Egawa S, Unno M. Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. J. Gastroenterol. 43: 538-549 (2008). *

• Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 21: 247-253 (2001). *

• Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U.S.A. 102: 17923-17928 (2005). *

• Oude Elferink RP. Cholestasis. Gut 52 Suppl. 2: ii42-ii48 (2003). *

• Oude Elferink RP. Understanding and controlling hepatobiliary function. Best Pract. Res. Clin. Gastroenterol. 16: 1025-1034 (2002).

• Oude Elferink RP, de Haan J, Lambert KJ, Hagey LR, Hofmann AF, Jansen PL. Selective hepatobiliary transport of nordeoxycholate side chain conjugates in mutant rats with a canalicular transport defect. Hepatology 9: 861-865 (1989).

• Oude Elferink RP, Groen AK. Genetic defects in hepatobiliary transport. Biochim. Biophys. Acta 1586: 129-145 (2002). *

• Oude Elferink RP, Groen AK. Mechanisms of biliary lipid secretion and their role in lipid homeostasis. Semin. Liver Dis. 20: 293-305 (2000). *

• Oude Elferink RP, Ottenhoff R, Fricker G, Seward DJ, Ballatori N, Boyer J. Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G762-G768 (2004). *

• Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects; pathophysiological mechanisms of rare diseases. Gastroenterology 130: 908-925 (2006). *

• Oude Elferink RP, Tytgat GN, Groen AK. Hepatic canalicular membrane 1: the role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J. 11: 19-28 (1997). *

• Pan DH, Chen F, Neimark E, Li X, Shneider BL. FTF and LRH-1, two related but different transcription factors in human Caco-2 cells: their different roles in the regulation of bile acid transport. Biochim. Biophys. Acta 1732: 31-37 (2005). *

• Panicot-Dubois L, Thomas GM, Furie BC, Furie B, Lombardo D, Dubois C. Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J. Clin. Invest. 117: 3708-3719 (2007). *

• Park JY, Park BK, Ko JS, Bang S, Song SY, Chung JB. Bile acid analysis in biliary tract cancer. Yonsei Med. J. 47: 817-825 (2006). *

• Park SC, Yoon JH, Kim W, Gwak GY, Kim KM, Lee SH, Lee SM, Lee HS. Eupatilin attenuates bile acid-induced hepatocyte apoptosis. J. Gastroenterol. 41: 772-778 (2006). *

• Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. 21: 904-913 (2004). *

• Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, Zimmermann R, Kenngott S, Beuers U, Reichel C, Kerb R, Penger A, Meier PJ, Kullak-Ublick GA. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 14: 91-102 (2004).

• Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics 13: 189-198 (2003).

• Pauli-Magnus C, Meier PJ. Hepatocellular transporters and cholestasis. J. Clin. Gastroenterol. 39: S103-S110 (2005).

• Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44: 778-787 (2006). *

• Pauli-Magnus C, Stieger B, Meier Y, Kullak-Ublick GA, Meier PJ. Enterohepatic transport of bile salts and genetics of cholestasis. J. Hepatol. 43: 342-357 (2005). *

• Paulusma CC, Dewaart DR, Kunne C, Mok KS, Elferink RP. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J. Biol. Chem. 284: 9947-9954 (2009). *

• Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, de Waart DR, Hoek FJ, Vreeling H, Hoeben KA, van Marle J, Pawlikowska L, Bull LN, Hofmann AF, Knisely AS, Oude Elferink RP. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 44: 195-204 (2006). *

• Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 25: 1539-1542 (1997). *

• Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhoff R, Borst P, Oude Elferink RP. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338: 393-401 (1999). *

• Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J. Gastroenterol. 12: 4445-4451 (2006). *

• Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531 (2002). *

• Payne CM, Fass R, Bernstein H, Giron J, Bernstein C, Dvorak K, Garewal H. Pathogenesis of diarrhea in the adult: diagnostic challenges and life-threatening conditions. Eur. J. Gastroenterol. Hepatol. 18: 1047-1051 (2006).

• Pellicoro A, Faber KN. Review article: the function and regulation of proteins involved in bile salt biosynthesis and transport. Aliment. Pharmacol. Ther. 26 Suppl. 2: 149-160 (2007). *

• Pellicoro A, van den Heuvel FA, Geuken M, Moshage H, Jansen PL, Faber KN. Human and rat bile acid-CoA:amino acid N-acyltransferase are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport. Hepatology 45: 340-348 (2007). *

• Peng X, Grosse B, Le Tiec B, Nicolas V, Delagebeaudeuf C, Bedda T, Decaens C, Cassio D. How to induce non-polarized cells of hepatic origin to express typical hepatocyte polarity: generation of new highly polarized cell models with developed and functional bile canaliculi. Cell Tissue Res. 323: 233-243 (2006). *

• Perez MJ, Castano B, Gonzalez-Buitrago JM, Marin JJ. Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver-placenta-maternal liver trio. J. Pineal Res. 43: 130-139 (2007).

• Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, Lennernas H. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab. Dispos. 34: 1182-1189 (2006). *

• Piazza F, Montagnani M, Russo C, Azzaroli F, Aldini R, Roda E, Roda A. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Dig. Liver Dis. 32: 318-328 (2000).

• Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278: 27703-27711 (2003). *

• Pizarro M, Balasubramaniyan N, Solis N, Solar A, Duarte I, Miquel JF, Suchy FJ, Trauner M, Accatino L, Ananthanarayanan M, Arrese M. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut 53: 1837-1843 (2004). *

• Planchamp C, Hadengue A, Stieger B, Bourquin J, Vonlaufen A, Frossard JL, Quadri R, Becker CD, Pastor CM. Function of both sinusoidal and canalicular transporters controls the concentration of organic anions within hepatocytes. Mol. Pharmacol. 71: 1089-1097 (2007). *

• Planchamp C, Montet X, Frossard JL, Quadri R, Stieger B, Meier PJ, Ivancevic MK, Vallee JP, Terrier F, Pastor CM. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest. Radiol. 40: 187-194 (2005).

• Plass JR, Mol O, Heegsma J, Geuken M, de Bruin J, Elling G, Muller M, Faber KN, Jansen PL. A progressive familial intrahepatic cholestasis type 2 mutation causes an unstable, temperature-sensitive bile salt export pump. J. Hepatol. 40: 24-30 (2004). *

• Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, Muller M. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35: 589-596 (2002). *

• Plosch T, Bloks VW, Terasawa Y, Berdy S, Siegler K, Van Der Sluijs F, Kema IP, Groen AK, Shan B, Kuipers F, Schwarz M, Schwartz M. Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor. Gastroenterology 126: 290-300 (2004). *

• Podevin P, Rosmorduc O, Conti F, Calmus Y, Meier PJ, Poupon R. Bile acids modulate the interferon signalling pathway. Hepatology 29: 1840-1847 (1999). *

• Popowski K, Eloranta JJ, Saborowski M, Fried M, Meier PJ, Kullak-Ublick GA. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol. Pharmacol. 67: 1629-1638 (2005). *

• Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr. Med. Chem. 13: 2889-2900 (2006).

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Poupon R. Molecular mechanisms of bile formation and cholestatic diseases. Bull. Acad. Natl. Med. 187: 1261-1274 (2003).

• Poupon R. Primary biliary cirrhosis: from ursodeoxycholic acid towards targeting strategies for therapy. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 63 (2006). *

• Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J. Hepatol. 32: S129-S140 (2000).

• Poupon R, Chignard N, Rosmorduc O, Barbu V, Housset C. Biliary function and its regulation. Med. Sci. (Paris) 20: 1096-1099 (2004).

• Poupon R, Ping C, Chretien Y, Corpechot C, Chazouilleres O, Simon T, Heath SC, Matsuda F, Poupon RE, Housset C, Barbu V. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J. Hepatol. 49: 1038-1045 (2008). *

• Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol. Ther. 66: 1-15 (1995). *

• Prall RT, LaRusso NF. Biliary tract physiology. Curr. Opin. Gastroenterol. 15: 423 (1999).

• Prall RT, LaRusso NF. Biliary tract physiology. Curr. Opin. Gastroenterol. 16: 432-436 (2000).

• Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 21: 270-274 (2005).

• Puengtomwatanakul S, Sirisinha S. Impaired biliary secretion of immunoglobulin A in vitamin A-deficient rats. Proc. Soc. Exp. Biol. Med. 182: 437-442 (1986).

• Purucker E, Marschall HU, Geier A, Gartung C, Matern S. Increase in renal glutathione in cholestatic liver disease is due to a direct effect of bile acids. Am. J. Physiol. Renal Physiol. 283: F1281-F1289 (2002). *

• Purucker E, Winograd R, Roeb E, Matern S. Glutathione status in liver and plasma during development of biliary cirrhosis after bile duct ligation. Res. Exp. Med. (Berl.) 198: 167-174 (1998).

• Putz G, Schmider W, Nitschke R, Kurz G, Blum HE. Synthesis of phospholipid conjugated bile salts and the suitability of bile salt coated liposomes for interaction with cultured hepatocytes. J. Lipid Res. 46: 2325-2338 (2005). *

• Qadri I, Hu LJ, Iwahashi M, Al-Zuabi S, Quattrochi LC, Simon FR. Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicol. Appl. Pharmacol. 234: 281-292 (2009). *

• Quondamatteo F, Krick W, Hagos Y, Kruger MH, Neubauer-Saile K, Herken R, Ramadori G, Burckhardt G, Burckhardt BC. Localization of the sulfate/anion exchanger in the rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1075-G1081 (2006). *

• Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. Role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50: S189-S194 (2009). *

• Ramenskaia GV, Fainshtein SL, Sychev DA. The role of changes in the functional activity and the amount of P-glycoprotein in drug pharmacokinetics. Eksp. Klin. Farmakol. 70: 72-80 (2007).

• Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105: 3891-3896 (2008). *

• Rausa FM, Tan Y, Zhou H, Yoo KW, Stolz DB, Watkins SC, Franks RR, Unterman TG, Costa RH. Elevated levels of hepatocyte nuclear factor 3beta in mouse hepatocytes influence expression of genes involved in bile acid and glucose homeostasis. Mol. Cell. Biol. 20: 8264-8282 (2000). *

• Redinger RN. The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: bile salts as ligands for nuclear hormone receptors. Can. J. Gastroenterol. 17: 265-271 (2003).

• Redinger RN. Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis. J. Lab. Clin. Med. 142: 7-20 (2003). *

• Redinger RN. The coming of age of our understanding of the enterohepatic circulation of bile salts. Am. J. Surg. 185: 168-172 (2003). *

• Reichel C, Meier-Abt PJ. Cholestatic liver diseases. Ther. Umsch. 54: 639-644 (1997).

• Reinehr R, Becker S, Keitel V, Eberle A, Grether-Beck S, Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 129: 2009-2031 (2005). *

• Ren S, Hylemon PB, Marques D, Gurley E, Bodhan P, Hall E, Redford K, Gil G, Pandak WM. Overexpression of cholesterol transporter StAR increases in vivo rates of bile acid synthesis in the rat and mouse. Hepatology 40: 910-917 (2004). *

• Ren S, Hylemon PB, Marques D, Hall EA, Redford K, Gil G, Pandak WM. Effect of increasing the expression of intracellular cholesterol transporters (StAR, MLN64, and SCP-2) on bile acid synthesis. J. Lipid Res. 45: 2123-2131 (2004). *

• Renner O, Harsch S, Schaeffeler E, Schwab M, Klass DM, Kratzer W, Stange EF. Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression. Hum. Genet. 125: 381-391 (2009). *

• Renner O, Harsch S, Strohmeyer A, Schimmel S, Stange EF. Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J. Lipid Res. 49: 2045-2054 (2008). *

• Repa JJ, Buhman KK, Farese RV Jr, Dietschy JM, Turley SD. ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis. Hepatology 40: 1088-1097 (2004). *

• Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289: 1524-1529 (2000). *

• Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32: 94-106 (2000).

• Rippin SJ, Hagenbuch B, Meier PJ, Stieger B. Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 33: 776-782 (2001). *

• Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G640-G649 (2006). *

• Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384 (2003). *

• Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S. The methyl transferase PRMT1 functions as co-activator of farnesoid X feceptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol. Pharmacol. 68: 551-558 (2005). *

• Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 289-303 (2005).

• Rodriguez-Agudo D, Ren S, Wong E, Marques D, Redford K, Gil G, Hylemon P, Pandak WM. Intracellular cholesterol transporter StarD4 binds free cholesterol and increases cholesterol ester formation. J. Lipid Res. 49: 1409-1419 (2008). *

• Rodriguez-Garay EA. Cholestasis: human disease and experimental animal models. Ann. Hepatol. 2: 150-158 (2003). *

• Rodriguez-Garay EA, Rodriguez GP, Pisani G, Taborda M, Viglianco RA. Reversible cholestasis induced by experimental partial obstruction of the bile duct: biochemical, morphometric and hepatic transport kinetic studies. Pathophysiology 11: 7-15 (2004).

• Roelofsen H, Hooiveld GJ, Koning H, Havinga R, Jansen PL, Muller M. Glutathione S-conjugate transport in hepatocytes entering the cell cycle is preserved by a switch in expression from the apical MRP2 to the basolateral MRP1 transporting protein. J. Cell Sci. 112: 1395-1404 (1999). *

• Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59: 855-861 (2004). *

• Rohacova J, Marin ML, Martinez-Romero A, Diaz L, O'Connor JE, Gomez-Lechon MJ, Donato MT, Castell JV, Miranda MA. Fluorescent benzofurazan-cholic acid conjugates for in vitro assessment of bile acid uptake and its modulation by drugs. ChemMedChem. 4: 466-472 (2009).

• Rolo AP, Palmeira CM, Wallace KB. Interactions of combined bile acids on hepatocyte viability: cytoprotection or synergism. Toxicol. Lett. 126: 197-203 (2002). *

• Roma MG, Crocenzi FA, Mottino AD. Dynamic localization of hepatocellular transporters in health and disease. World J. Gastroenterol. 14: 6786-6801 (2008). *

• Roma MG, Crocenzi FA, Sanchez Pozzi EA. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects. Clin. Sci. (Lond.) 114: 567-588 (2008). *

• Roma MG, Sanchez Pozzi EJ. Oxidative stress: a radical way to stop making bile. Ann. Hepatol. 7: 16-33 (2008). *

• Roman ID, Fernandez-Moreno MD, Fueyo JA, Roma MG, Coleman R. Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol. Sci. 71: 276-281 (2003). *

• Roman ID, Johnson GD, Coleman R. S-Adenosyl-L-methionine prevents disruption of canalicular function and pericanalicular cytoskeleton integrity caused by cyclosporin A in isolated rat hepatocyte couplets. Hepatology 24: 134-140 (1996). *

• Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J. Pathol. 200: 553-560 (2003). *

• Rose KA, Kostrubsky V, Sahi J. Hepatobiliary disposition in primary cultures of dog and monkey hepatocytes. Mol. Pharm. 3: 266-274 (2006). *

• Rost D, Herrmann T, Sauer P, Schmidts HL, Stieger B, Meier PJ, Stremmel W, Stiehl A. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate. Hepatology 38: 187-195 (2003). *

• Rost D, Kopplow K, Gehrke S, Stiehl A, Mayer D. Gender-specific expression of liver organic anion transporters. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 39. June 18-19 (2004). *

• Ruiz ML, M Villanueva SS, Luquita MG, Sanchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, Catania VA. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem. Pharmacol. 69: 531-539 (2005). *

• Russell DW. 50 years of advances in bile acid synthesis and metabolism. J. Lipid Res. Sep 24 [Epub ahead of print] (2008). *

• Russell DW, Setchell KD, Shea HC. Mice deficient in 3B-hydroxy-D5-C27 steroid oxidoreductase. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 21-22 (2006). *

• Rust C, Bernt C, Vennegeerts T, Beuers U. Role of Fas and caspase 8 in glycochenodeoxycholic acid induced hepatocellular apoptosis in human liver cell lines. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 59 (2006). *

• Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *

• Sabeva NS, Rouse EJ, Graf GA. Defects in the leptin axis reduce abundance of the ABCG5 ABCG8 sterol transporter in liver. J. Biol. Chem. 282: 22397-22405 (2007). *

• Saborowski M, Kullak-Ublick GA, Eloranta JJ. The human organic cation transporter 1 gene is transactivated by hepatocyte nuclear factor-4alpha. J. Pharmacol. Exp. Ther. 317: 778-785 (2006). *

• Saeki T, Munetaka Y, Ueda K, Iwami K, Kanamoto R. Effects of Ala substitution for conserved Cys residues in mouse ileal and hepatic Na(+)-dependent bile acid transporters. Biosci. Biotechnol. Biochem. 71: 1865-1872 (2007). *

• Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye Y, de Morais SM, Black C, Tugnait M, Keller LH. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem. Biol. Interact. 159: 156-168 (2006). *

• Sakamoto S, Kusuhara H, Horie K, Takahashi K, Baba T, Ishizaki J, Sugiyama Y. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of S-8921 glucuronide, a pharmacologically active metabolite of S-8921. Drug Metab. Dispos. 36: 1553-1561 (2008). *

• Sakamoto S, Kusuhara H, Miyata K, Shimaoka H, Kanazu T, Matsuo Y, Nomura K, Okamura N, Hara S, Horie K, Baba T, Sugiyama Y. Glucuronidation converting S-8921 to a potent ASBT inhibitor, resulting in a hypocholesterolemic action. J. Pharmacol. Exp. Ther. 322: 610-618 (2007). *

• Sakamoto S, Suzuki H, Kusuhara H, Sugiyama Y. Efflux mechanism of taurocholate across the rat intestinal basolateral membrane. Mol. Pharm. 3: 275-281 (2006). *

• Sakurai A, Kurata A, Onishi Y, Hirano H, Ishikawa T. Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump. Expert Opin. Drug Saf. 6: 71-86 (2007).

• Salen G, Starc T, McCrary Sisk C, Patel SB. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130: 1853-1857 (2006). *

• Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, Schuetz JD. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 4: E14 (2002). *

• Samstein RM, Perica K, Balderrama F, Look M, Fahmy TM. The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials 29: 703-708 (2008). *

• Sanchez-Mete L, Attili AF. Cholelithiasis: genetic hypothesis. Minerva Gastroenterol. Dietol. 46: 45-55 (2000).

• Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849 (2006). *

• Sauer P, Kloters-Plachky P, Stiehl A. Inhibition of ileal bile acid transport by cyclosporin A in rat. Eur. J. Clin. Invest. 25: 677-682 (1995).

• Sauer P, Rudolph G, Endele R, Senn M, Theilmann L, Otto G, Stremmel W, Stiehl A. Kinetics of primary bile acids in patients after orthotopic liver transplantation. Eur. J. Clin. Invest. 26: 979-982 (1996).

• Sauer P, Stiehl A, Fitscher BA, Riedel HD, Benz C, Kloters-Plachky P, Stengelin S, Stremmel W, Kramer W. Downregulation of ileal bile acid absorption in bile-duct-ligated rats. J. Hepatol. 33: 2-8 (2000). *

• Scanff P, Souidi M, Grison S, Griffiths NM, Gourmelon P. Alteration of the enterohepatic recirculation of bile acids in rats after exposure to ionizing radiation. Can. J. Physiol. Pharmacol. 82: 114-124 (2004).

• Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49: 1228-1235 (2009). *

• Scharschmidt BF, Lake JR. Hepatocellular bile acid transport and ursodeoxycholic acid hypercholeresis. Dig. Dis. Sci. 34: 5S-15S (1989).

• Schiff JM, Fisher MM, Jones AL, Underdown BJ. Human IgA as a heterovalent ligand: switching from the asialoglycoprotein receptor to secretory component during transport across the rat hepatocyte. J. Cell Biol. 102: 920-931 (1986). *

• Schlattjan JH, Benger S, Herrler A, von Rango U, Greven J. Regulation of taurocholate transport in freshly isolated proximal tubular cells of the rat kidney by protein kinases. Nephron. Physiol. 99: p35-p42 (2004).

• Schlattjan JH, Biggemann F, Greven J. Gender differences in renal tubular taurocholate transport. Naunyn. Schmiedebergs. Arch. Pharmacol. 371: 449-456 (2005). *

• Schliess F, Haussinger D. Osmosensing by integrins in rat liver. Methods Enzymol. 428: 129-144 (2007).

• Schloss JV. New targets for the treatment of vascular diseases and diabetes. IDrugs 1: 752-753 (1998).

• Schlosser PM, Borghoff SJ, Coldham NG, David JA, Ghosh SK. Physiologically-based pharmacokinetic modeling of genistein in rats, part I: model development. Risk Anal. 26: 483-500 (2006). *

• Schmassmann A, Angellotti MA, Clerici C, Hofmann AF, Ton-Nu HT, Schteingart CD, Marcus SN, Hagey LR, Rossi SS, Aigner A. Transport, metabolism, and effect of chronic feeding of lagodeoxycholic acid. A new, natural bile acid. Gastroenterology 99: 1092-1104 (1990).

• Schmassmann A, Fehr HF, Locher J, Lillienau J, Schteingart CD, Rossi SS, Hofmann AF. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology 104: 1171-1181 (1993).

• Schmassmann A, Hofmann AF, Angellotti MA, Ton-Nu HT, Schteingart CD, Clerici C, Rossi SS, Rothschild MA, Cohen BI, Stenger RJ, et al. Prevention of ursodeoxycholate hepatotoxicity in the rabbit by conjugation with N-methyl amino acids. Hepatology 11: 989-996 (1990).

• Schmidt R. Dialysis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 103-104. October 17 - 19 (2003). *

• Schmitt M, Kubitz R, Lizun S, Wettstein M, Haussinger D. Regulation of the dynamic localization of the rat Bsep gene-encoded bile salt export pump by anisoosmolarity. Hepatology 33: 509-518 (2001). *

• Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B. Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am. J. Physiol. 274: G370-G375 (1998). *

• Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat. Med. 7: 536-537 (2001). *

• Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276: 39411-39418 (2001). *

• Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer and output in vivo in humans. J. Lipid Res. 45: 1594-1607 (2004). *

• Scotti E, Gilardi F, Godio C, Gers E, Krneta J, Mitro N, De Fabiani E, Caruso D, Crestani M. Bile acids and their signaling pathways: eclectic regulators of diverse cellular functions. Cell. Mol. Life Sci. 64: 2477-2491 (2007). *

• Seeger MA, Schiefner A, Eicher T, Verrey F, Diederichs K, Pos KM. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 313: 1295-1298 (2006). *

• Seithel A, Glaeser H, Fromm MF, Konig J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin. Drug Metab. Toxicol. 4: 51-64 (2008).

• Sekine S, Ito K, Horie T. Canalicular Mrp2 localization is reversibly regulated by the intracellular redox status. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G1035-G1041 (2008). *

• Seo YK, Chung YT, Kim S, Echchgadda I, Song CS, Chatterjee B. Xenobiotic- and vitamin D-responsive induction of the steroid/bile acid-sulfotransferase Sult2A1 in young and old mice: the role of a gene enhancer in the liver chromatin. Gene 386: 218-223 (2007). *

• Serrano MA, Macias RI, Vallejo M, Briz O, Bravo A, Pascual MJ, St-Pierre MV, Stieger B, Meier PJ, Marin JJ. Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. J. Pharmacol. Exp. Ther. 305: 515-524 (2003). *

• Shaffer EA. Cholestasis: the ABCs of cellular mechanisms for impaired bile secretion - transporters and genes. Can. J. Gastroenterol. 16: 380-389 (2002).

• Shih DM, Kast-Woelbern HR, Wong J, Xia YR, Edwards PA, Lusis AJ. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J. Lipid Res. 47: 384-392 (2006). *

• Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27: 375-382 (2001). *

• Shim WS, Choi MK, Kim IW, Kwon TS, Song IS, Han L, Kim DD, Chung SJ, Shim CK. Decreased secretory transport of a quarternary ammonium, TBuMA, across LLC-PK1 cells by the anionic kidney extract. Arch. Pharm. Res. 31: 671-677 (2008). *

• Shimada S, Kawaguchi-Miyashita M, Kushiro A, Sato T, Nanno M, Sako T, Matsuoka Y, Sudo K, Tagawa Y, Iwakura Y, Ohwaki M. Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA. J. Immunol. 163: 5367-5373 (1999). *

• Shimizu N, Nakazono H, Takeshita Y, Ikeda C, Fujii H, Watanabe A, Yamaguchi Y, Hemmi H, Shimatake H, Aoki T. Molecular analysis and diagnosis in Japanese patients with Wilson's disease. Pediatr. Int. 41: 409-413 (1999). *

• Shneider BL. Regulation of intestinal bile acid transport in health and disease. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 44 (2006). *

• Shneider BL. Intestinal bile acid transport: biology, physiology, and pathophysiology. J. Pediatr. Gastroenterol. Nutr. 32: 407-417 (2001). *

• Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, Suzuki H, Sugiyama Y, Cohen DE, Tanaka N. Bezafibrate stimulates canalicular localization of NBD-labeled phosphatidylcholine in HepG2 cells by PPAR-mediated redistribution of ABCB4. J. Lipid Res. 45: 1813-1825 (2004). *

• Shoda J, Kano M, Oda K, Kamiya J, Nimura Y, Suzuki H, Sugiyama Y, Miyazaki H, Todoroki T, Stengelin S, Kramer W, Matsuzaki Y, Tanaka N. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol. 96: 3368-3378 (2001). *

• Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, Suzuki H, Sugiyama Y. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 39: 167-178 (2004). *

• Sidler Pfandler MA, Hochli M, Inderbitzin D, Meier PJ, Stieger B. Small hepatocytes in culture develop polarized transporter expression and differentiation. J. Cell. Sci. 117: 4077-4087 (2004). *

• Sievanen E. Exploitation of bile acid transport systems in prodrug design. Molecules 12: 1859-1889 (2007).

• Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40 Suppl.: S13-S19 (1997). *

• Silva VM, Hennig GE, Manautou JE. Cholestasis induced by model organic anions protects from acetaminophen hepatotoxicity in male CD-1 mice. Toxicol. Lett. 160: 204-211 (2005). *

• Silverman JA, Thorgeirsson SS. Regulation and function of the multidrug resistance genes in liver. Prog. Liver Dis. 13: 101-123 (1995).

• Simon FR, Fortune J, Iwahashi M, Qadri I, Sutherland E. Multihormonal regulation of hepatic sinusoidal Ntcp gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G782-G794 (2004). *

• Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744 (2000). *

• Sinel'nik TB, Sinel'nik OD, Ribal'chenko VK. Bile acids in the process of canalicular bile formation. Fiziol. Zh. 49: 80-93 (2003).

• Singh SK, Mennone A, Gigliozzi A, Fraioli F, Boyer JL. Cl(-)-dependent secretory mechanisms in isolated rat bile duct epithelial units. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G438-G446 (2001). *

• Sinha J, Chen F, Miloh T, Burns RC, Yu Z, Shneider BL. beta-Klotho and FGF 15/19 inhibit the apical sodium dependent bile acid transporter in enterocytes and cholangiocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G996-G1003 (2008). *

• Sjodin E, Fritsch H, Eriksson U, Logren U, Nordgren A, Forsell P, Knutson L, Lennernas H. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab. Dispos. 36: 1519-1528 (2008). *

• Slitt AL, Allen K, Morrone J, Aleksunes LM, Chen C, Maher JM, Manautou JE, Cherrington NJ, Klaassen CD. Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim. Biophys. Acta 1768: 637-647 (2007). *

• Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462 (1993).

• Smit MJ, Temmerman AM, Wolters H, Kuipers F, Beynen AC, Vonk RJ. Dietary fish oil-induced changes in intrahepatic cholesterol transport and bile acid synthesis in rats. J. Clin. Invest. 88: 943-951 (1991). *

• Smit MJ, Verkade HJ, Havinga R, Vonk RJ, Scherphof GL, In 't Veld G, Kuipers F. Dietary fish oil potentiates bile acid-induced cholesterol secretion into bile in rats. J. Lipid Res. 35: 301-310 (1994). *

• Snow KL, Moseley RH. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci. 80: 732-740 (2007). *

• Soccio RE, Breslow JL. Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 24: 1150-1160 (2004). *

• Solodun IuV, Klevno VA, Leliukh TD, Maslauskaite LS, Iaverbaum AP, Ermolaeva NB, Zobnin IuV, Provado IP, Kuchina EV, Bogomolova IN. Forensic-medical evaluation of toxic hepatitis associated with surrogate alcohol poisoning. Sud. Med. Ekspert. 51: 23-28 (2008).

• Song IS, Lee YM, Chung SJ, Shim CK. Multiple alterations of canalicular membrane transport activities in rats with CCl(4)-induced hepatic injury. Drug Metab. Dispos. 31: 482-490 (2003). *

• Song S, Suzuki H, Kawai R, Tanaka C, Akasaka I, Sugiyama Y. Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab. Dispos. 26: 1128-1133 (1998). *

• Sonoda J, Evans RM. Biological function and mode of action of nuclear xenobiotic receptors. Pure Appl. Chem. 75: 1733-1742 (2003). *

• Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33: 783-791 (2001). *

• Soroka CJ, Xu S, Cai SY, Boyer JL. Insights into the regulation of expression of human OSTalpha-OSTbeta. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 32 (2006). *

• Soroka CJ, Xu S, Mennone A, Lam P, Boyer JL. N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta. BMC Cell Biol. 9: 57 (2008). *

• Spirli C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, LaRusso NF, Sonzogni A, Okolicsanyi L, Strazzabosco M. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 124: 737-753 (2003). *

• Spirli C, Fiorotto R, Song L, Santos-Sacchi J, Okolicsanyi L, Masier S, Rocchi L, Pia Vairetti M, De Bernard M, Melero S, Pozzan T, Strazzabosco M. Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Gastroenterology 129: 220-233 (2005). *

• Spirli C, Granato A, Zsembery K, Anglani F, Okolicsanyi L, LaRusso NF, Crepaldi G, Strazzabosco M. Functional polarity of Na+/H+ and Cl-/HCO3- exchangers in a rat cholangiocyte cell line. Am. J. Physiol. 275: G1236-G1245 (1998). *

• Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, Di Virgilio F, Okolicsanyi L, Casagrande F, Strazzabosco M. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 121: 156-169 (2001). *

• Splinter PL, Lazaridis KN, Dawson PA, LaRrusso NF. Cloning and expression of SLC10A4, a putative organic anion transport protein. World J. Gastroenterol. 12: 6797-6805 (2006). *

• Srivastava A, Tulsyan S, Pandey SN, Choudhuri G, Mittal B. Single nucleotide polymorphism in the ABCG8 transporter gene is associated with gallbladder cancer susceptibility. Liver Int. 29: 831-837 (2009). *

• St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. Transport of bile acids in hepatic and non-hepatic tissues. J. Exp. Biol. 204: 1673-1686 (2001). *

• St-Pierre MV, Stallmach T, Freimoser Grundschober A, Dufour JF, Serrano MA, Marin JJ, Sugiyama Y, Meier PJ. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287: R1505-R1516 (2004). *

• Stahl S, Davies MR, Cook DI, Graham MJ. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. Xenobiotica 38: 725-777 (2008). *

• Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab. Dispos. 29: 1467-1472 (2001). *

• Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 98: 3369-3374 (2001). *

• Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146: 984-991 (2005). *

• Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, Downes M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U.S.A. 103: 11323-11328 (2006). *

• Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U.S.A. 102: 2063-2068 (2005). *

• Steinmetz I, Schiffmann P, Brenneke B. Secretory monoclonal IgA class-switch variants against bacterial enteric pathogens in bile and intestinal secretions. FEMS Immunol. Med. Microbiol. 11: 329-336 (1995).

• Stellaard F, Kuipers F. Assessment of modes of action and efficacy of plasma cholesterol-lowering drugs: measurement of cholesterol absorption, cholesterol synthesis and bile acid synthesis and turnover using novel stable isotope techniques. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 209-218 (2005).

• Stelzner M, Somasundaram S, Lee SP, Kuver R. Ileal mucosal bile acid absorption is increased in Cftr knockout mice. BMC Gastroenterol. 1: 10 (2001). *

• Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118: 422-430 (2000). *

• Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch. 453: 611-620 (2007). *

• Stiehl A. Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. Ital. J. Gastroenterol. 27: 193-195 (1995).

• Stiehl A, Raedsch R, Rudolph G. Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology 94: 1201-1206 (1988).

• Stienstra R, Lichtenauer-Kaligis E, Muller M. Stress- (and diet-) related regulation of hepatic nuclear receptors and its relevance for ABC-transporter functions. Drug Metab. Rev. 36: 391-406 (2004). *

• Strange RC. Hepatic bile flow. Physiol. Rev. 64: 1055-1102 (1984).

• Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20: 233-238 (1998). *

• Strautnieks SS, Byrne JA, Pawlikowska L, Nemeth A, Fischler B, Pawlowska J, Jankowska I, Jacquemin E, Hadchouel M, Sokal E, Wali S, Mieli-Vergani G, Knisely AS, Bull LN, Thompson RJ. Genetic analysis of the bile salt export pump. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 45. June 18-19 (2004). *

• Strazzabosco M. Transport systems in cholangiocytes: their role in bile formation and cholestasis. Yale J. Biol. Med. 70: 427-434 (1997). *

• Strazzabosco M, Joplin R, Zsembery A, Wallace L, Spirli C, Fabris L, Granato A, Rossanese A, Poci C, Neuberger JM, Okolicsanyi L, Crepaldi G. Na(+)-dependent and -independent Cl-/HCO3- exchange mediate cellular HCO3- transport in cultured human intrahepatic bile duct cells. Hepatology 25: 976-985 (1997). *

• Strazzabosco M, Spirli C, Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J. Gastroenterol. Hepatol. 15: 244-253 (2000). *

• Stroup D. Kinase/phosphatase regulation of CYP7A1. Front. Biosci. 10: 1678-1692 (2005).

• Sturm E, Havinga R, Baller JF, Wolters H, van Rooijen N, Kamps JA, Verkade HJ, Karpen SJ, Kuipers F. Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. J. Hepatol. 42: 102-109 (2005). *

• Sturm E, Wagner M, Trauner M. Nuclear receptor ligands in therapy of cholestatic liver disease. Front. Biosci. 14: 4299-4325 (2009).

• Suchy FJ, Ananthanarayanan M. Bile salt excretory pump: biology and pathobiology. J. Pediatr. Gastroenterol. Nutr. 43 (1 Suppl. 1): S10-S16 (2006). *

• Suchy FJ, Sippel CJ, Ananthanarayanan M. Bile acid transport across the hepatocyte canalicular membrane. FASEB J. 11: 199-205 (1997). *

• Sugiyama Y, Mita S, Maeda K, Suzuki H. Analysis of vectorial transport of bile salts using human NTCP and human BSEP doubly expressing cells: comparative studies with rat Ntcp and rat Bsep. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 40. June 18-19 (2004). *

• SugiyamaY, Maeda K. Assessment of inhibitory effect of many therapeutically important drugs on bile acid transport by NTCP, BSEP and other transporters. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 36-37 (2006). *

• Suh JI. Role of PXR and CAR in cholestasis. Korean J. Hepatol. 12: 5-15 (2006).

• Sun AQ, Balasubramaniyan N, Chen H, Shahid M, Suchy FJ. Identification of functionally relevant residues of the rat ileal apical sodium dependent bile acid cotransporter (rASBT). J. Biol. Chem. 281: 16410-16418 (2006). *

• Sun AQ, Balasubramaniyan N, Liu CJ, Shahid M, Suchy FJ. Association of the 16 kDa subunit c of vacuolar proton pump with the ileal Na+-dependent bile acid transporter: Protein-protein interaction and intracellular trafficking. J. Biol. Chem. 279: 16295-16300 (2004). *

• Sun AQ, Balasubramaniyan N, Xu K, Liu C, Ponamgi VM, Liu H, Suchy F. Protein-protein interaction and membrane localization of human organic solute transporter (hOST). Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1586-G1593 (2007). *

• Sun AQ, Ponamgi VM, Boyer JL, Suchy FJ. Membrane trafficking of the human organic anion-transporting polypeptide C (hOATPC). Pharm. Res. 25: 463-474 (2008). *

• Sun AQ, Swaby I, Xu S, Suchy FJ. Cell-specific basolateral membrane sorting of the human liver Na(+)-dependent bile acid cotransporter. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G1305-1G133 (2001). *

• Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32: 1239-1246 (2004). *

• Sundaram SS, Whitington PF, Green RM. Steatohepatitis develops rapidly in transgenic mice over-expressing Abcb11 fed a methionine-choline deficient diet. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1321-G1327 (2005). *

• Suzuki C, Sano N, Takikawa H. Effect of dexamethasone on biliary excretion of bile acids and organic anions in rats. Hepatol. Res. 25: 48-54 (2003). *

• Suzuki H. Analysis of xenobiotic detoxification system mediated by efflux transporters. Yakugaku Zasshi 119: 822-834 (1999).

• Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res. 66: 10120-10126 (2006). *

• Swartz-Basile DA, Lu D, Basile DP, Graewin SJ, Al-Azzawi H, Kiely JM, Mathur A, Yancey K, Pitt HA. Leptin regulates gallbladder genes related to absorption and secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G84-G90 (2007). *

• T Hart NA, Van der Plaats A, Moers C, Leuvenink HG, Wiersema-Buist J, Verkerke GJ, Rakhorst G, Ploeg RJ. Development of the isolated dual perfused rat liver model as an improved reperfusion model for transplantation research. Int. J. Artif. Organs 29: 219-227 (2006).

• Tachibana S, Hirano M, Hirata T, Matsuo M, Ikeda I, Ueda K, Sato R. Cholesterol and plant sterol efflux from cultured intestinal epithelial cells is mediated by ATP-binding cassette transporters. Biosci. Biotechnol. Biochem. 71: 1886-1895 (2007). *

• Tachizawa H, Sano N, Takikawa H. Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats. J. Gastroenterol. Hepatol. 19: 1016-1022 (2004). *

• Takada T, Weiss M, Kretz O, Gross G, Sugiyama Y. Hepatic transport of PKI166 - an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class - and its main metabolite ACU154. Drug Metab. Dispos. 32: 1272-1278 (2004). *

• Takahashi K, Kimura Y, Nagata K, Yamamoto A, Matsuo M, Ueda K. ABC proteins: key molecules for lipid homeostasis. Med. Mol. Morphol. 38: 2-12 (2005). *

• Takeyama Y, Uehara Y, Inomata S, Morihara D, Nishizawa S, Ueda S, Matsumoto T, Tanaka T, Anan A, Nishimura H, Irie M, Iwata K, Shakado S, Sohda T, Sakisaka S. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis. Liver Int. 29: 406-414 (2009). *

• Takikawa H. Hepatobiliary transport of bile acids and organic anions. J. Hepatobiliary Pancreat. Surg. 9: 443-447 (2002).

• Takikawa H. Organic anion carriers. Nippon Rinsho 54: 646-651 (1996).

• Tan LK. Obstetric cholestasis: current opinions and management. Ann. Acad. Med. Singapore 32: 294-298 (2003).

• Tan Y, Hughes D, Wang X, Costa RH. Adenovirus-mediated increase in HNF-3beta or HNF-3alpha shows differences in levels of liver glycogen and gene expression. Hepatology 35: 30-39 (2002). *

• Tanaka A, Nalbandian G, Leung PS, Benson GD, Munoz S, Findor JA, Branch AD, Coppel RL, Ansari AA, Gershwin ME. Mucosal immunity and primary biliary cirrhosis: presence of antimitochondrial antibodies in urine. Hepatology 32: 910-915 (2000). *

• Tanaka Y, Aleksunes LM, Cui YJ, Klaassen CD. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2 dependent and independent signaling. Toxicol. Sci. 108: 247-257 (2009). *

• Tanaka Y, Chen C, Maher JM, Klaassen CD. Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. Transplantation 82: 258-266 (2006).

• Tancevski I, Wehinger A, Demetz E, Eller P, Duwensee K, Huber J, Hochegger K, Schgoer W, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A. Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression. Endocrinology 149: 3708-3712 (2008). *

• Tang W, Yi C, Kalitsky J, Piquette-Miller M. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol. Cell. Biol. Res. Commun. 4: 90-97 (2000).

• Tauscher A, Kuver R. ABCG5 and ABCG8 are expressed in gallbladder epithelial cells. Biochem. Biophys. Res. Commun. 307: 1021-1028 (2003). *

• Tazuke Y, Kiristioglu I, Heidelberger KP, Eisenbraun MD, Teitelbaum DH. Hepatic P-glycoprotein changes with total parenteral nutrition administration. JPEN J. Parenter. Enteral Nutr. 28: 1-6 (2004).

• Tazuma S, Chayama K. Hepatic hydroxylation of bile acids and chronic liver diseases: do transporters play a mechanistic role? J. Gastroenterol. Hepatol. 16: 1313-1315 (2001).

• Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 31: 1296-1299 (2003). *

• Teng S, Piquette-Miller M. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br. J. Pharmacol. 151: 367-376 (2007). *

• Thalhammer T, Kaschnitz R, Mittermayer K, Haddad P, Graf J. Organic solvents increase membrane fluidity and affect bile flow and K+ transport in rat liver. Biochem. Pharmacol. 46: 1207-1215 (1993).

• Thomas C, Landrier JF, Gaillard D, Grober J, Monnot MC, Athias A, Besnard P. Cholesterol-dependent down-regulation of mouse and human apical sodium-dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. Gut 55: 1321-1331 (2006). *

• Thompson R, Jansen PL. Genetic defects in hepatocanalicular transport. Semin. Liver Dis. 20: 365-372 (2000).

• Thompson R, Strautnieks S. BSEP: function and role in progressive familial intrahepatic cholestasis. Semin. Liver Dis. 21: 545-550 (2001). *

• Thompson RJ. The consequence of not being able to transport bile acids. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 60 (2006). *

• Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother. 51: 3230-3234 (2007). *

• Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky M, Kruh G, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab. Dispos. 36: 911-915 (2008). *

• Tian X, Zamek-Gliszczynski MJ, Zhang P, Brouwer KL. Modulation of multidrug resistance-associated protein 2 (mrp2) and mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 66: 1004-1010 (2004). *

• Tietz P, Jefferson J, Pagano R, LaRusso NF. Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J. Lipid Res. 46: 1426-1432 (2005). *

• Tietz P, LaRusso NF. Cholangiocyte biology. Curr. Opin. Gastroenterol. 18: 360-365 (2002).

• Tietz PS, LaRusso NF. Cholangiocyte biology. Curr. Opin. Gastroenterol. 21: 337-343 (2005).

• Tietz PS, LaRusso NF. Cholangiocyte biology. Curr. Opin. Gastroenterol. 20: 270-274 (2004).

• Tietz PS, Marinelli RA, Chen XM, Huang B, Cohn J, Kole J, McNiven MA, Alper S, LaRusso NF. Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes. J. Biol. Chem. 278: 20413-20419 (2003). *

• Tomar BS. Infantile cholestasis - advances in its understanding: new concepts. Acta Paediatr. Taiwan 41: 6-12 (2000).

• Tomer G, Ananthanarayanan M, Weymann A, Balasubramanian N, Suchy FJ. Differential developmental regulation of rat liver canalicular membrane transporters Bsep and Mrp2. Pediatr. Res. 53: 288-294 (2003). *

• Tomer G, Shneider BL. Disorders of bile formation and biliary transport. Gastroenterol. Clin. North Am. 32: 839-855, vi (2003).

• Tong Y, Zhang R, Ngo SN, Davey AK. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. Clin. Exp. Pharmacol. Physiol. 33: 685-689 (2006). *

• Torchia EC, Cheema SK, Agellon LB. Coordinate regulation of bile acid biosynthetic and recovery pathways. Biochem. Biophys. Res. Commun. 225: 128-133 (1996). *

• Tradtrantip L, Piyachaturawat P, Soroka C, Harry K, Mennone A, Mahagita C, Ballatori N, Boyer JL. Phloracetophenone-induced choleresis in rats is mediated through Mrp2. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G66-G74 (2007). *

• Trauner M. Molecular mechanisms of cholestasis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 64-65 (2005). *

• Trauner M. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations. Yale J. Biol. Med. 70: 365-378 (1997). *

• Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40: 260-263 (2004). *

• Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J. Clin. Invest. 101: 2092-2100 (1998). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004).

• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83: 633-671 (2003). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 18: 314-329 (2002).

• Trauner M, Fickert P, Lammert F, Marschall HU. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 126: 1222-1223 (2004). *

• Trauner M, Fickert P, Moustafa T, Guelly C, Fuchsbichler A, Denk H, Wagner M, Zollner G. Side chain-shortened bile acids for the treatment of cholestasis: lessons from nor-ursodeoxycholic acid. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 77-78 (2006). *

• Trauner M, Fickert P, Stauber RE. Hepatocellular bile salt transport: lessons from cholestasis. Can. J. Gastroenterol. 14 Suppl. D: 99D-104D (2000).

• Trauner M, Fickert P, Stauber RE. New molecular aspects of cholestatic liver diseases. Z. Gastroenterol. 37: 639-647 (1999).

• Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis. 27: 77-98 (2007). *

• Trauner M, Fickert P, Wagner M, Zollner G. Adaptive hepatobiliary transporter regulation by ursodeoxycholic acid. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 48-49. June 18-19 (2004). *

• Trauner M, Fickert P, Zollner G. Abnormal hepatic sinusoidal bile acid transport: new insights into the pathogenesis of cholestasis? Gastroenterology 120: 321-323 (2001). *

• Trauner M, Fickert P, Zollner G. Genetic disorders and molecular mechanisms in cholestatic liver disease - a clinical approach. Semin. Gastrointest. Dis. 12: 66-88 (2001).

• Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 39: S111-S124 (2005).

• Tremont SJ, Lee LF, Huang HC, Keller BT, Banerjee SC, Both SR, Carpenter AJ, Wang CC, Garland DJ, Huang W, Jones C, Koeller KJ, Kolodziej SA, Li J, Manning RE, Mahoney MW, Miller RE, Mischke DA, Rath NP, Fletcher T, Reinhard EJ, et al. Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1). J. Med. Chem. 48: 5837-5852 (2005). *

• Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. J. Gastroenterol. Hepatol. 23: 527-533 (2008). *

• Tsuboi K, Tazuma S, Nishioka T, Chayama K. Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage. J. Gastroenterol. 39: 955-960 (2004). *

• Tsuboi K, Tazuma S, Ochi H, Chayama K. Hydrophilic bile salts have a cytoprotective effect against cyclosporine A-induced cholestasis through enhanced canalicular membrane fluidity and transporter activity. Hepatol. Res. 25: 38-47 (2003). *

• Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I. Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm. Res. 23: 2646-2656 (2006). *

• Tsukanov VV, Nozdrachev KG, Tonkikh IuL, Bronnikova EP, Kupershteie Eiu. The mechanism of reverse cholesterol transport and cholelithiasis in northern nationalities. Klin. Med. (Mosk.) 85: 33-35 (2007).

• Tsuneyama K, Kono N, Hoso M, Sugahara H, Yoshida K, Katayanagi K, Gershwin ME, Saito K, Nakanuma Y. aly/aly mice: a unique model of biliary disease. Hepatology 27: 1499-1507 (1998). *

• Tsuzuki W, Yunoki R, Yoshimura H. Intestinal epithelial cells absorb gamma-tocotrienol faster than alpha-tocopherol. Lipids 42: 163-170 (2007).

• Turley SD. The role of Niemann-Pick C1-like 1 (NPC1L1) in intestinal sterol absorption. J. Clin. Lipidol. 2: S20-S28 (2008). *

• Turley SD. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin. Cardiol. 27 (6 Suppl. 3): 16-21 (2004).

• Turncliff RZ, Meier PJ, Brouwer KL. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 32: 834-839 (2004). *

• Ulmasov B, Bruno J, Woost PG, Edwards JC. Tissue and subcellular distribution of CLIC1. BMC Cell Biol. 8: 8 (2007). *

• Uppal H, Saini SP, Moschetta A, Mu Y, Zhou J, Gong H, Zhai Y, Ren S, Michalopoulos GK, Mangelsdorf DJ, Xie W. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45: 422-432 (2007). *

• Uppal H, Toma D, Saini SPS, Ren S, Jones TJ, Xie W. Combined loss of orphan receptors PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 41: 168-176 (2005). *

• Uppal H, Zhai Y, Gangopadhyay A, Khadem S, Ren S, Moser JA, Xie W. Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization. Hepatology 47: 1331-1342 (2008). *

• Vaerman JP, Langendries AE, Giffroy DA, Kaetzel CS, Fiani CM, Moro I, Brandtzaeg P, Kobayashi K. Antibody against the human J chain inhibits polymeric Ig receptor-mediated biliary and epithelial transport of human polymeric IgA. Eur. J. Immunol. 28: 171-182 (1998). *

• Vaidya SS, Gerk PM. Lack of interaction between tauroursodeoxycholate and ATP-binding cassette transporter isoform G2 (ABCG2). Mol. Pharm. 3: 303-306 (2006). *

• Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J. Hepatol. 44: 1150-1157 (2006). *

• van der Leij FR, Bloks VW, Grefhorst A, Hoekstra J, Gerding A, Kooi K, Gerbens F, Te Meerman G, Kuipers F. Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics 90: 680-689 (2007). *

• van der Velde AE, Vrins CL, van den Oever K, Seemann I, Oude Elferink RP, van Eck M, Kuipers F, Groen AK. Regulation of direct transintestinal cholesterol excretion in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G203-G208 (2008). *

• van Erpecum KJ. Biliary lipids, water and cholesterol gallstones. Biol. Cell. 97: 815-822 (2005). *

• van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133: 507-516 (2007). *

• van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4: 185-211 (2003).

• vanBerge-Henegouwen GP, Venneman NG, Portincasa P, Kosters A, van Erpecum KJ, Groen AK. Relevance of hereditary defects in lipid transport proteins for the pathogenesis of cholesterol gallstone disease. Scand. J. Gastroenterol. Suppl. 241: 60-69 (2004). *

• Vasku V, Bienertova-Vasku J, Necas M, Vasku A. MTHFR (methylenetetrahydrofolate reductase) C677T polymorphism and psoriasis. Clin. Exp. Med. May 30 [Epub ahead of print] (2009). *

• Venglovecz V, Rakonczay Z Jr, Ozsvari B, Takacs T, Lonovics J, Varro A, Gray MA, Argent BE, Hegyi P. Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. Gut 57: 1102-1112 (2008).

• Venteclef N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J. Biol. Chem. 283: 3694-3701 (2008). *

• Venteclef N, Smith JC, Goodwin B, Delerive P. Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response. Mol. Cell. Biol. 26: 6799-6807 (2006). *

• Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110: 3259-3269 (2004). *

• Vicens M, Medarde M, Macias RI, Larena MG, Villafaina A, Serrano MA, Marin JJ. Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorg. Med. Chem. 15: 2359-2367 (2007). *

• Vilhelmsson OT, Martin SA, Medale F, Kaushik SJ, Houlihan DF. Dietary plant-protein substitution affects hepatic metabolism in rainbow trout (Oncorhynchus mykiss). Br. J. Nutr. 92: 71-80 (2004). *

• Villanueva SS, Ruiz ML, Luquita MG, Sanchez Pozzi EJ, Catania VA, Mottino AD. Involvement of MRP2 in hepatic and intestinal disposition of dinitrophenyl-S-glutathione in partially hepatectomized rats. Toxicol. Sci. 84: 4-11 (2005). *

• Visser WF, van Roermund CW, Ijlst L, Waterham HR, Wanders RJ. Demonstration of bile acid transport across the mammalian peroxisomal membrane. Biochem. Biophys. Res. Commun. 357: 335-340 (2007). *

• Vitek L, Carey MC. Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life. Eur. J. Clin. Invest. 33: 799-810 (2003). *

• Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. Carcinogen and anti-cancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 318: 319-327 (2006). *

• Vleggaar FP, Van Ooteghem NA, Van Buuren HR, Van Berge Henegouwen GP. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders. Scand. J. Gastroenterol. Suppl. 232: 86-92 (2000).

• von Bergmann K, Sudhop T, Lutjohann D. Cholesterol and plant sterol absorption: recent insights. Am. J. Cardiol. 96: S10-S14 (2005). *

• Vore M, Gerk P. Activation of MRP2 transport by ursodeoxycholic acid (UDCA) and its amidates. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 60. June 18-19 (2004). *

• Voronina SG, Gryshchenko OV, Gerasimenko OV, Green AK, Petersen OH, Tepikin AV. Bile acids induce a cationic current, depolarizing pancreatic acinar cells and increasing the intracellular Na+ concentration. J. Biol. Chem. 280: 1764-1770 (2005). *

• Vos TA, Hooiveld GJ, Koning H, Childs S, Meijer DK, Moshage H, Jansen PL, Muller M. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28: 1637-1644 (1998). *

• Vos TA, Ros JE, Havinga R, Moshage H, Kuipers F, Jansen PL, Muller M. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology 29: 1833-1839 (1999). *

• Voshol PJ, Koopen NR, de Vree JM, Havinga R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. Dietary cholesterol does not normalize low plasma cholesterol levels but induces hyperbilirubinemia and hypercholanemia in Mdr2 P-glycoprotein-deficient mice. J. Hepatol. 34: 202-209 (2001). *

• Vrins C, Vink E, Vandenberghe KE, Frijters R, Seppen J, Groen AK. The sterol transporting heterodimer ABCG5/ABCG8 requires bile salts to mediate cholesterol efflux. FEBS Lett. 581: 4616-4620 (2007). *

• Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125: 825-838 (2003). *

• Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42: 420-430 (2005). *

• Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rational approach to the treatment of intrahepatic cholestasis. Ann. Hepatol. 4: 77-99 (2005). *

• Wagner M, Zollner G, Fickert P, Gumhold J, Silbert D, Fuchsbichler A, Gujral J, Zatloukal K, Denk H, Jaeschke H, Trauner M. Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. Drug Metab. Dispos. 35: 1694-1699 (2007). *

• Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. [In Press] (2009).

• Wakabayashi Y, Lippincott-Schwartz J, Arias IM. Intracellular trafficking of bile salt export pump (ABCB11) in polarized hepatic cells: constitutive cycling between the canalicular membrane and rab11 positive endosomes. Mol. Biol. Cell 15: 3485-3496 (2004). *

• Walters JR. Bile acids are physiological ligands for a nuclear receptor. Gut 46: 308-309 (2000). *

• Wang DQ, Lee SP. Physical chemistry of intestinal absorption of biliary cholesterol in mice. Hepatology 48: 177-185 (2008).

• Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42: 1331-1357 (2003).

• Wang HH, Patel SB, Carey MC, Wang DQ. Quantifying anomalous intestinal sterol uptake, lymphatic transport, and biliary secretion in Abcg8(-/-) mice. Hepatology 45: 998-1006 (2007). *

• Wang L, Dong H, Soroka CJ, Wei N, Boyer JL, Hochstrasser M. Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II. Hepatology 48: 1558-1569 (2008).

• Wang L, Soroka CJ, Boyer JL. The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J. Clin. Invest. 110: 965-972 (2002). *

• Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler. Thromb. Vasc. Biol. 27: 1837-1842 (2007). *

• Wang MD, Kiss RS, Franklin V, McBride HM, Whitman SC, Marcel YL. Different intracellular trafficking of LDL- and acetylated LDL-derived cholesterol lead to distinct reverse cholesterol transport mechanisms. J. Lipid Res. 48: 633-645 (2007). *

• Wang R, Lam P, Liu L, Forrest D, Yousef IM, Mignault D, Phillips MJ, Ling V. Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. Hepatology 38: 1489-1499 (2003). *

• Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, Helgason CD, Ackerley C, Phillips MJ, Ling V. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc. Natl. Acad. Sci. U.S.A. 98: 2011-2016 (2001). *

• Wang W, Seward DJ, Li L, Boyer JL, Ballatori N. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc. Natl. Acad. Sci. U.S.A. 98: 9431-9436 (2001). *

• Wang W, Soroka CJ, Mennone A, Rahner C, Harry K, Pypaert M, Boyer JL. Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. Gastroenterology 131: 878-884 (2006). *

• Wang W, Xue S, Ingles SA, Chen Q, Diep AT, Frankl HD, Stolz A, Haile RW. An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 10: 931-936 (2001). *

• Wang XJ, Chamberlain MP, Vassieva O, Henderson CJ, Wolf CR. Relationship between hepatic phenotype and changes in gene expression in the cytochrome P450 reductase (POR) null mice. Biochem. J. 388: 857-867 (2005). *

• Wang Y, Jiang ZY, Fei J, Xin L, Cai Q, Jiang ZH, Zhu ZG, Han TQ, Zhang SD. ATP binding cassette G8 T400K polymorphism may affect the risk of gallstone disease among Chinese males. Clin. Chim. Acta 384: 80-85 (2007). *

• Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Monnighoff I, Buchczyk D, Donner M, Flogel U, Kappert G, Soboll S, Beer S, Pfeffer K, Marschall HU, Gabrielsen M, Amiry-Moghaddam M, Ottersen OP, Dienes HP, Haussinger D. Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J. 20: 574-576 (2006). *

• Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson LA, Marschall HU, Lammert F. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter gene ABCB4. Gut 56: 265-270 (2007). *

• Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T, Matsuzaki S. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol. Res. 37: 598-607 (2007). *

• Watanabe T, Asaka S, Kitagawa D, Saito K, Kurashige R, Sasado T, Morinaga C, Suwa H, Niwa K, Henrich T, Hirose Y, Yasuoka A, Yoda H, Deguchi T, Iwanami N, Kunimatsu S, Osakada M, Loosli F, Quiring R, Carl M, Grabher C, Winkler S, Del Bene F, Wittbrodt J,. Mutations affecting liver development and function in Medaka, Oryzias latipes, screened by multiple criteria. Mech. Dev. 121: 791-802 (2004). *

• Watanabe T, Suzuki H, Sawada Y, Naito M, Tsuruo T, Inaba M, Hanano M, Sugiyama Y. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J. Hepatol. 23: 440-448 (1995). *

• Webster CR, Boria P, Usechak P, Anwer MS. S-Adenosylmethionine and cAMP confer differential cytoprotection against bile acid-induced apoptosis in canine renal tubular cells and primary rat hepatocytes. Vet. Ther. 3: 474-484 (2002).

• Weihrauch D, Kanchanapoo J, Ao M, Prasad R, Piyachaturawat P, Rao MC. Weanling, but not adult, rabbit colon absorbs bile acids: flux is linked to expression of putative bile acid transporters. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G439-G450 (2006). *

• Westergaard H. Bile acid malabsorption. Curr. Treat. Options Gastroenterol. 10: 28-33 (2007).

• Westin MA, Alexson SE, Hunt MC. Molecular cloning and characterization of two mouse peroxisome proliferator-activated receptor alpha (PPARa) regulated peroxisomal acyl-CoA thioesterases. J. Biol. Chem. 279: 21841-21848 (2004). *

• Westin S, Heyman RA, Martin R. FXR, a therapeutic target for bile acid and lipid disorders. Mini. Rev. Med. Chem. 5: 719-727 (2005).

• Williamson G, Aeberli I, Miguet L, Zhang Z, Sanchez MB, Crespy V, Barron D, Needs P, Kroon PA, Glavinas H, Krajcsi P, Grigorov M. Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (CMOAT, MRP2). Drug Metab. Dispos. 35: 1262-1268 (2007). *

• Willson TM, Jones SA, Moore JT, Kliewer SA. Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med. Res. Rev. 21: 513-522 (2001). *

• Wittenburg H, Lyons MA, Li R, Churchill GA, Carey MC, Paigen B. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology 125: 868-881 (2003). *

• Wojtal KA, de Vries E, Hoekstra D, van Ijzendoorn SC. Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring and glucosylceramide. Mol. Biol. Cell 17: 3638-3650 (2006). *

• Wolkoff AW, Cohen DE. Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G175-G179 (2003). *

• Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F. Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J. Hepatol. 37: 556-563 (2002). *

• Wong H, Lehman-McKeeman LD, Grubb MF, Grossman SJ, Bhaskaran VM, Solon EG, Shen HS, Gerson RJ, Car BD, Zhao B, Gemzik B. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. Toxicol. Sci. 84: 232-242 (2005). *

• Wong MH, Rao PN, Pettenati MJ, Dawson PA. Localization of the ileal sodium-bile acid cotransporter gene (SLC10A2) to human chromosome 13q33. Genomics 33: 538-540 (1996). *

• Woo K, Dutta AK, Patel V, Kresge C, Feranchak AP. Fluid-flow induces mechanosensitive ATP release, calcium signalling, and Cl- transport in biliary epithelial cells through a PKCzeta-dependent pathway. J. Physiol. 586: 2779-2798 (2008). *

• Woydziak ZR, Boiadjiev SE, Norona WS, McDonagh AF, Lightner DA. Synthesis and hepatic transport of strongly fluorescent cholephilic dipyrrinones. J. Org. Chem. 70: 8417-8423 (2005). *

• Wright AW, Dickinson RG. Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat. J. Pharmacol. Exp. Ther. 310: 584-588 (2004). *

• Wu JE, Basso F, Shamburek RD, Amar MJ, Vaisman B, Szakacs G, Joyce C, Tansey T, Freeman L, Paigen BJ, Thomas F, Brewer HB Jr, Santamarina-Fojo S. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but alter aortic atherosclerosis in transgenic mice. J. Biol. Chem. 279: 22913-22925 (2004). *

• Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol. 121: 185-193 (2009).

• Wu MK, Hyogo H, Yadav SK, Novikoff PM, Cohen DE. Impaired response of biliary lipid secretion to a lithogenic diet in phosphatidycholine transfer protein-deficient mice. J. Lipid Res. 46: 422-431 (2005). *

• Xia X, Francis H, Glaser S, Alpini G, Lesage G. Bile acid interactions with cholangiocytes. World J. Gastroenterol. 12: 3553-3563 (2006). *

• Xia X, Roundtree M, Merikhi A, Lu X, Shentu S, LeSage G. Degradation of the apical sodium-dependent bile acid transporter (ASBT) by the Ubiquitin-proteasome pathway in cholangiocytes. J. Biol. Chem. 279: 44931-44937 (2004). *

• Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT, Laitila J, Neuvonen PJ, Niemi M. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet. Genomics 19: 447-457 (2009).

• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28: 249-268 (2005).

• Xu G, Li H, Pan LX, Shang Q, Honda A, Ananthanarayanan M, Erickson SK, Shneider BL, Shefer S, Bollineni J, Forman BM, Matsuzaki Y, Suchy FJ, Tint GS, Salen G. FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits. J. Lipid Res. 44: 1956-1962 (2003). *

• Xu G, Pan LX, Erickson SK, Forman BM, Shneider BL, Ananthanarayanan M, Li X, Shefer S, Balasubramanian N, Ma L, Asaoka H, Lear SR, Nguyen LB, Dussault I, Suchy FJ, Tint GS, Salen G. Removal of the bile acid pool upregulates cholesterol 7alpha-hydroxylase by deactivating FXR in rabbits. J. Lipid Res. 43: 45-50 (2002). *

• Xu Z, Ke JC, Xing AY. Study on relationship between expression of familial intrahepatic cholestasis 1 mRNA in placenta and Intrahepatic cholestasis of pregnancy. Sichuan Da Xue Xue Bao Yi Xue Ban 39: 430-433 (2008).

• Yabuuchi H, Tanaka K, Maeda M, Takemura M, Oka M, Ohashi R, Tamai I. Cloning of the dog bile salt export pump (BSEP; ABCB11) and functional comparison with the human and rat proteins. Biopharm. Drug Dispos. 29: 441-448 (2008).

• Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, Sato M, Matsuura M, Saga T, Unno M, Abe T, Mano N, Hishinuma T, Goto J. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J. Lipid Res. 47: 1196-1202 (2006). *

• Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M. Estrogen receptor alpha mediates 17alpha-ethynylestradiol-causing hepatotoxicity. J. Biol. Chem. 281: 16625-16631 (2006). *

• Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34: 1247-1254 (2006). *

• Yatskar L, Fisher EA, Schwartzbard A. Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin. Cardiol. 29: 52-55 (2006).

• Yokomori H, Oda M, Wakabayashi G, Kitajima M, Yoshimura K, Nomura M, Hibi T. High expressions of caveolins on the proliferating bile ductules in primary biliary cirrhosis. World J. Gastroenterol. 11: 3710-3713 (2005). *

• Yoon YB, Hagey LR, Hofmann AF, Gurantz D, Michelotti EL, Steinbach JH. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 90: 837-852 (1986).

• Yu J, Lo JL, Huang L, Zhao A, Metzger E, Adams A, Meinke PT, Wright SD, Cui J. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem. 277: 31441-31447 (2002). *

• Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, Hobbs HH, Cohen JC. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J. Biol. Chem. 280: 8742-8747 (2005). *

• Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. U.S.A. 99: 16237-16242 (2002). *

• Yu Z, Serra A, Sauter D, Loffing J, Ackermann D, Frey FJ, Frey BM, Vogt B. Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC). Nephrol. Dial. Transplant. 20: 1833-1841 (2005).

• Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa KI, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J. Pharmacol. Exp. Ther. 319: 459-467 (2006). *

• Zanlungo S, Rigotti A. Determinants of transhepatic cholesterol flux and their relevance for gallstone formation. Liver Int. 29: 323-330 (2009). *

• Zanlungo S, Rigotti A, Nervi F. Hepatic cholesterol transport from plasma into bile: implications for gallstone disease. Curr. Opin. Lipidol. 15: 279-286 (2004).

• Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J. 371: 361-367 (2003). *

• Zelcer N, Saeki T, Bot I, Kuil A, Borst P. Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem. J. 369: 23-30 (2003). *

• Zelcer N, van de Wetering K, de Waart R, Scheffer GL, Marschall HU, Wielinga PR, Kuil A, Kunne C, Smith A, van der Valk M, Wijnholds J, Oude Elferink R, Borst P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 44: 768-775 (2006). *

• Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61: 7225-7232 (2001). *

• Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 60: 4779-4784 (2000). *

• Zhang AH, Gao S, Fan JL, Huang W, Zhao TQ, Liu G. Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpression. FEBS Lett. 570: 25-29 (2004). *

• Zhang DW, Graf GA, Gerard R, Cohen JC, Hobbs HH. Functional asymmetry of nucleotide binding domains in ABCG5 and ABCG8. J. Biol. Chem. 281: 4507-4516 (2006). *

• Zhang EY, Knipp GT, Ekins S, Swaan PW. Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab. Rev. 34: 709-750 (2002). *

• Zhang EY, Phelps MA, Banerjee A, Khantwal CM, Chang C, Helsper F, Swaan PW. Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry 43: 11380-11392 (2004). *

• Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279: 49517-49522 (2004). *

• Zhao B, Song J, Ghosh S. Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. J. Lipid Res. 49: 2212-2217 (2008). *

• Zhao XM, Montet JC. Effects of bile salt supplementation on biliary secretion in estrogen-treated rats. J. Nutr. Biochem. 1: 420-425 (1990). *

• Zhou J, Liu M, Zhai Y, Xie W. The anti-apoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol. 22: 868-880 (2008). *

• Zimber A, Gespach C. Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med. Chem. 8: 540-563 (2008).

• Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med. Toxicol. 2: 112-160 (1987).

• Zimmermann C, Hruz P, Gutmann H, Terracciano L, Beuers U, Lehmann F, Beglinger C, Drewe J. Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis. Digestion 74: 101-108 (2006). *

• Zimniak P. Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin. Liver Dis. 13: 248-260 (1993).

• Zinchuk V, Zinchuk O, Akimaru K, Moriya F, Okada T. Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem. Cell Biol. 127: 503-512 (2007). *

• Zinchuk VS, Okada T, Akimaru K, Seguchi H. Asynchronous expression and colocalization of Bsep and Mrp2 during development of rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G540-G548 (2002). *

• Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, Trauner M. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. 39: 480-488 (2003). *

• Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J. Hepatol. 38: 717-727 (2003). *

• Zollner G, Fickert P, Silbert D, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H, Trauner M. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G184-G191 (2002). *

• Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33: 633-646 (2001). *

• Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 156: 7-27 (2009). *

• Zollner G, Trauner M. Molecular mechanisms of cholestasis. Wien. Med. Wochenschr. 156: 380-385 (2006). *

• Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25: 367-379 (2005). *

• Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 27: 920-929 (2007). *

• Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter alpha/beta in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G923-G932 (2006). *

• Zou SL, Liu J, Lan Y, Cheng H, Gan XL. Effects of farnesoid X receptor ligand on the metabolism of bile acids in rats with estrogen-induced intrahepatic cholestasis of pregnancy. Zhonghua Gan Zang Bing Za Zhi 16: 383-386 (2008).

• Zouboulis-Vafiadis I, Dumont M, Erlinger S. Conjugation is rate limiting in hepatic transport of ursodeoxycholate in the rat. Am. J. Physiol. 243: G208-G213 (1982).

• Zsembery A, Thalhammer T, Graf J. Bile formation: a concerted action of membrane transporters in hepatocytes and cholangiocytes. News Physiol. Sci. 15: 6-11 (2000). *

• Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, Arrese M, Lammert F, Miquel JF. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int. 28: 935-947 (2008). *

Number of references = 1268

www psc-literature.org